<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31649546</article-id>
<article-id pub-id-type="pmc">6792167</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2019.01192</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Inflammation in Renal Diseases: New and Old Players</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Andrade-Oliveira</surname>
<given-names>Vinicius</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>†</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/683007" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Foresto-Neto</surname>
<given-names>Orestes</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>†</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/506303" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Watanabe</surname>
<given-names>Ingrid Kazue Mizuno</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>†</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/669149" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zatz</surname>
<given-names>Roberto</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Câmara</surname>
<given-names>Niels Olsen Saraiva</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup><institution>Bernardo’s Lab, Center for Natural and Human Sciences, Federal University of ABC</institution>, <addr-line>Santo André</addr-line>, <country>Brazil</country></aff>
<aff id="aff2">
<sup>2</sup><institution>Laboratory of Transplantation Immunobiology, Department of Immunology, Institute of Biomedical Sciences, University of São Paulo</institution>, <addr-line>São Paulo</addr-line>, <country>Brazil</country></aff>
<aff id="aff3">
<sup>3</sup><institution>Renal Division, Department of Clinical Medicine, Faculty of Medicine, University of São Paulo</institution>, <addr-line>São Paulo</addr-line>, <country>Brazil</country></aff>
<aff id="aff4">
<sup>4</sup><institution>Nephrology Division, Federal University of São Paulo</institution>, <addr-line>São Paulo</addr-line>, <country>Brazil</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Matthew Griffin, National University of Ireland Galway, Ireland</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Rohan Samarakoon, Albany Medical College, United States; Bairbre Mcnicholas, Saolta University Health Care Group, Ireland</p>
</fn>
<corresp id="fn001">*Correspondence: Roberto Zatz, <email xlink:href="mailto:roberto.zatz@gmail.com" xlink:type="simple">roberto.zatz@gmail.com</email>; Niels Olsen Saraiva Câmara, <email xlink:href="mailto:niels@icb.usp.br" xlink:type="simple">niels@icb.usp.br</email>
</corresp>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Renal Pharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>†These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>08</day>
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>10</volume>
<elocation-id>1192</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>2</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>9</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Andrade-Oliveira, Foresto-Neto, Watanabe, Zatz and Câmara</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Andrade-Oliveira, Foresto-Neto, Watanabe, Zatz and Câmara</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Inflammation, a process intimately linked to renal disease, can be defined as a complex network of interactions between renal parenchymal cells and resident immune cells, such as macrophages and dendritic cells, coupled with recruitment of circulating monocytes, lymphocytes, and neutrophils. Once stimulated, these cells activate specialized structures such as Toll-like receptor and Nod-like receptor (NLR). By detecting danger-associated molecules, these receptors can set in motion major innate immunity pathways such as nuclear factor ĸB (NF-ĸB) and NLRP3 inflammasome, causing metabolic reprogramming and phenotype changes of immune and parenchymal cells and triggering the secretion of a number of inflammatory mediators that can cause irreversible tissue damage and functional loss. Growing evidence suggests that this response can be deeply impacted by the crosstalk between the kidneys and other organs, such as the gut. Changes in the composition and/or metabolite production of the gut microbiota can influence inflammation, oxidative stress, and fibrosis, thus offering opportunities to positively manipulate the composition and/or functionality of gut microbiota and, consequentially, ameliorate deleterious consequences of renal diseases. In this review, we summarize the most recent evidence that renal inflammation can be ameliorated by interfering with the gut microbiota through the administration of probiotics, prebiotics, and postbiotics. In addition to these innovative approaches, we address the recent discovery of new targets for drugs long in use in clinical practice. Angiotensin II receptor antagonists, NF-ĸB inhibitors, thiazide diuretics, and antimetabolic drugs can reduce renal macrophage infiltration and slow down the progression of renal disease by mechanisms independent of those usually attributed to these compounds. Allopurinol, an inhibitor of uric acid production, has been shown to decrease renal inflammation by limiting activation of the NLRP3 inflammasome. So far, these protective effects have been shown in experimental studies only. Clinical studies will establish whether these novel strategies can be incorporated into the arsenal of treatments intended to prevent the progression of human disease.</p>
</abstract>
<kwd-group>
<kwd>inflammation</kwd>
<kwd>chronic kidney disease (CKD)</kwd>
<kwd>NF- kappa B</kwd>
<kwd>gut microbiota</kwd>
<kwd>acute kidney injury (AKI)</kwd>
</kwd-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="258"></ref-count>
<page-count count="19"></page-count>
<word-count count="8966"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Acute kidney injury (AKI) and chronic kidney disease (CKD) are highly prevalent conditions associated with significant levels of morbidity and mortality. According to the US Renal Data System, about 30 millions of Americans were afflicted with CKD in 2017, a prevalence of almost 15% (<xref ref-type="bibr" rid="B192">Saran et al., 2017</xref>; <xref ref-type="bibr" rid="B193">Saran et al., 2018</xref>). As to AKI, recent evidence indicates that it affects almost 60% of intensive care unit (ICU) patients, whereas its severity is directly related to mortality (<xref ref-type="bibr" rid="B88">Hoste et al., 2015</xref>).</p>
<p>Although the mechanisms underlying CKD and AKI are quite distinct, clinical evidence suggests that the two conditions are inextricably interconnected (<xref ref-type="bibr" rid="B39">Chawla et al., 2014</xref>). Inflammation, a process aimed in principle at detecting and fighting harmful pathogens, is a major pathogenic mechanism for both CKD and AKI. Both resident and circulating immune cells can interact with parenchymal renal cells to trigger an inflammatory response when subjected to stress, causing irreversible tissue damage and eventuating in organ failure (<xref ref-type="bibr" rid="B203">Singbartl et al., 2019</xref>). Thus, targeting inflammation constitutes a rational strategy in the management of both CKD and AKI.</p>
</sec>
<sec id="s2">
<title>Kidney Resident Immune Cells</title>
<p>The kidney harbors a variety of resident immune cells, which play an important role in the maintenance of tissue homeostasis. Dendritic cells (DCs), macrophages, regulatory T cells (Tregs), CD8, and NK lymphocytes, among other cell types, are in close contact with parenchymal cells (<xref ref-type="bibr" rid="B116">Kurts et al., 2013</xref>; <xref ref-type="bibr" rid="B212">Stamatiades et al., 2016</xref>) (<xref ref-type="fig" rid="f1">
<bold>Figure 1</bold>
</xref>, left side). Once activated by external (for instance, microbial antigens) or by internal events, these cells produce inflammatory mediators that can initiate kidney disease and, concomitantly, trigger a regulatory response aimed at curbing inflammation, repairing tissue damage, and restoring homeostasis. For instance, microbial products and alarmins can bind to innate immune receptors on the surface of DC, leading these cells to secrete a number of chemokines and cytokines (<xref ref-type="bibr" rid="B53">Dong et al., 2007</xref>; <xref ref-type="bibr" rid="B224">Tittel et al., 2011</xref>) and to migrate to draining lymph nodes, where they can amplify the immune response by activating T lymphocytes (T<sub>H</sub>1 CD4<sup>+</sup> and cytotoxic cells). At the same time, DCs can limit inflammation by stimulating the production of interleukin 10 (IL-10) by Treg lymphocytes (<xref ref-type="bibr" rid="B108">Kinsey et al., 2009</xref>; <xref ref-type="bibr" rid="B150">Monteiro et al., 2009</xref>). Another clear example of this dichotomous activity is given by macrophages, which, by sensing alarmins through innate immune receptors, can initiate/enhance inflammation <italic>via</italic> the M1 subset and, simultaneously, exert an anti-inflammatory effect <italic>via</italic> the M2 subset (<xref ref-type="bibr" rid="B155">Nelson et al., 2012</xref>;<xref ref-type="bibr" rid="B24">Braga et al., 2017a</xref>) (<xref ref-type="fig" rid="f1">
<bold>Figure 1</bold>
</xref>, right side).</p>
<fig id="f1" position="float">
<label>Figure 1</label>
<caption>
<p>Inflammation in acute kidney diseases. Under physiologic conditions, endothelial, epithelial, and immune cells (around parenchymal structures and/or vessels) interact harmonically within the kidney (left side). Upon an insult by bacteria or bacterial products, drug toxicity, or following nonsterile stimulation, epithelial and endothelial cells undergo necrosis or apoptosis, releasing products that can activate Toll-like receptors (TLR), NOD-like receptors (NLR), and NLPR3 inflammasome in immune and kidney cells. This activation leads to the production of chemokines and proinflammatory cytokines, which recruit monocytes and neutrophils to the organ. Concomitantly, resident immune cells (mainly dendritic cells) get activated and induce the proliferation of T cells (T<sub>H</sub>1, T<sub>H</sub>17, and CD8 cytotoxic cells), which in turn produce cytokines, exacerbating the inflammation process (right). </p>
</caption>
<graphic xlink:href="fphar-10-01192-g001"></graphic>
</fig>
</sec>
<sec id="s3">
<title>Inflammation in AKI</title>
<sec id="s3_1">
<title>Role of Toll-Like Receptor– and Nod-Like Receptor–Dependent Pathways</title>
<p>Ischemia–reperfusion injury (IRI) is a major cause of AKI in ICU patients (<xref ref-type="bibr" rid="B88">Hoste et al., 2015</xref>). Transcriptome analysis in whole tissue as well as cell-specific analysis using Cre/Lox techniques revealed that IRI is associated with a myriad of events ranging from organelle stress to activation of complex intracellular pathways (<xref ref-type="bibr" rid="B45">Correa-Costa et al., 2012</xref>; <xref ref-type="bibr" rid="B133">Liu et al., 2014</xref>). One of the earliest events in the development of IRI is sterile (nonmicrobial) activation of innate immune receptors such as TLRs (Toll-like receptors) and NLRs (Nod-like receptors). These structures, expressed in renal parenchymal cells as well as in resident immune cells, can recognize pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Activation of these receptors triggers a number of intracellular pathways such as c-Jun N-terminal kinases (JNK), mitogen-activated protein kinase (MAPK), and nuclear factor kB (NF-ĸB), culminating with the secretion of proinflammatory cytokines and chemokines (<xref ref-type="bibr" rid="B238">Wang and Zhang, 2017</xref>). Much of the current knowledge about the role of these receptors in AKI came from studies of knockout (KO) mice. Lack of TLR4 and/or TLR2, as well as of their adaptor molecule, <italic>myeloid differentiation factor 88 (MyD88)</italic>, prevented the development of kidney injury in mice undergoing IRI (<xref ref-type="bibr" rid="B123">Leemans et al., 2005</xref>; <xref ref-type="bibr" rid="B197">Shigeoka et al., 2007</xref>; <xref ref-type="bibr" rid="B248">Wu et al., 2007</xref>). Available evidence indicates that activation of these receptors and the development of downstream inflammatory events follow the binding of alarmins released after cell injury and/or death (<xref ref-type="bibr" rid="B182">Rosin and Okusa, 2011</xref>; <xref ref-type="bibr" rid="B5">Allam et al., 2012</xref>). Accordingly, upregulation and blockage of one of these alarmins, high-mobility group box 1, was associated with aggravation and lessening of renal injury, respectively (<xref ref-type="bibr" rid="B249">Wu et al., 2010</xref>; <xref ref-type="bibr" rid="B40">Chen et al., 2017</xref>). A similar mechanism seems to be operative in murine models of sterile (cisplatin toxicity) and nonsterile (sepsis) AKI (<xref ref-type="bibr" rid="B35">Castoldi et al., 2012</xref>; <xref ref-type="bibr" rid="B11">Andrade-Silva et al., 2018</xref>). Castoldi et al. (<xref ref-type="bibr" rid="B35">Castoldi et al., 2012</xref>) showed that lack of TLR4, TLR2, and <italic>MyD88</italic> limited renal damage in a sepsis model, mainly by decreasing the recruitment of neutrophils. In mice with cisplatin-induced AKI, we showed evidence that the presence of TLR4 is needed for the development of renal damage (<xref ref-type="bibr" rid="B11">Andrade-Silva et al., 2018</xref>), an action that can be mediated by p38 MAPK pathways (<xref ref-type="bibr" rid="B254">Zhang et al., 2008</xref>). Additional evidence of participation of these receptors is provided by deceased-donor renal grafts, in which the inevitable IRI is associated with increased expression of TLR4 (<xref ref-type="bibr" rid="B115">Kruger et al., 2009</xref>; <xref ref-type="bibr" rid="B9">Andrade-Oliveira et al., 2012</xref>). Conversely, a mutation in the tlr4 gene decreases the signaling through TLR4 receptor, which may attenuate the response of kidney grafts to alarmins, hence limiting cytokine production, inflammation, and eventual organ failure (<xref ref-type="bibr" rid="B157">Nogueira et al., 2010</xref>).</p>
<p>Inflammation initiated in the kidneys can lead to the release of cytokines and chemokines to the circulation, resulting in dysfunction of distant organs such as heart and lungs (<xref ref-type="bibr" rid="B112">Kramer et al., 1999</xref>; <xref ref-type="bibr" rid="B29">Campanholle et al., 2010</xref>; <xref ref-type="bibr" rid="B184">Rostron et al., 2010</xref>; <xref ref-type="bibr" rid="B225">Trentin-Sonoda et al., 2015</xref>). Thus, activation of renal TLR4 sets off an important signaling pathway that acts both locally and at remote organs, contributing to build up a state of systemic inflammation that considerably aggravates the clinical scenario. TLR4 blockade or inactivation constitutes a promising target for the prevention or mitigation of AKI.</p>
<p>Whereas TLRs can be located on the surface of cells and endosomes, NLRs are equally complex intracellular sensors that are expressed throughout the kidney and have been associated with several models of AKI. On the basis of their structure, NLRs are subdivided into three subgroups, namely, NOD1 and NOD2 or NLRP (<xref ref-type="bibr" rid="B117">Latz et al., 2013</xref>). Activation of NOD1/NOD2 sets in motion the NF-ĸB and MAPK cascades (<xref ref-type="bibr" rid="B34">Carneiro et al., 2008</xref>), whereas that of NLRP leads to cleavage of IL-1β and IL-18 (<xref ref-type="bibr" rid="B245">Wen et al., 2013</xref>). Shigeoka et al. (<xref ref-type="bibr" rid="B198">Shigeoka et al., 2010a</xref>) showed that, when subjected to renal ischemia, NOD2 KO and NOD1/NOD2 double KO mice develop less renal inflammation and tubular cell apoptosis than wild mice, being thus protected from IRI. Similar protection against tubular cell death and renal functional loss was observed in NLRP3 KO mice subjected to renal ischemia (<xref ref-type="bibr" rid="B91">Iyer et al., 2009</xref>; <xref ref-type="bibr" rid="B199">Shigeoka et al., 2010b</xref>; <xref ref-type="bibr" rid="B105">Kim et al., 2013</xref>). Together, these studies lend support to the notion that the NLRP3 pathway plays a key role in the pathogenesis of inflammation and cell death in IRI-associated AKI. The participation of NLRP3 may be less prominent in other modalities of AKI, since NLRP3 KO mice were not protected against kidney damage induced by cisplatin (<xref ref-type="bibr" rid="B105">Kim et al., 2013</xref>).</p>
</sec>
<sec id="s3_2">
<title>Immune Cells in AKI</title>
<sec id="s3_2_1">
<title>Monocytes and Macrophages</title>
<p>In mice, circulating monocytes can be subdivided into inflammatory (Cx3CR1<sup>low</sup>, CCR2<sup>+</sup>, and Ly6C<sup>high</sup>) and resident (Cx3CR1<sup>high</sup>, CCR2<sup>neg</sup>, and Ly6C<sup>low</sup>) cells (<xref ref-type="bibr" rid="B70">Geissmann et al., 2003</xref>). Ly6C<sup>high</sup> monocytes protect the kidney from damage induced by sepsis, presumably by sensing and orchestrating a response against bacterial proliferation. Ly6C<sup>low</sup> monocytes are located at the perivascular space. Their interaction with endothelial cells decreases intercellular adhesion molecule 1 expression, thus preventing neutrophil infiltration and inflammation in IRI (<xref ref-type="bibr" rid="B102">Karasawa et al., 2015</xref>).</p>
<p>Macrophage depletion in rats protects kidney function from IRI injury (<xref ref-type="bibr" rid="B96">Jo et al., 2006</xref>), whereas blockade of the migration inhibitory factor was shown to inhibit macrophage infiltration and to ameliorate inflammation in cisplatin-induced AKI (<xref ref-type="bibr" rid="B129">Li et al., 2018</xref>). These findings suggest that macrophages exert a central pathogenic role in this setting. However, others reported opposite results (<xref ref-type="bibr" rid="B137">Lu et al., 2008</xref>). The reason for this discrepancy is unclear but may be related to the existence of two different macrophage populations. As pointed out earlier, monocytes can differentiate into M1 or M2 macrophages, which are induced by distinct factors and acquire distinct functions (<xref ref-type="bibr" rid="B241">Wang et al., 2014</xref>). M1 macrophages appear early in the course of kidney IRI, suggesting that they contribute to initial injury, whereas the presence of M2 macrophages is predominantly seen at later phases, presumably as part of a repair process (<xref ref-type="bibr" rid="B121">Lee et al., 2011</xref>). Interestingly, transference of M1 macrophages into macrophage-depleted mice subjected to IRI rescued the adverse phenotype observed in control animals (<xref ref-type="bibr" rid="B121">Lee et al., 2011</xref>). Thus, macrophages, mainly M1, play an important pathogenic role at the onset of AKI. The existence of other macrophage subsets, their plasticity, and their role in AKI models are currently the object of intense investigation.</p>
</sec>
<sec id="s3_2_2">
<title>Neutrophils</title>
<p>Renal infiltration by neutrophils can be detected as early as 2 h after IRI, remaining elevated up to 72 h after the insult (<xref ref-type="bibr" rid="B15">Awad et al., 2009</xref>). Upon reaching the renal parenchyma, neutrophils are exposed to DAMPs and PAMPs, leading to activation of TLRs and NLRs (<xref ref-type="bibr" rid="B35">Castoldi et al., 2012</xref>; <xref ref-type="bibr" rid="B49">Deng et al., 2017</xref>) and to the secretion of a number of inflammatory factors such as proteases, reactive oxygen species (ROS), and lytic enzymes (<xref ref-type="bibr" rid="B125">Leliefeld et al., 2016</xref>). These compounds interact with the vascular endothelium, leading to vessel tumefaction and, consequently, impairing blood flow (<xref ref-type="bibr" rid="B93">Jerke et al., 2015</xref>). Accordingly, neutrophil depletion exerts a protective effect in several AKI models (<xref ref-type="bibr" rid="B223">Thornton et al., 1989</xref>; <xref ref-type="bibr" rid="B35">Castoldi et al., 2012</xref>). Recently, Raup-Konsavage et al. (<xref ref-type="bibr" rid="B177">Raup-Konsavage et al., 2018</xref>) showed that the formation of neutrophil extracellular traps (NETs), which are instrumental for neutrophils to kill microorganisms (<xref ref-type="bibr" rid="B27">Brinkmann et al., 2004</xref>), could be one of the mechanisms by which these cells cause tissue damage during AKI. They showed that mice KO for PAD4, an enzyme involved in NET formation, exhibited partial preservation of kidney function after IRI (<xref ref-type="bibr" rid="B177">Raup-Konsavage et al., 2018</xref>). However, it must be stressed that these harmful effects constitute collateral damage and that, since the primary function of neutrophils is to fight infection, their absence can be detrimental. In the model of sepsis by cecal ligation and puncture, Hoesel et al. (<xref ref-type="bibr" rid="B87">Hoesel et al., 2005</xref>) showed that neutrophil depletion at the onset of sepsis can impair survival due to loss of antibacterial power and that a protective effect is achieved only when neutrophil depletion is performed at a later phase.</p>
<p>Since neutrophils appear so early in AKI, neutrophil-related proteins such as neutrophil gelatinase-associated lipocalin can be used as biomarkers of kidney damage and potential predictors of renal dysfunction and survival, as for instance in critically ill patients and in recipients of renal grafts (<xref ref-type="bibr" rid="B162">Parikh et al., 2006</xref>; <xref ref-type="bibr" rid="B227">Valette et al., 2013</xref>).</p>
</sec>
<sec id="s3_2_3">
<title>Dendritic Cells</title>
<p>DCs are mononuclear phagocytes that, as resident cells in several organs, perform a variety of functions, acting as a bridge between innate and adaptive immunity. In the kidneys, DCs heterogeneous population, exerting several functions, such as antigen-presenting, T-cell stimulation, and production of anti-inflammatory IL-10, (<xref ref-type="bibr" rid="B103">Kawakami et al., 2013</xref>). Kidney DCs are located between tubules and peritubular capillaries, allowing them to interact with effector cells as well as with endothelial and epithelial cells (<xref ref-type="bibr" rid="B126">Lemley and Kriz, 1991</xref>). During AKI, kidney DCs are activated by binding of TLRs and NLRs to cell debris and other DAMPs, thus increasing the expression of costimulatory molecules and proinflammatory cytokines such as tumor necrosis factor α (TNF-α) and antigen presentation to T cells in draining lymph nodes (<xref ref-type="bibr" rid="B53">Dong et al., 2007</xref>; <xref ref-type="bibr" rid="B208">Snelgrove et al., 2017</xref>), thus contributing to T-cell–mediated inflammation. By contrast, renal infiltration by neutrophils and monocytes, as well as tubular injury, was worsened in DC-depleted mice undergoing cisplatin-induced AKI compared to control animals (<xref ref-type="bibr" rid="B216">Tadagavadi and Reeves, 2010</xref>), suggesting that, in this setting, the presence of DCs may exert renoprotective rather than deleterious effects. The reason for this unexpected effect is unclear and may be related to a modulatory effect of DCs on the inflammatory response (<xref ref-type="bibr" rid="B216">Tadagavadi and Reeves, 2010</xref>). Alternatively, since DCs constitute a heterogeneous population, it is conceivable that, depending on the context, one or more subtypes exert a crucial anti-inflammatory function. Another possibility would be that monocytes and neutrophils simply occupied the niche left by the missing DCs and necrotic tubular cells. These hypotheses are currently speculative and need further investigation to be tested.</p>
</sec>
<sec id="s3_2_4">
<title>T Cells</title>
<p>Several lines of evidence indicate that the adaptive immune response is also involved in the pathogenesis of AKI. Animals lacking CD4<sup>+</sup> and CD8<sup>+</sup> T cells are protected from IRI-induced AKI (<xref ref-type="bibr" rid="B173">Rabb et al., 2000</xref>; <xref ref-type="bibr" rid="B49">Deng et al., 2017</xref>), an effect associated with reduced neutrophil infiltration. CD4<sup>+</sup> T cells can differentiate into different subsets—effector T-helper (T<sub>H</sub>) T<sub>H</sub>1/T<sub>H</sub>2/T<sub>H</sub>17 or Tregs, according to the microenvironment, to the expression of costimulatory molecules, to the presence of cytokines, and, as recently demonstrated, to variations in cell metabolism (<xref ref-type="bibr" rid="B163">Parish and Kaech, 2009</xref>; <xref ref-type="bibr" rid="B257">Zhu et al., 2010</xref>; <xref ref-type="bibr" rid="B139">MacIver et al., 2013</xref>). Evaluation of specific subtypes of CD4<sup>+</sup> T cells in IRI-induced AKI indicates that T<sub>H</sub>1 cells tend to worsen kidney damage, since mice KO for IL-12, a cytokine known to induce T<sub>H</sub>1 cells, are protected from IRI, whereas in mice KO for IL-4, cytokine known to induce T<sub>H</sub>2 cells, kidney damage is exacerbated (<xref ref-type="bibr" rid="B142">Marques et al., 2006</xref>; <xref ref-type="bibr" rid="B47">de Paiva et al., 2009</xref>). Moreover, T-cell–specific deletion of STAT-3, a transcription factor associated with T<sub>H</sub>17 differentiation, was renoprotective in animals subjected to IRI (<xref ref-type="bibr" rid="B122">Lee et al., 2018</xref>). IL-17 production by T<sub>H</sub>17 cells is known to increase the recruitment of neutrophils. Accordingly, IL-17 KO mice undergoing sepsis exhibited limited renal recruitment of neutrophils, associated with reduced apoptosis and less severe AKI. Consistent with these findings, higher IL-17 levels have been associated with worse outcomes in septic patients (<xref ref-type="bibr" rid="B141">Maravitsa et al., 2016</xref>). Thus, IL-17 and T<sub>H</sub>17 cells are likely to exert a prominent role in kidney injury during sepsis. Tregs have also received considerable attention in the context of AKI. Kinsey et al. (<xref ref-type="bibr" rid="B108">Kinsey et al., 2009</xref>) showed that depletion of Tregs worsened kidney damage during IRI-induced AKI by enhancing renal infiltration of macrophages and neutrophils and by augmenting the local levels of proinflammatory cytokines. Likewise, exacerbated kidney injury and impaired renal function after Tregs depletion were reported by Monteiro et al. (<xref ref-type="bibr" rid="B150">Monteiro et al., 2009</xref>). The renoprotective role of Treg was also shown in cisplatin-induced AKI (<xref ref-type="bibr" rid="B120">Lee et al., 2010</xref>). Recently, an interesting population of T cells double negative for CD4 and CD8 was described, which may represent yet another physiologic anti-inflammatory mechanism. These cells can be detected early in the course of AKI, playing a renoprotective role in an IL-10–dependent manner (<xref ref-type="bibr" rid="B144">Martina et al., 2016</xref>).</p>
</sec>
</sec>
</sec>
<sec id="s4">
<title>Inflammation in CKD</title>
<p>The mechanisms underlying the progression of CKD involve a complex interaction between hemodynamic, immunologic, metabolic, and inflammatory events (<xref ref-type="bibr" rid="B258">Zoccali et al., 2017</xref>). The development of inflammation, previously associated with immune dysfunction only, is currently considered a fundamental component of the pathogenesis of even non–immune-mediated CKD (<xref ref-type="bibr" rid="B60">Floege et al., 1992</xref>). Activation of DCs was shown to enhance the activity of CD8+ T cells, thus promoting glomerular injury in two different experimental models of progressive renal disease (<xref ref-type="bibr" rid="B83">Heymann et al., 2009</xref>; <xref ref-type="bibr" rid="B33">Cao et al., 2016</xref>). Accordingly, inhibition of DC activation or of their interaction with CD8+ T cells preserved kidney function and decreased inflammation and fibrosis in adriamycin glomerulopathy (<xref ref-type="bibr" rid="B242">Wang et al., 2018</xref>). Other subtypes of T cells, especially TH2, may also contribute to renal damage. <xref ref-type="bibr" rid="B132">Liu et al. (2012)</xref> showed massive infiltration by CD4+ T lymphocytes in advanced human immunoglobulin A nephropathy and that depletion of CD4+ T lymphocytes prevented renal fibrosis in UUO (unilateral ureteral obstruction) mice. They also showed that the TH2/TH1 ratio increased progressively after UUO and that TH2-reconstituted mice were more prone to develop renal fibrosis than TH1-reconstituted animals. Likewise, <xref ref-type="bibr" rid="B21">Braga et al. (2012)</xref> observed an increase in TH2-related cytokines 7 days after UUO in mice, as well as an accumulation of M2 macrophages in an MyD88 pathway–dependent manner.</p>
<p>The role of macrophages and that of its subtypes M1 and M2 have been extensively investigated in different models of CKD. Given their properties, the notion has been established that, in various organs and experimental models of disease, M1 macrophages act in early phases of inflammation and, as this process evolves, M2 macrophages eventually predominate to promote repairing and fibrosis (<xref ref-type="bibr" rid="B250">Wynn and Barron, 2010</xref>). In UUO mice, <xref ref-type="bibr" rid="B22">Braga et al. (2016)</xref> observed that infiltration by M1 macrophages occurs early in the course of the inflammatory process, whereas M2 macrophages accumulate only at more advanced phases, suggesting that these cells possess a resolutive, rather than profibrotic, phenotype. While this relationship between M2 macrophages and fibrosis development seems to be clear, a study using CRE-lox techniques to deplete IL-4Rα in lysozyme<sup>+</sup> cells (macrophages and neutrophils), therefore preventing macrophages from interacting with IL-4 and IL-13—two type 2 cytokines responsible for macrophage M2 polarization —showed that, in such context, mice developed an extremely severe, and often fatal, T<sub>H</sub>1-associated inflammatory response to schistosomal infestation, whereas the reaction against a form of murine strongyloidiasis was adequate (<xref ref-type="bibr" rid="B82">Herbert et al., 2004</xref>). These findings suggest that, at least in some forms of inflammation, the M2 phenotype is essential not only for tissue repair but also to prevent excessive inflammation and organ damage. Together, these findings indicate that the recruitment and differentiation of macrophages are crucial to all phases of renal injury, from triggering tissue injury to tissue repair. Any disturbance of this delicate equilibrium and/or the persistence of tissue insults will tip the balance in favor of macrophages directly involved in the development of renal inflammation (<xref ref-type="bibr" rid="B46">Correa-Costa et al., 2014</xref>; <xref ref-type="bibr" rid="B6">Amano et al., 2018</xref>; <xref ref-type="bibr" rid="B25">Braga et al., 2018</xref>)(<xref ref-type="fig" rid="f2">
<bold>Figure 2</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure 2</label>
<caption>
<p>Actors in the transition from acute kidney injury (AKI) to chronic kidney disease (CKD). Inflammation is a common link between AKI and CKD, and increased expression and/or activation of TLR, NLRP3 inflammasome, and NF-ĸB are present in both scenarios. The composition of the immune cell population depends on the context. In AKI, a large number of T<sub>H</sub>1/T<sub>H</sub>17 lymphocytes and neutrophils concentrate around parenchymal structures and/or vessels, whereas in CKD T<sub>H</sub>2 lymphocytes and M2 macrophages predominate. M1 macrophages, dendritic cells, and CD8<sup>+</sup> T cells are seen in both processes. In CKD, epithelial– and/or endothelial–mesenchymal transition, with fibroblast proliferation, may contribute substantially to the development of inflammation and fibrosis. Gut microbiota composition, along with its subproducts, can have an important role in both AKI and CKD. Short-chain fatty acid (SCFA) can inhibit inflammation in different models of AKI, whereas in CKD there is a reciprocal relationship, with gut microbiota modulating the development of CKD, and, conversely, uremic toxins (e.g., p-cresol and indol) promoting changes in the composition of gut microbiota. Repurposed drugs and compounds that limit lymphocyte proliferation, M1 infiltration, and specific inflammatory pathways can exert renoprotective and anti-inflammatory effects. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers inhibit the NF-ĸB system, whereas the experimental compounds pyrrolidine dithiocarbamate and parthenolide provide more specific inhibition. Allopurinol reduces activation of the NLRP3 inflammasome.</p>
</caption>
<graphic xlink:href="fphar-10-01192-g002"></graphic>
</fig>
<p>The mechanisms leading from the initial insult to the development of inflammation and consequent renal fibrosis are incompletely understood and may involve, among others, mechanical stress to the glomerular walls due to intracapillary hypertension and/or tuft hypertrophy, direct chemical aggression to podocytes and other glomerular barrier elements, exposure of tubular cells to high protein concentrations in situations of intense proteinuria, and the participation of the renin–angiotensin–aldosterone system (RAAS) and of numerous cytokines, chemokines and growth factors. In recent years, the concept has been established that activation of innate immunity pathways, particularly that of the NF-ĸB system and of the NLPR3 inflammasome, is an important link between early events such as glomerular hypertension and advanced phenomena such as the development of renal fibrosis. This pathogenic association has been shown in several CKD models.</p>
<p>The expression of NLRP3, TLRs, and biglycan was shown to increase in mice subjected to UUO (<xref ref-type="bibr" rid="B124">Leemans et al., 2009</xref>; <xref ref-type="bibr" rid="B171">Pulskens et al., 2010</xref>; <xref ref-type="bibr" rid="B21">Braga et al., 2012</xref>; <xref ref-type="bibr" rid="B172">Pulskens et al., 2014</xref>). Conversely, MyD88 KO mice exhibited less fibrosis after UUO (<xref ref-type="bibr" rid="B21">Braga et al., 2012</xref>). TLR2 and TLR4, as well as the NLRP3 inflammasome, seem to be activated during the development of tubulointerstitial inflammation in mice receiving dietary adenine overload, which were protected from renal fibrosis when genes coding for these molecules were deleted (<xref ref-type="bibr" rid="B44">Correa-Costa et al., 2011</xref>). Accordingly, NLRP3 activation was associated with increased inflammation in a rat model of heavy proteinuria (<xref ref-type="bibr" rid="B59">Faustino et al., 2018</xref>). Recent data suggest that activation of these pathways persists throughout the development of CKD. In the 5/6 renal ablation model (Nx), the expression of innate immune-related molecules was highly expressed as early as 15 days and, for at least 60 days, after renal ablation (<xref ref-type="bibr" rid="B58">Fanelli et al., 2017</xref>).</p>
<p>The NF-ĸB cascade is another major intracellular pathway for the development of inflammation. In canonical NF-ĸB activation, the IkB kinase (IKK) degrades the inhibitory protein IkB, allowing heterodimers (e.g., p50/p65) to translocate from the cytosol to the nucleus, where they bind to the DNA and promote the transcription of a number of genes that code for proinflammatory mediators (<xref ref-type="bibr" rid="B81">Henkel et al., 1993</xref>). Evidence that the NF-ĸB system is involved in the development of renal inflammation and injury has been described in a variety of clinical and experimental renal diseases, such as diabetic kidney disease (<xref ref-type="bibr" rid="B119">Lee et al., 2004</xref>; <xref ref-type="bibr" rid="B234">Verzola et al., 2014</xref>), 5/6 renal ablation (<xref ref-type="bibr" rid="B66">Fujihara et al., 2007a</xref>;<xref ref-type="bibr" rid="B58">Fanelli et al., 2017</xref>), adenine overload (<xref ref-type="bibr" rid="B44">Correa-Costa et al., 2011</xref>; <xref ref-type="bibr" rid="B159">Okabe et al., 2013</xref>), and adriamycin nephropathy (<xref ref-type="bibr" rid="B59">Faustino et al., 2018</xref>).</p>
<p>Although diabetic nephropathy, hypertensive nephrosclerosis, and primary glomerulopathies are currently considered the main cause of end-stage renal disease (ESRD) (<xref ref-type="bibr" rid="B192">Saran et al., 2017</xref>), growing evidence indicates that AKI-associated renal inflammation may persist even after acute injury is overcome and renal function restored, giving rise to slowly progressive renal fibrosis (<xref ref-type="bibr" rid="B130">Liano et al., 2007</xref>; <xref ref-type="bibr" rid="B233">Venkatachalam et al., 2010</xref>; <xref ref-type="bibr" rid="B38">Chawla and Kimmel, 2012</xref>).</p>
<p>As a whole, these observations indicate that AKI and CKD share a number of inflammatory pathways whereby TLRs and NLRs are activated, along with immune cells such as macrophages, DCs, and lymphocytes. The exact mechanisms by which these cells and receptors are stimulated and the full consequences of their activation are currently under intense investigation, which is expected to provide novel therapeutic strategies for these diseases. In recent years, evidence has accumulated that the gut microbiota composition may be different in those two different diseases, and may trigger and/or amplify the inflammatory response in the kidney.</p>
</sec>
<sec id="s5">
<title>The Mutualistic Relationship Between Microbes and Human Body</title>
<p>The human body harbors complex communities of commensal microbes, including bacteria, archaea, fungi, viruses, and protozoa. The gastrointestinal tract is one of the largest interfaces between the human body (host) and the environment. The composition and activity of gut microbiota start before birth (<xref ref-type="bibr" rid="B94">Jimenez et al., 2005</xref>; <xref ref-type="bibr" rid="B95">Jimenez et al., 2008</xref>;<xref ref-type="bibr" rid="B1">Aagaard et al., 2014</xref>) and are influenced by a variety of factors, including birth mode (<xref ref-type="bibr" rid="B52">Dominguez-Bello et al., 2010</xref>), breastfeeding (<xref ref-type="bibr" rid="B143">Martin et al., 2012</xref>), age (<xref ref-type="bibr" rid="B252">Yatsunenko et al., 2012</xref>), geography (<xref ref-type="bibr" rid="B252">Yatsunenko et al., 2012</xref>), sanitation (<xref ref-type="bibr" rid="B68">Gao et al., 2017</xref>), use of antibiotics (<xref ref-type="bibr" rid="B166">Perez-Cobas et al., 2013</xref>), and exercising (<xref ref-type="bibr" rid="B43">Clarke et al., 2014</xref>).</p>
<p>Throughout the past century, evidence was amassed that microbe–host interactions modulate a large number of vital functions in the healthy human body, including host metabolism (<xref ref-type="bibr" rid="B156">Nicholson et al., 2012</xref>) and immunity (<xref ref-type="bibr" rid="B181">Rooks and Garrett, 2016</xref>), as well as cardiovascular and brain functions. In this mutualistic relationship, the intestine provides a very favorable environment for microbes, with free access to nutrients and controlled temperature. The gut microbiota, on the other hand, is intrinsically involved in the morphogenesis and physiology of the immune system, protecting the host from potential pathogens and regulating metabolism and nutrition. Additionally, the microbial metabolism utilizes enzymes that are not encoded by the human genome and generates several biologic products essential to the host’s health, such as bile acids, choline, vitamins, and short-chain fatty acids (SCFAs) (<xref ref-type="bibr" rid="B185">Rowland et al., 2018</xref>).</p>
<p>SCFAs are the main end products of dietary carbohydrate metabolized by the gut microbiota and made available to the host. The three most abundant SCFAs, acetate, propionate, and butyrate, participate in several host vital functions. Besides being used as energy source by colonocytes, SCFAs play a key role in the maintenance of intestinal barrier integrity. Butyrate seems to regulate the expression of claudin-1 and the redistribution of zona occludens-1 and occludin, which are essential components of the tight junction assembly (<xref ref-type="bibr" rid="B239">Wang H et al., 2012</xref>). SCFAs have also extraintestinal actions, including appetite regulation (<xref ref-type="bibr" rid="B63">Frost et al., 2014</xref>), glucose and lipid metabolism (<xref ref-type="bibr" rid="B48">den Besten et al., 2015</xref>; <xref ref-type="bibr" rid="B211">Soty et al., 2015</xref>), and immune regulation (<xref ref-type="bibr" rid="B181">Rooks and Garrett, 2016</xref>), as shown by recent studies. Exposure of neutrophils and peripheral blood mononuclear cells to SCFAs attenuated the activation of NF-ĸB and inhibited the production of proinflammatory cytokines (<xref ref-type="bibr" rid="B226">Usami et al., 2008</xref>; <xref ref-type="bibr" rid="B235">Vinolo et al., 2011</xref>; <xref ref-type="bibr" rid="B36">Chang et al., 2014</xref>). SCFAs also modulate the activity of Tregs, conferring protection conditions of sustained activation of immune system (<xref ref-type="bibr" rid="B207">Smith et al., 2013</xref>; <xref ref-type="bibr" rid="B222">Thorburn et al., 2015</xref>). These functions rely on the ability of SCFAs to inhibit histone deacetylases and their actions through a group of G protein–coupled receptors, which are able to respond to short-, medium-, or long-chain free fatty acids (<xref ref-type="bibr" rid="B79">Hara et al., 2013</xref>). This group includes GPR41 (FFAR3), GPR43 (FFAR2), and GPR109a (HCAR2), which are responsible for the action of SCFAs in a dose-dependent manner (<xref ref-type="bibr" rid="B28">Brown et al., 2003</xref>) and have been described in several cell types, such as adipocytes (<xref ref-type="bibr" rid="B69">Ge et al., 2008</xref>; <xref ref-type="bibr" rid="B237">Wanders et al., 2012</xref>), neurons (<xref ref-type="bibr" rid="B107">Kimura et al., 2011</xref>), immune cells (<xref ref-type="bibr" rid="B118">Le Poul et al., 2003</xref>; <xref ref-type="bibr" rid="B111">Kostylina et al., 2008</xref>), and vascular cells (<xref ref-type="bibr" rid="B89">Hughes-Large et al., 2014</xref>).</p>
<sec id="s5_1">
<title>Kidney Diseases and Dysbiosis</title>
<p>Low-grade inflammation is a major component not only of renal diseases but is also common ground for a variety of other noncommunicable diseases, including cardiovascular disease, metabolic syndrome, neurological disorders, and allergic conditions (<xref ref-type="bibr" rid="B30">Camps and Garcia-Heredia, 2014</xref>). The development and activation of the immune system are highly dependent on microbial–host interactions, and an unbalanced relationship can lead to sustained immune activation or inappropriate suppression (<xref ref-type="bibr" rid="B180">Rook, 2013</xref>). Several environmental and host-related factors can disturb the microbial ecosystem to such an extent that its resilience and resistance abilities are overcome. Despite the inexistence of a core microbiome shared among healthy individuals (<xref ref-type="bibr" rid="B90">Human Microbiome Project, 2012</xref>; <xref ref-type="bibr" rid="B252">Yatsunenko et al., 2012</xref>; <xref ref-type="bibr" rid="B135">Lloyd-Price et al., 2016</xref>), a common bacterial core is composed of four main phyla: Actinobacteria, Proteobacteria, Firmicutes, and Bacteroidetes (<xref ref-type="bibr" rid="B13">Arumugam et al., 2011</xref>). Mounting evidence indicates that compositional and functional changes in the gut microbiota (dysbiosis) are associated with intestinal and extraintestinal diseases.</p>
<p>Although it remains unclear whether alterations in gut microbiota caused by extrinsic factors could be the primary agent to trigger kidney injury, in the past years several studies clearly showed that impaired kidney function contributes to gut dysbiosis, which in turn aggravates kidney injury. The importance of gut microbiota in kidney diseases was demonstrated by <xref ref-type="bibr" rid="B92">Jang et al. (2009)</xref>, who showed that germ-free mice are more susceptible to kidney injury, whereas reintroduction of a gut microbiota conferred protection against the disease. Germ-free mice exhibited an abnormal high number of natural killer T cells and lower IL-4 levels in the kidneys, which were more susceptible to ischemia–reperfusion damage.</p>
<p>Growing evidence indicates that gut dysbiosis causes gut inflammation and impairs intestinal barrier integrity, resulting in activation of the NF-ĸB pathway and, ultimately, systemic inflammation (<xref ref-type="bibr" rid="B7">Anders et al., 2013</xref>). Disruption of intestinal barrier enables the translocation of bacterial endotoxins, such as lipopolysaccharide (LPS), leading to activation of immune cells at the lamina propria and to enhanced secretion of proinflammatory cytokines. Of note, endotoxemia is correlated with the risk of mortality in CKD patients (<xref ref-type="bibr" rid="B146">McIntyre et al., 2011</xref>). Microbial dysbiosis can also contribute to kidney failure through the accumulation of bacterial-produced uremic toxins, such as indoxyl sulfate (IS), p-cresol sulfate, and trimethylamine-N-oxide (TMAO). Using germ-free technology, <xref ref-type="bibr" rid="B246">Wikoff et al. (2009)</xref> demonstrated that the gut microbiome strongly influences the levels of several protein-bound uremic toxins. Under healthy conditions, these toxins are partially eliminated with the feces, whereas whatever amount absorbed by the intestine is excreted by the kidneys. Therefore, impairment of kidney function can lead to the retention of uremic toxins that originated in the gut. Several studies have observed high levels of these toxins in patients with kidney failure. Increased levels of p-cresol sulfate were found in patients with mild to moderate CKD and were associated with low estimated glomerular filtration rate (<xref ref-type="bibr" rid="B147">Meijers et al., 2010a</xref>). Likewise, circulating TMAO levels rise as kidney function declines in CKD patients (<xref ref-type="bibr" rid="B214">Stubbs et al., 2016</xref>) and correlate with lower long-term survival rates (<xref ref-type="bibr" rid="B220">Tang et al., 2015</xref>). Some studies reported adverse effects of uremic toxins on the kidney. These toxins instigate inflammation (<xref ref-type="bibr" rid="B151">Motojima et al., 2003</xref>) by increasing ROS production and the levels of proinflammatory cytokines (<xref ref-type="bibr" rid="B243">Watanabe et al., 2013</xref>) (<xref ref-type="fig" rid="f2">
<bold>Figure 2</bold>
</xref>). In addition, they can promote renal fibrosis through reduction of klotho expression and cell senescence (<xref ref-type="bibr" rid="B2">Adijiang et al., 2011</xref>).</p>
<p>It is noteworthy that, in turn, CKD can affect the status of gut microbiota, thus contributing to dysbiosis. Growing evidence has shown significant changes in the gut microbiota of CKD patients in terms of individual species (<xref ref-type="bibr" rid="B84">Hida et al., 1996</xref>; <xref ref-type="bibr" rid="B240">Wang I et al., 2012</xref>; <xref ref-type="bibr" rid="B230">Vaziri et al., 2013</xref>). Kidney diseases lead to metabolic acidosis, volume overload, recurrent use of antibiotics, prolonged colonic transit time (<xref ref-type="bibr" rid="B17">Bammens et al., 2003</xref>), intestinal wall edema (<xref ref-type="bibr" rid="B230">Vaziri et al., 2013</xref>), and reduction of dietary fiber intake (<xref ref-type="bibr" rid="B100">Kalantar-Zadeh et al., 2002</xref>), which can not only alter the intestinal permeability, but may cause an imbalance in gut microbiota. Moreover, profound changes can be induced by uremia <italic>per se</italic>. <xref ref-type="bibr" rid="B231">Vaziri et al. (2013)</xref> observed significant alterations in the abundance of 175 bacterial operational taxonomic units in nephrectomized rats, indicating that the effect of uremia is independent from interindividual variations, comorbid conditions, and dietary and medical interventions. Furthermore, ESRD patients showed expansion of bacterial families possessing enzymes that produce uremic toxins in detriment of those expressing enzymes that degrade fibers and generate SCFAs (<xref ref-type="bibr" rid="B247">Wong et al., 2014</xref>). This adverse scenario is further aggravated by the medical recommendation to reduce the intake of fruits and vegetables to avoid hyperkalemia. Because fiber-rich foods are the major source of resistance starch used to generate SCFAs, one can speculate that the consequent reduction in the production of SCFAs may contribute to kidney damage. Indeed, low intake of fiber forces a switch in the gut microbiota metabolism leading to decreased production of SCFAs and to the generation of harmful metabolites (<xref ref-type="bibr" rid="B54">Duncan et al., 2007</xref>; <xref ref-type="bibr" rid="B188">Russell et al., 2011</xref>). A potential additional adverse effect of fiber restriction was pointed out in an elegant experimental study showing that, in a scenario of dietary fiber deficiency, gut microbiota resorts to host-secreted mucus glycoproteins as a nutrient source, resulting in a thinner colonic mucus layer, which could contribute to enhanced pathogen susceptibility, endotoxemia, and, ultimately, systemic inflammation (<xref ref-type="bibr" rid="B50">Desai et al., 2016</xref>).</p>
</sec>
<sec id="s5_2">
<title>Gut Microbiota–Based Therapies</title>
<p>In an elegant study, <xref ref-type="bibr" rid="B169">Poesen et al. (2016)</xref> reported a high resemblance between the fecal metabolite profiles of CKD patients and those of their household contacts on the same diet, after adjustment for age, gender, body mass index, and the presence of diabetes mellitus. CKD-related changes in the human colonic microbial metabolism were largely attributable to dietary restrictions and, to a lesser extent, to loss of renal function. Thus, the plasticity of gut microbiota in response to environmental factors offers a potential avenue for therapeutic interventions aimed at slowing the progression of kidney disease and reducing cardiovascular risk factors in these patients.</p>
<sec id="s5_2_1">
<title>Dietary Fiber and Prebiotics</title>
<p>Dietary fiber has been defined as edible carbohydrate polymers (with three or more monomeric units), which are not enzymatically digested, hydrolyzed, or absorbed in the small intestine (<xref ref-type="bibr" rid="B98">Jones, 2014</xref>). Consumption of a fiber-rich diet has been linked to lower risk of allergy, depression, and cardiovascular disease (<xref ref-type="bibr" rid="B57">Estruch et al., 2013</xref>; <xref ref-type="bibr" rid="B178">Rice et al., 2015</xref>; <xref ref-type="bibr" rid="B189">Sanchez-Villegas et al., 2015</xref>). However, reduction in the intake of dietary fiber, present mostly in fruits and vegetables, is usually recommended to patients with advanced CKD in order to avoid the accumulation of potassium. Unfortunately, as mentioned earlier, fiber deprivation leads to a reduction of intestinal mucus barrier due to the overgrowth of mucin-degrading bacteria (<xref ref-type="bibr" rid="B50">Desai et al., 2016</xref>). Furthermore, mucus degradation may enhance pathogen susceptibility and bacteria translocation and exacerbate local and systemic inflammation status (<xref ref-type="bibr" rid="B50">Desai et al., 2016</xref>; <xref ref-type="bibr" rid="B8">Andersen et al., 2017</xref>). This dilemma can be addressed by a novel approach based on the administration of substances or living organisms aimed at modifying the intestinal bioma. This goal can be achieved by so-called prebiotics, probiotics, symbiotics, or postbiotics.</p>
</sec>
<sec id="s5_2_2">
<title>Prebiotics</title>
<p>The use of prebiotics, defined as nondigestible ingredients capable of stimulating the growth and/or activity of health-promoting bacteria, is a widely known strategy to alter the gut microbiota (<xref ref-type="bibr" rid="B19">Bindels et al., 2015</xref>). In both healthy and pathological conditions, prebiotics favor the growth of beneficial bacteria (e.g., bifidobacteria and lactobacilli), while suppressing potentially pathogenic microorganisms such as clostridia and enterobacteria (<xref ref-type="bibr" rid="B201">Silk et al., 2009</xref>). Inulin supplementation induced a selective increase of “healthy” gut microbiota components, including bifidobacteria, in a randomized double-blind, placebo-controlled, crossover trial (<xref ref-type="bibr" rid="B229">Vandeputte et al., 2017</xref>). In a similar study involving obese women, inulin treatment afforded equally beneficial results (<xref ref-type="bibr" rid="B51">Dewulf et al., 2013</xref>). Shifts in the gut microbiota composition induced by prebiotics are dependent on their carbon structure (<xref ref-type="bibr" rid="B145">Martinez et al., 2010</xref>) and on the microbial enzymatic ability to process them (<xref ref-type="bibr" rid="B110">Koropatkin et al., 2012</xref>). Recent data showed that, in patients with type 2 diabetes, dietary fiber intake promoted selective growth of a group of SCFA-producing strains, while most other potential SCFA producers were inhibited or remained unchanged. In addition, the growth of producers of harmful metabolites was diminished. These changes were accompanied by clinical benefits such as lower hemoglobin A<sub>1c</sub> levels (<xref ref-type="bibr" rid="B256">Zhao et al., 2018</xref>).</p>
<p>Besides their potential effect on the generation of SCFAs, plant-based diets exert other effects on metabolites produced by the gut microbiota. For instance, they contain less TMAO precursors compared to an animal-based diet (<xref ref-type="bibr" rid="B179">Richter et al., 2015</xref>). Experimental data showed that the consumption of amylose-enriched diet retards the progression of kidney damage through the attenuation of oxidative stress, inflammation, and fibrosis (<xref ref-type="bibr" rid="B232">Vaziri et al., 2014</xref>). Additionally, human interventional studies showed that fiber-rich diets and prebiotics ameliorated metabolic disorders (<xref ref-type="bibr" rid="B210">Sola et al., 2007</xref>; <xref ref-type="bibr" rid="B4">Aliasgharzadeh et al., 2015</xref>), reduced uremic toxins (<xref ref-type="bibr" rid="B148">Meijers et al., 2010b</xref>), and delayed the decline in glomerular filtration rate (<xref ref-type="bibr" rid="B165">Pavan, 2016</xref>). Moreover, epidemiological studies indicated that high total fiber intake is associated with lower risk of inflammation and mortality in CKD (<xref ref-type="bibr" rid="B113">Krishnamurthy et al., 2012</xref>). <xref ref-type="bibr" rid="B148">Meijers et al. (2010b)</xref> observed low serum concentrations of IS and p-cresol in hemodialysis patients under dietary prebiotic oligofructose-enriched inulin supplementation. Likewise, the intake of resistant starch improved renal function in CKD (<xref ref-type="bibr" rid="B41">Chiavaroli et al., 2015</xref>) and significantly decreased serum concentrations of uremic toxins in hemodialysis patients (<xref ref-type="bibr" rid="B205">Sirich et al., 2014</xref>). Extrarenal benefits have also been observed, such as weight loss and improved metabolism of glucose and lipids, lending further support to the therapeutic use of prebiotics (<xref ref-type="bibr" rid="B148">Meijers et al., 2010b</xref>; <xref ref-type="bibr" rid="B32">Cani et al., 2007</xref>).</p>
</sec>
<sec id="s5_2_3">
<title>Probiotics</title>
<p>The Food and Agriculture Organization of the United Nations and the World Health Organization define probiotics as “live microorganisms that when administered in adequate amounts confer a health benefit on the host” (<xref ref-type="bibr" rid="B85">Hill et al., 2014</xref>). Probiotics consist of living bacteria (mostly bifidobacteria and lactobacilli species) that can be added to food, drugs, and dietary supplements. As with prebiotics, oral administration of live microorganisms does not significantly change the composition of the indigenous gut microbiota in healthy adults (<xref ref-type="bibr" rid="B114">Kristensen et al., 2016</xref>). However, benefits of probiotic therapy have been extensively observed in several pathological scenarios, probably through the generation of bioactive metabolites and immunomodulation (<xref ref-type="bibr" rid="B109">Konstantinov et al., 2008</xref>).</p>
<p>Animal studies support the beneficial effects of probiotic therapy in CKD. Administration of <italic>Bacillus pasteurii</italic> and <italic>Lactobacillus sporogenes</italic> reduced blood urea nitrogen (BUN) levels and prolonged the life span of uremic rats (<xref ref-type="bibr" rid="B174">Ranganathan et al., 2005</xref>). Treatment with the urease-positive bacterium <italic>Sprosarcina pasteurii</italic> showed similar benefits by removing urea from the gut (<xref ref-type="bibr" rid="B175">Ranganathan et al., 2006</xref>). Similar to these findings, treatment of rats with 5/6 renal ablation with <italic>Lactobacillus acidophilus</italic> attenuated inflammation by reducing the serum levels of uremic toxins, such as IS and p-cresyl sulfate, and inflammatory mediators (LPS, C-reactive protein, and IL-6). At the same time, this treatment ameliorated urinary protein excretion and reduced the glomerulosclerosis index (<xref ref-type="bibr" rid="B253">Yoshifuji et al., 2016</xref>).</p>
<p>Clinical studies have also demonstrated that probiotic supplementation improves renal function. Simenhoff et al. (<xref ref-type="bibr" rid="B202">Simenhoff et al., 1996</xref>) first reported that oral administration of <italic>L. acidophilus</italic> lowered serum levels of the potential uremic toxin dimethylamine and nitrosodimethylamine in hemodialysis patients. Likewise, other studies have observed reduced levels of homocysteine and IS in hemodialysis patients under oral treatment with <italic>Bifidobacterium longum</italic> (<xref ref-type="bibr" rid="B217">Takayama et al., 2003</xref>; <xref ref-type="bibr" rid="B218">Taki et al., 2005</xref>). A 6-month supplementation with a blend of <italic>L. acidophilus</italic>, <italic>B. longum</italic>, and <italic>Streptococcus thermophilus</italic> ameliorated renal function and the quality of life of 46 patients in stage III or IV of CKD (<xref ref-type="bibr" rid="B176">Ranganathan et al., 2010</xref>).</p>
<p>Recently, genetically engineered bacteria have been used to reduce renal inflammation and proinflammatory mediators in intestinal diseases. Bacteria can be genetically modified to sense, kill, or restrain specific pathogens or to produce biomolecules, such as human hormones, ILs, and antibodies within specific organs or tissues (<xref ref-type="bibr" rid="B168">Pinero-Lambea et al., 2015</xref>). Oral administration of <italic>Lactococcus lactis</italic> resulted in local delivery of anti-TNF nanobodies at the colon and significantly reduced inflammation in mice with dextran sulfate sodium–induced chronic colitis (<xref ref-type="bibr" rid="B228">Vandenbroucke et al., 2010</xref>). Beneficial effects were also reported using a <italic>L. lactis</italic> strain engineered to secrete the anti-inflammatory cytokine IL-10 in Crohn disease (<xref ref-type="bibr" rid="B20">Braat et al., 2006</xref>). This cutting-edge therapeutic approach has also been applied in extraintestinal diseases. A strategy using a <italic>L. lactis</italic> strain engineered to secrete proinsulin and IL-10 induced autoantigen-specific long-term tolerance, allowing reversal of established autoimmune diabetes in mice (<xref ref-type="bibr" rid="B219">Takiishi et al., 2012</xref>). Engineered bacteria have also been used to emulate urease-producing bacteria. <xref ref-type="bibr" rid="B170">Prakash and Chang (1996)</xref> successfully used genetically modified <italic>Escherichia coli</italic> DH5 to remove urea and ammonia, hence lowering BUN in uremic rats.</p>
</sec>
<sec id="s5_2_4">
<title>Symbiotics</title>
<p>Combined therapies using prebiotics and probiotics (symbiotics) have been explored in an attempt to alleviate both the toxic effects of uremia and the gut dysbiosis associated with CKD. A randomized double-blind pilot study of CKD stages IV and V reported that a combination of high-molecular-weight inulin, fructo-oligosaccharides, galacto-oligosaccharides, lactobacilli, bifidobacteria, and streptococci altered the stool microbiome, particularly with enrichment of <italic>Bifidobacterium</italic> and depletion of <italic>Ruminococcaceae</italic>, and reduced plasma concentrations of p-cresol (<xref ref-type="bibr" rid="B183">Rossi et al., 2016</xref>). Likewise, 4-week treatment with the commercially available symbiotic Probinul-neutro<sup>®</sup> decreased p-cresol levels in patients with CKD stages III and IV (<xref ref-type="bibr" rid="B77">Guida et al., 2014</xref>). Additionally, a therapeutic combination of galacto-oligosaccharides and <italic>Lactobacillus casei</italic> strain Shirota and <italic>Bifidobacterium breve</italic> strain Yakult led to normalization of bowel habits and a decrease of serum p-cresol levels in hemodialysis patients (<xref ref-type="bibr" rid="B153">Nakabayashi et al., 2011</xref>).</p>
<p>Despite the benefits observed in a variety of diseases, the success of probiotic-based therapies seems to depend heavily on the pathological condition and on the selected microbial species chosen. For example, treatment with <italic>E. coli</italic> Nissle 1917 is recommended in cases of constipation in adults (<xref ref-type="bibr" rid="B42">Chmielewska and Szajewska, 2010</xref>), while <italic>Bacillus coagulans</italic> seems suitable to treat antibiotic-associated diarrhea (<xref ref-type="bibr" rid="B80">Hempel et al., 2012</xref>). Further investigation is needed to ensure the safety and the effectiveness of probiotics in different populations and diseases.</p>
</sec>
<sec id="s5_2_5">
<title>Postbiotics</title>
<p>The use of postbiotics, also known as metabiotics, has been recently proposed as an adjunctive or alternative therapeutic approach for a healthier gut homeostasis and mucosal immune system. The term <italic>postbiotic</italic> has been coined to designate products from nonviable bacteria or metabolic byproducts from probiotic microorganisms, such as vitamins, SCFAs, cell surface proteins, and enzymes that can affect positively the gut microbiome and the host (<xref ref-type="bibr" rid="B164">Patel and Denning, 2013</xref>). According to <xref ref-type="bibr" rid="B196">Shenderov (2013)</xref>, postbiotics have favorable absorption, metabolism, distribution, and excretion properties, which could indicate a high capacity to elicit favorable biological responses in different organs in the host (<xref ref-type="bibr" rid="B3">Aguilar-Toala et al., 2018</xref>). Although the postbiotic therapy has never been applied in CKD, it is noteworthy that many commensal bacteria produce SCFAs, which, as pointed out earlier, exert a number of beneficial effects. Regarding kidney diseases, <xref ref-type="bibr" rid="B10">Andrade-Oliveira et al. (2015)</xref> reported that treatment with SCFAs reduces kidney injury induced by ischemia–reperfusion by protecting the renal tissue against inflammation and oxidative stress and by increasing autophagy, reducing apoptosis, and improving mitochondrial biogenesis.</p>
</sec>
<sec id="s5_2_6">
<title>Fecal Microbiota Transplantation</title>
<p>Fecal microbiota transplantation (FMT) refers to the introduction of indigenous intestinal microbes from a healthy donor using capsules or colonoscopy into a dysbiotic gut, aiming to restore the microbial community. FMT differs from probiotic therapy in that the donor material is a mixture of undefined microorganisms, including bacteria, yeasts, parasites, and viruses (<xref ref-type="bibr" rid="B85">Hill et al., 2014</xref>). Although the first reports date back over 1,700 years (<xref ref-type="bibr" rid="B255">Zhang et al., 2012</xref>), FMT is a relatively new therapy for recurrent or refractory <italic>Clostridium difficile</italic> infection (CDI), being moderately recommended as an alternative treatment for a third recurrent CDI after a pulsed vancomycin regimen (<xref ref-type="bibr" rid="B215">Surawicz et al., 2013</xref>). The mechanism of action of FMT is unclear. The high rates of resolution of CDI may be due to the infusion of large amounts of bacteria to the gut and/or a variety of metabolites present in the donor sample (<xref ref-type="bibr" rid="B37">Chanyi et al., 2017</xref>). FMT has been used in conditions other than CDI, such as metabolic syndrome (<xref ref-type="bibr" rid="B236">Vrieze et al., 2012</xref>), autism (<xref ref-type="bibr" rid="B101">Kang et al., 2017</xref>), and multiple sclerosis (<xref ref-type="bibr" rid="B140">Makkawi et al., 2018</xref>), although the results with irritable bowel syndrome were disappointing (<xref ref-type="bibr" rid="B78">Halkjaer et al., 2018</xref>). Clinical studies focusing on the possible beneficial effects of FMT on CKD are lacking. Only anecdotal cases of recurrent infections in a patient with ESRD (<xref ref-type="bibr" rid="B204">Singh et al., 2014</xref>) and in a kidney graft recipient (<xref ref-type="bibr" rid="B18">Biehl et al., 2018</xref>) have been reported.</p>
<p>Despite their positive effects on the levels of uric acid and BUN, no prebiotic-, probiotic-, or symbiotic-based approaches have been shown to normalize the levels of uremic toxins. Moreover, the long-term impact of these therapies on CKD progression remains unknown due to a number of limitations, such as small sample size and short duration of studies. Larger clinical studies are needed in order to ascertain the possible application of these innovative strategies in the treatment of CKD.</p>
</sec>
</sec>
</sec>
<sec id="s6">
<title>Repurposed Drugs to Target Renal Inflammation</title>
<p>Recent studies have shown unexpected beneficial effects for repurposed or emerging drugs in the context of AKI and CKD. Several drugs and compounds used to modulate inflammation and immune response in experimental and/or human conditions, such as gout, hypertension, autoimmune diseases, cancer, and organ transplantation, may exert renoprotection by limiting oxidative stress and inflammation. These drugs may exert anti-inflammatory effects by acting on one or more pathogenic pathways such as the RAAS, the innate immune response, and/or the adaptive immunity.</p>
<sec id="s6_1">
<title>RAAS Inhibition in Kidney Inflammation</title>
<p>RAAS inhibition is one of the most widely used therapies for the control of hypertension, a leading risk factor for CKD, along with diabetes mellitus. In addition, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are extensively used to prevent or delay the progression of established CKD (<xref ref-type="bibr" rid="B127">Lewis et al., 1993</xref>; <xref ref-type="bibr" rid="B26">Brenner et al., 2001</xref>; <xref ref-type="bibr" rid="B128">Lewis et al., 2001</xref>). Evidence amassed in the past three decades shows that, besides their hemodynamic effects, ACEIs and ARBs directly influence the immune response (<xref ref-type="bibr" rid="B200">Shimada and Yazaki, 1978</xref>). Angiotensin II stimulates the expression of inflammatory mediators such as cytokines, chemokines (<xref ref-type="bibr" rid="B186">Ruiz-Ortega et al., 1998</xref>; <xref ref-type="bibr" rid="B86">Hisada et al., 1999</xref>), growth factors (<xref ref-type="bibr" rid="B99">Kagami et al., 1994</xref>; <xref ref-type="bibr" rid="B97">Johnson et al., 1992</xref>), and adhesion molecules (<xref ref-type="bibr" rid="B75">Gräfe et al., 1997</xref>) in renal parenchymal and immune cells, as well as splenic lymphocyte proliferation (<xref ref-type="bibr" rid="B154">Nataraj et al., 1999</xref>). Moreover, intrarenal angiotensin II production may participate in local inflammation (<xref ref-type="bibr" rid="B71">Gilbert et al., 1999</xref>; <xref ref-type="bibr" rid="B74">Gonçalves et al., 2004</xref>), whereas RAAS blockade was shown to provide hemodynamic-independent renoprotection (<xref ref-type="bibr" rid="B76">Griffin and Bidani, 2006</xref>). An extremely high dose of losartan ameliorated renal injury and promoted regression of hypertension and albuminuria in the Nx model by reducing the renal macrophage infiltration and the interstitial angiotensin II expression, rather than by lowering intraglomerular pressure (<xref ref-type="bibr" rid="B64">Fujihara et al., 2005</xref>). Losartan also exerted effective renoprotection and anti-inflammatory effects in the streptozotocin diabetes model (<xref ref-type="bibr" rid="B221">Teles et al., 2009</xref>). These beneficial effects were markedly amplified when losartan was administered along with hydrochlorothiazide (<xref ref-type="bibr" rid="B65">Fujihara et al., 2007b</xref>), even when the combined therapy was started after renal injury was already advanced (<xref ref-type="bibr" rid="B12">Arias et al., 2013</xref>). The renoprotective effect of RAAS inhibitors may be partially mediated by limiting activation of the NF-κB pathway (<xref ref-type="fig" rid="f2">
<bold>Figure 2</bold>
</xref>), known to be activated by angiotensin II in experimental CKD (<xref ref-type="bibr" rid="B187">Ruiz-Ortega et al., 2006</xref>).</p>
<p>Few studies have investigated the anti‐inflammatory potential of RAAS-blocking agents in humans. The use of ACEIs is associated with lower plasma TNF-α and C‐reactive protein levels in patients with advanced CKD (<xref ref-type="bibr" rid="B213">Stenvinkel et al., 1999</xref>). A comparative study showed that the ACEI ramipril and, especially, the ARB valsartan lowered the IL-6 levels in hemodialysis patients (<xref ref-type="bibr" rid="B67">Gamboa et al., 2012</xref>). In addition, losartan treatment prevented the differentiation of monocytes into proinflammatory CD14<sup>+</sup>CD16<sup>+</sup> cells (<xref ref-type="bibr" rid="B149">Merino et al., 2012</xref>) and of oxidative stress–related inflammation (<xref ref-type="bibr" rid="B104">Kayabasi et al., 2013</xref>) in hemodialysis patients. However, other studies failed to show blood pressure–independent anti-inflammatory effects of ARBs in hemodialysis patients (<xref ref-type="bibr" rid="B161">Ordaz-Medina et al., 2010</xref>; <xref ref-type="bibr" rid="B167">Peters et al., 2017</xref>). Thus, further studies are needed to clarify the effect of the RAAS blockers on human renal inflammation.</p>
</sec>
<sec id="s6_2">
<title>Allopurinol Inhibits Activation of the Renal NLRP3 Inflammasome</title>
<p>Hyperuricemia is present in 20% to 35% of patients with CKD (<xref ref-type="bibr" rid="B195">Shan et al., 2010</xref>; <xref ref-type="bibr" rid="B131">Lin et al., 2012</xref>). Although hyperuricemia is usually asymptomatic, urate crystals may accumulate in tissues such as articular synovium, causing joint inflammation and the symptoms usually associated with gout (<xref ref-type="bibr" rid="B244">Watson, 1899</xref>; <xref ref-type="bibr" rid="B158">Ogryzlo et al., 1966</xref>; <xref ref-type="bibr" rid="B209">So and Thorens, 2010</xref>). Whether hyperuricemia is a real risk factor or just a biomarker of renal and cardiovascular injury is presently unclear. However, recent studies suggest that reducing circulating uric acid slows the progression of CKD (<xref ref-type="bibr" rid="B206">Siu et al., 2006</xref>; <xref ref-type="bibr" rid="B72">Goicoechea et al., 2010</xref>). Allopurinol, a prodrug of oxipurinol, a xanthine oxidase inhibitor, is widely employed in the treatment of hyperuricemia (<xref ref-type="bibr" rid="B190">Sanders et al., 1997</xref>). Besides reducing uric acid production, xanthine oxidase inhibition by allopurinol also diminishes ROS production, thus exerting antioxidant and anti-inflammatory effects (<xref ref-type="bibr" rid="B16">Bakris et al., 1990</xref>; <xref ref-type="bibr" rid="B44">Correa-Costa et al., 2011</xref>). It is noteworthy that both crystals of uric acid and ROS can activate the NLRP3 inflammasome (<xref ref-type="bibr" rid="B152">Mulay and Anders, 2017</xref>). Furthermore, emerging evidence indicates that soluble uric acid is equally capable of activating this inflammasome complex in renal cells and that allopurinol inhibits this process (<xref ref-type="bibr" rid="B44">Correa-Costa et al., 2011</xref>; <xref ref-type="bibr" rid="B251">Xiao et al., 2015</xref>) (<xref ref-type="fig" rid="f2">
<bold>Figure 2</bold>
</xref>). Accordingly, NLRP3 inhibition following allopurinol treatment ameliorated renal inflammation and injury in experimental diabetic kidney disease (<xref ref-type="bibr" rid="B106">Kim et al., 2015</xref>). In the UUO model, allopurinol reduced the renal content of soluble uric acid and inhibited NLRP3 activation, preventing the progression of proteinuria, as well as renal fibrosis and inflammation (<xref ref-type="bibr" rid="B23">Braga et al., 2017b</xref>). In a recent study of the Nx model, we showed that allopurinol reduced soluble renal uric acid and oxidative stress, thus reducing NLRP3 activation and IL-1β levels, as well as tubulointerstitial inflammation and fibrosis (<xref ref-type="bibr" rid="B61">Foresto-Neto et al., 2018</xref>).</p>
<p>Inhibition of uric acid synthesis can also exert beneficial effects in human CKD. In a 2-year randomized controlled trial, Goicoechea et al. (<xref ref-type="bibr" rid="B72">Goicoechea et al., 2010</xref>) showed that treatment with allopurinol prevented the progressive decline in glomerular filtration rate in patients with CKD of various etiologies. In a <italic>post hoc</italic> analysis of these patients 5 years later, it was shown that long-term treatment with allopurinol not only slowed CKD progression, but also reduced cardiovascular risk (<xref ref-type="bibr" rid="B73">Goicoechea et al., 2015</xref>). Similar findings were obtained in a 3-year randomized parallel-controlled study of type 2 diabetic patients with asymptomatic hyperuricemia (<xref ref-type="bibr" rid="B134">Liu et al., 2015</xref>). As a whole, these experimental studies and randomized trials reinforce the view that allopurinol can contribute to slow the progression of renal disease.</p>
</sec>
<sec id="s6_3">
<title>NF-κB Inhibition Slows CKD Progression</title>
<p>Inhibition of NF-κB, a major innate immunity pathway, has been proposed as a strategy to reduce inflammation and retard or detain the progression of a number of renal diseases (<xref ref-type="bibr" rid="B191">Sanz et al., 2010</xref>). NF-κB activation can be blocked by preventing IkB degradation. The antioxidant compound pyrrolidine dithiocarbamate (PDTC) inhibits IKK, thus preventing NF-ĸB activation (<xref ref-type="bibr" rid="B194">Schreck et al., 1992</xref>) (<xref ref-type="fig" rid="f2">
<bold>Figure 2</bold>
</xref>). In NX model, PDTC treatment inhibited activation of renal NF-ĸB and, ameliorated glomerular and interstitial injury in the Nx model (<xref ref-type="bibr" rid="B66">Fujihara et al., 2007a</xref>). In rats receiving adenine overload, PDTC strongly attenuated renal interstitial fibrosis (<xref ref-type="bibr" rid="B160">Okabe et al., 2013</xref>). In both studies, PDTC markedly reduced renal infiltration by macrophages, underlining its anti-inflammatory effect. Accordingly, in an experimental model of CKD by type 1 diabetes, renal NF-ĸB was activated in association with increased MCP-1 gene expression and macrophage infiltration as early as 1 month after induction of diabetes mellitus. PDTC reduced renal inflammation at this time point, although its long-term effect on kidney injury was not assessed (<xref ref-type="bibr" rid="B119">Lee et al., 2004</xref>).</p>
<p>Interestingly, rats treated with PDTC during lactation developed hypertension as adults, in association with early activation of the RAAS and upregulation of sodium transporters, without renal structural damage or functional impairment (<xref ref-type="bibr" rid="B31">Canale et al., 2011</xref>), in contrast with the severe renal damage caused by neonatal losartan (<xref ref-type="bibr" rid="B138">Machado et al., 2008</xref>). This finding suggests that the NF-κB system is needed during nephrogenesis for adequate renal control of blood pressure in adult life, but not for nephrogenesis. In a subsequent study (<xref ref-type="bibr" rid="B14">Ávila et al., 2019</xref>), rats that had received neonatal PDTC were subjected to uninephrectomy and salt overload in adult life. These animals exhibited marked NF-ĸB activation and developed severe inflammation and injury to glomerular, interstitial, and arterioles. Curiously, treatment of adult rats with losartan inhibited renal NF-κB and attenuated renal injury/inflammation.</p>
<p>Parthenolide is a sesquiterpene lactone that occurs naturally in some plants and has been proposed as an NF-ĸB inhibitor (<xref ref-type="bibr" rid="B136">López-Franco et al., 2006</xref>) (<xref ref-type="fig" rid="f2">
<bold>Figure 2</bold>
</xref>). However, few data are available regarding the effect of parthenolide in kidney diseases. In cisplatin-induced renal damage, parthenolide reduced renal injury and inflammation (<xref ref-type="bibr" rid="B62">Francescato et al., 2007</xref>). In the UUO model, parthenolide reduced renal monocyte/macrophage infiltration and attenuated renal injury (<xref ref-type="bibr" rid="B56">Esteban et al., 2004</xref>). Although some drugs currently employed in the treatment of kidney diseases possess anti-inflammatory effects and can inhibit renal NF-κB activation (<xref ref-type="bibr" rid="B55">Esteban et al., 2003</xref>), no specific NF-κB inhibitor is available for human use. Systemic inhibition of NF-κB may cause substantial adverse effects, since NF-κB is required for adequate nephrogenesis, immune responses, and cell survival. Thus, understanding the mechanisms underlying NF-κB activation and/or inhibition in renal diseases is crucial for the development of more specific regulators, allowing this system to become an important therapeutic target in the quest to prevent the progression of human kidney disease.</p>
</sec>
</sec>
<sec id="s7">
<title>Concluding Remarks</title>
<p>Renal inflammation is central to the development of both AKI and CKD, as well as to the transition of AKI to CKD. Activation of major pathways of innate immunity, such as the NF-ĸB system and the NLRP3 inflammasome, is one of the main factors triggering renal inflammation in both AKI and CKD. The role of the gut microbiota in the pathogenesis of inflammation and its dynamic relationship with renal disease have been unraveled in recent years. New avenues of investigation and new therapeutic perspectives have been opened with the development of suitable NLRP3 and NF-ĸB inhibitors, as well as of strategies centered on the manipulation of the gut microbiota. Additional therapeutic possibilities are provided by the repurposing of old drugs such as allopurinol. New clinical trials will establish the value of these novel approaches for a better comprehension of the mechanisms underlying the pathogenesis of AKI and CKD and for the development of innovative therapeutic strategies in the management of these serious conditions.</p>
</sec>
<sec id="s8">
<title>Author Contributions</title>
<p>VA-O, OF-N and IW conceived the figures and wrote the manuscript. RZ and NC conceived the idea, wrote and supervisioned the manuscript.</p>
</sec>
<sec id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This work was financially supported by the São Paulo Research Foundation (FAPESP- grants n° 2012/10926-5, 2013/12256-0, 2017/05264-7, 2018/17513-4, and 2019/02893-9) and the National Council for Scientific and Technological Development (CNPq) award (303684/2013-5). This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior–Brasil (CAPES)–Finance Code 001.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aagaard</surname><given-names>K.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Antony</surname><given-names>K. M.</given-names></name><name><surname>Ganu</surname><given-names>R.</given-names></name><name><surname>Petrosino</surname><given-names>J.</given-names></name><name><surname>Versalovic</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>The placenta harbors a unique microbiome</article-title>. <source/>Sci. Translatl. Med.
<volume>6</volume> (<issue>237</issue>), <fpage>237ra65</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3008599</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adijiang</surname><given-names>A.</given-names></name><name><surname>Shimizu</surname><given-names>H.</given-names></name><name><surname>Higuchi</surname><given-names>Y.</given-names></name><name><surname>Nishijima</surname><given-names>F.</given-names></name><name><surname>Niwa</surname><given-names>T.</given-names></name></person-group> (<year>2011</year>). <article-title>Indoxyl sulfate reduces klotho expression and promotes senescence in the kidneys of hypertensive rats</article-title>. <source/>J. Renal Nutr.
<volume>21</volume> (<issue>1</issue>), <fpage>105</fpage>–<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1053/j.jrn.2010.10.020</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aguilar-Toala</surname><given-names>J. E.</given-names></name><name><surname>Garcia-Valera</surname><given-names>H.</given-names></name><name><surname>Garcia</surname><given-names>H. S.</given-names></name><name><surname>Mata-Haro</surname><given-names>V.</given-names></name><name><surname>Gonzalez-Cordova</surname><given-names>A. F.</given-names></name><name><surname>Vallejo-Cordoba</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Postbiotics: an evolving term within the functional foods field</article-title>. <source/>Trends Food Sci. Technol.
<volume>75</volume>, <fpage>105</fpage>–<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1016/j.tifs.2018.03.009</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aliasgharzadeh</surname><given-names>A.</given-names></name><name><surname>Dehghan</surname><given-names>P.</given-names></name><name><surname>Gargari</surname><given-names>B. P.</given-names></name><name><surname>Asghari-Jafarabadi</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Resistant dextrin, as a prebiotic, improves insulin resistance and inflammation in women with type 2 diabetes: a randomised controlled clinical trial</article-title>. <source/>Br. J. Nutr.
<volume>113</volume> (<issue>2</issue>), <fpage>321</fpage>–<lpage>330</lpage>. <pub-id pub-id-type="doi">10.1017/S0007114514003675</pub-id>
<pub-id pub-id-type="pmid">27028002</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Allam</surname><given-names>R.</given-names></name><name><surname>Scherbaum</surname><given-names>C. R.</given-names></name><name><surname>Darisipudi</surname><given-names>M. N.</given-names></name><name><surname>Mulay</surname><given-names>S. R.</given-names></name><name><surname>Hagele</surname><given-names>H.</given-names></name><name><surname>Lichtnekert</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Histones from dying renal cells aggravate kidney injury <italic>via</italic> TLR2 and TLR4</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>23</volume> (<issue>8</issue>), <fpage>1375</fpage>–<lpage>1388</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2011111077</pub-id>
<pub-id pub-id-type="pmid">22677551</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amano</surname><given-names>M. T.</given-names></name><name><surname>Castoldi</surname><given-names>A.</given-names></name><name><surname>Andrade-Oliveira</surname><given-names>V.</given-names></name><name><surname>Latancia</surname><given-names>M. T.</given-names></name><name><surname>Terra</surname><given-names>F. F.</given-names></name><name><surname>Correa-Costa</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>The lack of PI3Kgamma favors M1 macrophage polarization and does not prevent kidney diseases progression</article-title>. <source/>Int. Immunopharmacol.
<volume>64</volume>, <fpage>151</fpage>–<lpage>161</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2018.08.020</pub-id>
<pub-id pub-id-type="pmid">30176533</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anders</surname><given-names>H. J.</given-names></name><name><surname>Andersen</surname><given-names>K.</given-names></name><name><surname>Stecher</surname><given-names>B.</given-names></name></person-group> (<year>2013</year>). <article-title>The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease</article-title>. <source/>Kidney Int.
<volume>83</volume> (<issue>6</issue>), <fpage>1010</fpage>–<lpage>1016</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2012.440</pub-id>
<pub-id pub-id-type="pmid">23325079</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andersen</surname><given-names>K.</given-names></name><name><surname>Kesper</surname><given-names>M. S.</given-names></name><name><surname>Marschner</surname><given-names>J. A.</given-names></name><name><surname>Konrad</surname><given-names>L.</given-names></name><name><surname>Ryu</surname><given-names>M.</given-names></name><name><surname>Kumar Vr</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Intestinal dysbiosis, barrier dysfunction, and bacterial translocation account for CKD-related systemic inflammation</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>28</volume> (<issue>1</issue>), <fpage>76</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2015111285</pub-id>
<pub-id pub-id-type="pmid">27151924</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andrade-Oliveira</surname><given-names>V.</given-names></name><name><surname>Campos</surname><given-names>E. F.</given-names></name><name><surname>Goncalves-Primo</surname><given-names>A.</given-names></name><name><surname>Grenzi</surname><given-names>P. C.</given-names></name><name><surname>Medina-Pestana</surname><given-names>J. O.</given-names></name><name><surname>Tedesco-Silva</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>TLR4 mRNA levels as tools to estimate risk for early posttransplantation kidney graft dysfunction</article-title>. <source/>Transplantation
<volume>94</volume> (<issue>6</issue>), <fpage>589</fpage>–<lpage>595</lpage>. <pub-id pub-id-type="doi">10.1097/TP.0b013e31825db680</pub-id>
<pub-id pub-id-type="pmid">22892989</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andrade-Oliveira</surname><given-names>V.</given-names></name><name><surname>Amano</surname><given-names>M. T.</given-names></name><name><surname>Correa-Costa</surname><given-names>M.</given-names></name><name><surname>Castoldi</surname><given-names>A.</given-names></name><name><surname>Felizardo</surname><given-names>R. J.</given-names></name><name><surname>de Almeida</surname><given-names>D. C.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Gut bacteria products prevent aki induced by ischemia–reperfusion</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>26</volume> (<issue>8</issue>), <fpage>1877</fpage>–<lpage>1888</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2014030288</pub-id>
<pub-id pub-id-type="pmid">25589612</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andrade-Silva</surname><given-names>M.</given-names></name><name><surname>Cenedeze</surname><given-names>M. A.</given-names></name><name><surname>Perandini</surname><given-names>L. A.</given-names></name><name><surname>Felizardo</surname><given-names>R. J. F.</given-names></name><name><surname>Watanabe</surname><given-names>I. K. M.</given-names></name><name><surname>Agudelo</surname><given-names>J. S. H.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>TLR2 and TLR4 play opposite role in autophagy associated with cisplatin-induced acute kidney injury</article-title>. <source/>Clin. Sci. (Lond)
<volume>132</volume> (<issue>16</issue>), <fpage>1725</fpage>–<lpage>1739</lpage>. <pub-id pub-id-type="doi">10.1042/CS20170262</pub-id>
<pub-id pub-id-type="pmid">29500224</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arias</surname><given-names>S. C.</given-names></name><name><surname>Valente</surname><given-names>C. P.</given-names></name><name><surname>Machado</surname><given-names>F. G.</given-names></name><name><surname>Fanelli</surname><given-names>C.</given-names></name><name><surname>Origassa</surname><given-names>C. S.</given-names></name><name><surname>de Brito</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan–hydrochlorothiazide association in a model of very advanced nephropathy</article-title>. <source/>PLoS One
<volume>8</volume> (<issue>2</issue>), <elocation-id>e56215</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0056215</pub-id>
<pub-id pub-id-type="pmid">23431367</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arumugam</surname><given-names>M.</given-names></name><name><surname>Raes</surname><given-names>J.</given-names></name><name><surname>Pelletier</surname><given-names>E.</given-names></name><name><surname>Le Paslier</surname><given-names>D.</given-names></name><name><surname>Yamada</surname><given-names>T.</given-names></name><name><surname>Mende</surname><given-names>D. R.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Enterotypes of the human gut microbiome</article-title>. <source/>Nature.
<volume>473</volume> (<issue>7346</issue>), <fpage>174</fpage>–<lpage>180</lpage>. <pub-id pub-id-type="doi">10.1038/nature09944</pub-id>
<pub-id pub-id-type="pmid">21508958</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ávila</surname><given-names>V. F.</given-names></name><name><surname>Foresto-Neto</surname><given-names>O.</given-names></name><name><surname>Arias</surname><given-names>S. C. A.</given-names></name><name><surname>Faustino</surname><given-names>V. D.</given-names></name><name><surname>Malheiros</surname><given-names>D. M. A. C.</given-names></name><name><surname>Camara</surname><given-names>N. O. S.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Pathogenic role of angiotensin II and the NF-κB system in a model of malignant hypertensive nephrosclerosis</article-title>. <source/>Hypertens. Res.
<volume>42</volume>, <fpage>779</fpage>–<lpage>789</lpage>. <pub-id pub-id-type="doi">10.1038/s41440-019-0226-6</pub-id>
<pub-id pub-id-type="pmid">30809002</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Awad</surname><given-names>A. S.</given-names></name><name><surname>Rouse</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Vergis</surname><given-names>A. L.</given-names></name><name><surname>Reutershan</surname><given-names>J.</given-names></name><name><surname>Cathro</surname><given-names>H. P.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury</article-title>. <source/>Kidney Int.
<volume>75</volume> (<issue>7</issue>), <fpage>689</fpage>–<lpage>698</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2008.648</pub-id>
<pub-id pub-id-type="pmid">19129795</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bakris</surname><given-names>G. L.</given-names></name><name><surname>Lass</surname><given-names>N.</given-names></name><name><surname>Gaber</surname><given-names>A. O.</given-names></name><name><surname>Jones</surname><given-names>J. D.</given-names></name><name><surname>Burnett</surname><given-names>J. C.</given-names></name></person-group> (<year>1990</year>). <article-title>Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals</article-title>. <source/>Am. J. Physiol.
<volume>258</volume> (<issue>1 Pt 2</issue>), <fpage>F115</fpage>–<lpage>F120</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.1990.258.1.F115</pub-id>
<pub-id pub-id-type="pmid">2301588</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bammens</surname><given-names>B.</given-names></name><name><surname>Verbeke</surname><given-names>K.</given-names></name><name><surname>Vanrenterghem</surname><given-names>Y.</given-names></name><name><surname>Evenepoel</surname><given-names>P.</given-names></name></person-group> (<year>2003</year>). <article-title>Evidence for impaired assimilation of protein in chronic renal failure</article-title>. <source/>Kidney Int.
<volume>64</volume> (<issue>6</issue>), <fpage>2196</fpage>–<lpage>2203</lpage>. <pub-id pub-id-type="doi">10.1046/j.1523-1755.2003.00314.x</pub-id>
<pub-id pub-id-type="pmid">14633143</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Biehl</surname><given-names>L. M.</given-names></name><name><surname>Cruz Aguilar</surname><given-names>R.</given-names></name><name><surname>Farowski</surname><given-names>F.</given-names></name><name><surname>Hahn</surname><given-names>W.</given-names></name><name><surname>Nowag</surname><given-names>A.</given-names></name><name><surname>Wisplinghoff</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Fecal microbiota transplantation in a kidney transplant recipient with recurrent urinary tract infection</article-title>. <source/>Infection
<volume>46</volume> (<issue>6</issue>), <fpage>871</fpage>–<lpage>874</lpage>. <pub-id pub-id-type="doi">10.1007/s15010-018-1190-9</pub-id>
<pub-id pub-id-type="pmid">30109576</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bindels</surname><given-names>L. B.</given-names></name><name><surname>Delzenne</surname><given-names>N. M.</given-names></name><name><surname>Cani</surname><given-names>P. D.</given-names></name><name><surname>Walter</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Towards a more comprehensive concept for prebiotics</article-title>. <source/>Nat. Rev. Gastroenterol. Hepatol.
<volume>12</volume> (<issue>5</issue>), <fpage>303</fpage>–<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1038/nrgastro.2015.47</pub-id>
<pub-id pub-id-type="pmid">25824997</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Braat</surname><given-names>H.</given-names></name><name><surname>Rottiers</surname><given-names>P.</given-names></name><name><surname>Hommes</surname><given-names>D. W.</given-names></name><name><surname>Huyghebaert</surname><given-names>N.</given-names></name><name><surname>Remaut</surname><given-names>E.</given-names></name><name><surname>Remon</surname><given-names>J. P.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease</article-title>. <source/>Clinical Gastroenterol. Hepatol.
<volume>4</volume> (<issue>6</issue>), <fpage>754</fpage>–<lpage>759</lpage>. <pub-id pub-id-type="doi">10.1016/j.cgh.2006.03.028</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Braga</surname><given-names>T. T.</given-names></name><name><surname>Correa-Costa</surname><given-names>M.</given-names></name><name><surname>Guise</surname><given-names>Y. F.</given-names></name><name><surname>Castoldi</surname><given-names>A.</given-names></name><name><surname>de Oliveira</surname><given-names>C. D.</given-names></name><name><surname>Hyane</surname><given-names>M. I.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>MyD88 signaling pathway is involved in renal fibrosis by favoring a T<sub>H</sub>2 immune response and activating alternative M2 macrophages</article-title>. <source/>Mol Med.
<month>10</month>
<volume>2418</volume>, <fpage>1231</fpage>–<lpage>1239</lpage>. <pub-id pub-id-type="doi">10.2119/molmed.2012.00131</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Braga</surname><given-names>T. T.</given-names></name><name><surname>Correa-Costa</surname><given-names>M.</given-names></name><name><surname>Azevedo</surname><given-names>H.</given-names></name><name><surname>Silva</surname><given-names>R. C.</given-names></name><name><surname>Cruz</surname><given-names>M. C.</given-names></name><name><surname>Almeida</surname><given-names>M. E.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Early infiltration of p40IL12(+)CCR7(+)CD11b(+) cells is critical for fibrosis development</article-title>. <source/>Immun. Inflamm. Dis.
<volume>4</volume> (<issue>3</issue>), <fpage>300</fpage>–<lpage>314</lpage>. <pub-id pub-id-type="doi">10.1002/iid3.114</pub-id>
<pub-id pub-id-type="pmid">27621813</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Braga</surname><given-names>T. T.</given-names></name><name><surname>Forni</surname><given-names>M. F.</given-names></name><name><surname>Correa-Costa</surname><given-names>M.</given-names></name><name><surname>Ramos</surname><given-names>R. N.</given-names></name><name><surname>Barbuto</surname><given-names>J. A.</given-names></name><name><surname>Branco</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2017</year>b). <article-title>Soluble uric acid activates the NLRP3 inflammasome</article-title>. <source/>Sci. Rep.
<volume>7</volume>, <fpage>39884</fpage>. <pub-id pub-id-type="doi">10.1038/srep39884</pub-id>
<pub-id pub-id-type="pmid">28084303</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Braga</surname><given-names>T. T.</given-names></name><name><surname>Moura</surname><given-names>I. C.</given-names></name><name><surname>Lepique</surname><given-names>A. P.</given-names></name><name><surname>Camara</surname><given-names>N. O. S.</given-names></name></person-group> (<year>2017</year>a). <article-title>Editorial: macrophages role in integrating tissue signals and biological processes in chronic inflammation and fibrosis</article-title>. <source/>Front. Immunol.
<volume>8</volume>, <fpage>845</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2017.00845</pub-id>
<pub-id pub-id-type="pmid">28785266</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Braga</surname><given-names>T. T.</given-names></name><name><surname>Correa-Costa</surname><given-names>M.</given-names></name><name><surname>Silva</surname><given-names>R. C.</given-names></name><name><surname>Cruz</surname><given-names>M. C.</given-names></name><name><surname>Hiyane</surname><given-names>M. I.</given-names></name><name><surname>da Silva</surname><given-names>J. S.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>CCR2 contributes to the recruitment of monocytes and leads to kidney inflammation and fibrosis development</article-title>. <source/>Inflammopharmacology
<volume>26</volume> (<issue>2</issue>), <fpage>403</fpage>–<lpage>411</lpage>. <pub-id pub-id-type="doi">10.1007/s10787-017-0317-4</pub-id>
<pub-id pub-id-type="pmid">28168553</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brenner</surname><given-names>B. M.</given-names></name><name><surname>Cooper</surname><given-names>M. E.</given-names></name><name><surname>de Zeeuw</surname><given-names>D.</given-names></name><name><surname>Keane</surname><given-names>W. F.</given-names></name><name><surname>Mitch</surname><given-names>W. E.</given-names></name><name><surname>Parving</surname><given-names>H. H.</given-names></name><etal></etal></person-group> (<year>2001</year>). <article-title>Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy</article-title>. <source/>N. Engl. J. Med.
<volume>345</volume> (<issue>12</issue>), <fpage>861</fpage>–<lpage>869</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa011161</pub-id>
<pub-id pub-id-type="pmid">11565518</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brinkmann</surname><given-names>V.</given-names></name><name><surname>Reichard</surname><given-names>U.</given-names></name><name><surname>Goosmann</surname><given-names>C.</given-names></name><name><surname>Fauler</surname><given-names>B.</given-names></name><name><surname>Uhlemann</surname><given-names>Y.</given-names></name><name><surname>Weiss</surname><given-names>D. S.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Neutrophil extracellular traps kill bacteria</article-title>. <source/>Science
<volume>303</volume> (<issue>5663</issue>), <fpage>1532</fpage>–<lpage>1535</lpage>. <pub-id pub-id-type="doi">10.1126/science.1092385</pub-id>
<pub-id pub-id-type="pmid">15001782</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brown</surname><given-names>A. J.</given-names></name><name><surname>Goldsworthy</surname><given-names>S. M.</given-names></name><name><surname>Barnes</surname><given-names>A. A.</given-names></name><name><surname>Eilert</surname><given-names>M. M.</given-names></name><name><surname>Tcheang</surname><given-names>L.</given-names></name><name><surname>Daniels</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2003</year>). <article-title>The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids</article-title>. <source/>J. Biol. Chem.
<volume>278</volume> (<issue>13</issue>), <fpage>11312</fpage>–<lpage>11319</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M211609200</pub-id>
<pub-id pub-id-type="pmid">12496283</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Campanholle</surname><given-names>G.</given-names></name><name><surname>Landgraf</surname><given-names>R. G.</given-names></name><name><surname>Goncalves</surname><given-names>G. M.</given-names></name><name><surname>Paiva</surname><given-names>V. N.</given-names></name><name><surname>Martins</surname><given-names>J. O.</given-names></name><name><surname>Wang</surname><given-names>P. H.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Lung inflammation is induced by renal ischemia and reperfusion injury as part of the systemic inflammatory syndrome</article-title>. <source/>Inflammation Res.
<volume>59</volume> (<issue>10</issue>), <fpage>861</fpage>–<lpage>869</lpage>. <pub-id pub-id-type="doi">10.1007/s00011-010-0198-0</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Camps</surname><given-names>J.</given-names></name><name><surname>Garcia-Heredia</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>Introduction: oxidation and inflammation, a molecular link between non-communicable diseases</article-title>. <source/>Adv. Exp. Med. Biol.
<volume>824</volume>, <fpage>1</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-319-07320-0_1</pub-id>
<pub-id pub-id-type="pmid">25038988</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Canale</surname><given-names>D.</given-names></name><name><surname>Rodrigues</surname><given-names>M. V.</given-names></name><name><surname>Ferreira</surname><given-names>D. N.</given-names></name><name><surname>Machado</surname><given-names>F. G.</given-names></name><name><surname>Veras</surname><given-names>M. M.</given-names></name><name><surname>Malheiros</surname><given-names>D. M.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Programmed hypertension in rats treated with a NF-κB inhibitor during nephrogenesis: renal mechanisms</article-title>. <source/>Hypertens. Res.
<volume>34</volume> (<issue>6</issue>), <fpage>693</fpage>–<lpage>700</lpage>. <pub-id pub-id-type="doi">10.1038/hr.2011.4</pub-id>
<pub-id pub-id-type="pmid">21326302</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cani</surname><given-names>P. D.</given-names></name><name><surname>Neyrinck</surname><given-names>A. M.</given-names></name><name><surname>Fava</surname><given-names>F.</given-names></name><name><surname>Knauf</surname><given-names>C.</given-names></name><name><surname>Burcelin</surname><given-names>R. G.</given-names></name><name><surname>Tuohy</surname><given-names>K. M.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia</article-title>. <source/>Diabetologia
<volume>50</volume> (<issue>11</issue>), <fpage>2374</fpage>–<lpage>2383</lpage>. <pub-id pub-id-type="doi">10.1007/s00125-007-0791-0</pub-id>
<pub-id pub-id-type="pmid">17823788</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cao</surname><given-names>Q.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>X. M.</given-names></name><name><surname>Lee</surname><given-names>V. W.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>CD103<sup>+</sup> dendritic cells elicit CD8<sup>+</sup> T cell responses to accelerate kidney injury in adriamycin nephropathy</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>27</volume> (<issue>5</issue>), <fpage>1344</fpage>–<lpage>1360</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2015030229</pub-id>
<pub-id pub-id-type="pmid">26376858</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carneiro</surname><given-names>L. A.</given-names></name><name><surname>Magalhaes</surname><given-names>J. G.</given-names></name><name><surname>Tattoli</surname><given-names>I.</given-names></name><name><surname>Philpott</surname><given-names>D. J.</given-names></name><name><surname>Travassos</surname><given-names>L. H.</given-names></name></person-group> (<year>2008</year>). <article-title>Nod-like proteins in inflammation and disease</article-title>. <source/>J. Pathol.
<volume>214</volume> (<issue>2</issue>), <fpage>136</fpage>–<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1002/path.2271</pub-id>
<pub-id pub-id-type="pmid">18161746</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Castoldi</surname><given-names>A.</given-names></name><name><surname>Braga</surname><given-names>T. T.</given-names></name><name><surname>Correa-Costa</surname><given-names>M.</given-names></name><name><surname>Aguiar</surname><given-names>C. F.</given-names></name><name><surname>Bassi</surname><given-names>E. J.</given-names></name><name><surname>Correa-Silva</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>TLR2, TLR4 and the MYD88 signaling pathway are crucial for neutrophil migration in acute kidney injury induced by sepsis</article-title>. <source/>PloS one
<volume>7</volume> (<issue>5</issue>), <elocation-id>e37584</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0037584</pub-id>
<pub-id pub-id-type="pmid">22655058</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>P. V.</given-names></name><name><surname>Hao</surname><given-names>L.</given-names></name><name><surname>Offermanns</surname><given-names>S.</given-names></name><name><surname>Medzhitov</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>The microbial metabolite butyrate regulates intestinal macrophage function <italic>via</italic> histone deacetylase inhibition</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>111</volume> (<issue>6</issue>), <fpage>2247</fpage>–<lpage>2252</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1322269111</pub-id>
<pub-id pub-id-type="pmid">24390544</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chanyi</surname><given-names>R. M.</given-names></name><name><surname>Craven</surname><given-names>L.</given-names></name><name><surname>Harvey</surname><given-names>B.</given-names></name><name><surname>Reid</surname><given-names>G.</given-names></name><name><surname>Silverman</surname><given-names>M. J.</given-names></name><name><surname>Burton</surname><given-names>J. P.</given-names></name></person-group> (<year>2017</year>). <article-title>Faecal microbiota transplantation: where did it start? What have studies taught us? Where is it going</article-title>? <source/>SAGE Open Med.
<volume>5</volume>, <elocation-id>2050312117708712</elocation-id>. <pub-id pub-id-type="doi">10.1177/2050312117708712</pub-id>
<pub-id pub-id-type="pmid">28540051</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chawla</surname><given-names>L. S.</given-names></name><name><surname>Kimmel</surname><given-names>P. L.</given-names></name></person-group> (<year>2012</year>). <article-title>Acute kidney injury and chronic kidney disease: an integrated clinical syndrome</article-title>. <source/>Kidney Int.
<volume>82</volume> (<issue>5</issue>), <fpage>516</fpage>–<lpage>524</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2012.208</pub-id>
<pub-id pub-id-type="pmid">22673882</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chawla</surname><given-names>L. S.</given-names></name><name><surname>Eggers</surname><given-names>P. W.</given-names></name><name><surname>Star</surname><given-names>R. A.</given-names></name><name><surname>Kimmel</surname><given-names>P. L.</given-names></name></person-group> (<year>2014</year>). <article-title>Acute kidney injury and chronic kidney disease as interconnected syndromes</article-title>. <source/>N. Eng. J. Med.
<volume>371</volume> (<issue>1</issue>), <fpage>58</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra1214243</pub-id>
</mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>C. B.</given-names></name><name><surname>Liu</surname><given-names>L. S.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>X. P.</given-names></name><name><surname>Han</surname><given-names>M.</given-names></name><name><surname>Jiao</surname><given-names>X. Y.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Up-regulation of HMGB1 exacerbates renal ischemia–reperfusion injury by stimulating inflammatory and immune responses through the TLR4 signaling pathway in mice</article-title>. <source/>Cell Physiol. Biochem.
<volume>41</volume> (<issue>6</issue>), <fpage>2447</fpage>–<lpage>2460</lpage>. <pub-id pub-id-type="doi">10.1159/000475914</pub-id>
<pub-id pub-id-type="pmid">28472797</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chiavaroli</surname><given-names>L.</given-names></name><name><surname>Mirrahimi</surname><given-names>A.</given-names></name><name><surname>Sievenpiper</surname><given-names>J. L.</given-names></name><name><surname>Jenkins</surname><given-names>D. J.</given-names></name><name><surname>Darling</surname><given-names>P. B.</given-names></name></person-group> (<year>2015</year>). <article-title>Dietary fiber effects in chronic kidney disease: a systematic review and meta-analysis of controlled feeding trials</article-title>. <source/>Eur. J. Clin. Nutr.
<volume>69</volume> (<issue>7</issue>), <fpage>761</fpage>–<lpage>768</lpage>. <pub-id pub-id-type="doi">10.1038/ejcn.2014.237</pub-id>
<pub-id pub-id-type="pmid">25387901</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chmielewska</surname><given-names>A.</given-names></name><name><surname>Szajewska</surname><given-names>H.</given-names></name></person-group> (<year>2010</year>). <article-title>Systematic review of randomised controlled trials: probiotics for functional constipation</article-title>. <source/>World J. Gastroenterol.
<volume>16</volume> (<issue>1</issue>), <fpage>69</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v16.i1.69</pub-id>
<pub-id pub-id-type="pmid">20039451</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clarke</surname><given-names>S. F.</given-names></name><name><surname>Murphy</surname><given-names>E. F.</given-names></name><name><surname>O’Sullivan</surname><given-names>O.</given-names></name><name><surname>Lucey</surname><given-names>A. J.</given-names></name><name><surname>Humphreys</surname><given-names>M.</given-names></name><name><surname>Hogan</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Exercise and associated dietary extremes impact on gut microbial diversity</article-title>. <source/>Gut
<volume>63</volume> (<issue>12</issue>), <fpage>1913</fpage>–<lpage>1920</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2013-306541</pub-id>
<pub-id pub-id-type="pmid">25021423</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Correa-Costa</surname><given-names>M.</given-names></name><name><surname>Braga</surname><given-names>T. T.</given-names></name><name><surname>Semedo</surname><given-names>P.</given-names></name><name><surname>Hayashida</surname><given-names>C. Y.</given-names></name><name><surname>Bechara</surname><given-names>L. R.</given-names></name><name><surname>Elias</surname><given-names>R. M.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Pivotal role of Toll-like receptors 2 and 4, its adaptor molecule MyD88, and inflammasome complex in experimental tubule-interstitial nephritis</article-title>. <source/>PloS one
<volume>6</volume> (<issue>12</issue>), <elocation-id>e29004</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0029004</pub-id>
<pub-id pub-id-type="pmid">22194975</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Correa-Costa</surname><given-names>M.</given-names></name><name><surname>Azevedo</surname><given-names>H.</given-names></name><name><surname>Amano</surname><given-names>M. T.</given-names></name><name><surname>Goncalves</surname><given-names>G. M.</given-names></name><name><surname>Hyane</surname><given-names>M. I.</given-names></name><name><surname>Cenedeze</surname><given-names>M. A.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Transcriptome analysis of renal ischemia/reperfusion injury and its modulation by ischemic pre-conditioning or hemin treatment</article-title>. <source/>PloS one
<volume>7</volume> (<issue>11</issue>), <elocation-id>e49569</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0049569</pub-id>
<pub-id pub-id-type="pmid">23166714</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Correa-Costa</surname><given-names>M.</given-names></name><name><surname>Braga</surname><given-names>T. T.</given-names></name><name><surname>Felizardo</surname><given-names>R. J.</given-names></name><name><surname>Andrade-Oliveira</surname><given-names>V.</given-names></name><name><surname>Perez</surname><given-names>K. R.</given-names></name><name><surname>Cuccovia</surname><given-names>I. M.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Macrophage trafficking as key mediator of adenine-induced kidney injury</article-title>. <source/>Mediators Inflamm.
<volume>2014</volume>, <fpage>291024</fpage>. <pub-id pub-id-type="doi">10.1155/2014/291024</pub-id>
<pub-id pub-id-type="pmid">25132730</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Paiva</surname><given-names>V. N.</given-names></name><name><surname>Monteiro</surname><given-names>R. M.</given-names></name><name><surname>Marques Vde</surname><given-names>P.</given-names></name><name><surname>Cenedeze</surname><given-names>M. A.</given-names></name><name><surname>Teixeira Vde</surname><given-names>P.</given-names></name><name><surname>dos Reis</surname><given-names>M. A.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Critical involvement of T<sub>H</sub>1-related cytokines in renal injuries induced by ischemia and reperfusion</article-title>. <source/>Int. Immunopharmacol.
<volume>9</volume> (<issue>6</issue>), <fpage>668</fpage>–<lpage>672</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2008.11.012</pub-id>
<pub-id pub-id-type="pmid">19095086</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>den Besten</surname><given-names>G.</given-names></name><name><surname>Bleeker</surname><given-names>A.</given-names></name><name><surname>Gerding</surname><given-names>A.</given-names></name><name><surname>van Eunen</surname><given-names>K.</given-names></name><name><surname>Havinga</surname><given-names>R.</given-names></name><name><surname>van Dijk</surname><given-names>T. H.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Short-chain fatty acids protect against high-fat diet–induced obesity <italic>via a</italic> PPARgamma-dependent switch from lipogenesis to fat oxidation</article-title>. <source/>Diabetes.
<volume>64</volume> (<issue>7</issue>), <fpage>2398</fpage>–<lpage>2408</lpage>. <pub-id pub-id-type="doi">10.2337/db14-1213</pub-id>
<pub-id pub-id-type="pmid">25695945</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deng</surname><given-names>B.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>S.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>The leukotriene B4-leukotriene B4 receptor axis promotes cisplatin-induced acute kidney injury by modulating neutrophil recruitment</article-title>. <source/>Kidney Int.
<volume>92</volume> (<issue>1</issue>), <fpage>89</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/j.kint.2017.01.009</pub-id>
<pub-id pub-id-type="pmid">28318626</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Desai</surname><given-names>M. S.</given-names></name><name><surname>Seekatz</surname><given-names>A. M.</given-names></name><name><surname>Koropatkin</surname><given-names>N. M.</given-names></name><name><surname>Kamada</surname><given-names>N.</given-names></name><name><surname>Hickey</surname><given-names>C. A.</given-names></name><name><surname>Wolter</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>A dietary fiber–deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility</article-title>. <source/>Cell
<volume>167</volume> (<issue>5</issue>), <page-range>1339–53</page-range>
<elocation-id>e21</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.10.043</pub-id>
</mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dewulf</surname><given-names>E. M.</given-names></name><name><surname>Cani</surname><given-names>P. D.</given-names></name><name><surname>Claus</surname><given-names>S. P.</given-names></name><name><surname>Fuentes</surname><given-names>S.</given-names></name><name><surname>Puylaert</surname><given-names>P. G.</given-names></name><name><surname>Neyrinck</surname><given-names>A. M.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women</article-title>. <source/>Gut
<volume>62</volume> (<issue>8</issue>), <fpage>1112</fpage>–<lpage>1121</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2012-303304</pub-id>
<pub-id pub-id-type="pmid">23135760</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dominguez-Bello</surname><given-names>M. G.</given-names></name><name><surname>Costello</surname><given-names>E. K.</given-names></name><name><surname>Contreras</surname><given-names>M.</given-names></name><name><surname>Magris</surname><given-names>M.</given-names></name><name><surname>Hidalgo</surname><given-names>G.</given-names></name><name><surname>Fierer</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>107</volume> (<issue>26</issue>), <fpage>11971</fpage>–<lpage>11975</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1002601107</pub-id>
<pub-id pub-id-type="pmid">20566857</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Swaminathan</surname><given-names>S.</given-names></name><name><surname>Bachman</surname><given-names>L. A.</given-names></name><name><surname>Croatt</surname><given-names>A. J.</given-names></name><name><surname>Nath</surname><given-names>K. A.</given-names></name><name><surname>Griffin</surname><given-names>M. D.</given-names></name></person-group> (<year>2007</year>). <article-title>Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia–reperfusion injury</article-title>. <source/>Kidney Int.
<volume>71</volume> (<issue>7</issue>), <fpage>619</fpage>–<lpage>628</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ki.5002132</pub-id>
<pub-id pub-id-type="pmid">17311071</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duncan</surname><given-names>S. H.</given-names></name><name><surname>Belenguer</surname><given-names>A.</given-names></name><name><surname>Holtrop</surname><given-names>G.</given-names></name><name><surname>Johnstone</surname><given-names>A. M.</given-names></name><name><surname>Flint</surname><given-names>H. J.</given-names></name><name><surname>Lobley</surname><given-names>G. E.</given-names></name></person-group> (<year>2007</year>). <article-title>Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces</article-title>. <source/>Appl. Environ. Microbiol.
<volume>73</volume> (<issue>4</issue>), <fpage>1073</fpage>–<lpage>1078</lpage>. <pub-id pub-id-type="doi">10.1128/AEM.02340-06</pub-id>
<pub-id pub-id-type="pmid">17189447</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Esteban</surname><given-names>V.</given-names></name><name><surname>Ruperez</surname><given-names>M.</given-names></name><name><surname>Vita</surname><given-names>J. R.</given-names></name><name><surname>López</surname><given-names>E. S.</given-names></name><name><surname>Mezzano</surname><given-names>S.</given-names></name><name><surname>Plaza</surname><given-names>J. J.</given-names></name><etal></etal></person-group> (<year>2003</year>). <article-title>Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response</article-title>. <source/>Kidney Int Suppl.
<volume>64</volume> (<issue>86</issue>), <fpage>S33</fpage>–<lpage>S38</lpage>. <pub-id pub-id-type="doi">10.1046/j.1523-1755.64.s86.7.x</pub-id>
</mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Esteban</surname><given-names>V.</given-names></name><name><surname>Lorenzo</surname><given-names>O.</given-names></name><name><surname>Rupérez</surname><given-names>M.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name><name><surname>Mezzano</surname><given-names>S.</given-names></name><name><surname>Blanco</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Angiotensin II, <italic>via</italic> AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>15</volume> (<issue>6</issue>), <fpage>1514</fpage>–<lpage>1529</lpage>. <pub-id pub-id-type="doi">10.1097/01.ASN.0000130564.75008.F5</pub-id>
<pub-id pub-id-type="pmid">15153562</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Estruch</surname><given-names>R.</given-names></name><name><surname>Ros</surname><given-names>E.</given-names></name><name><surname>Salas-Salvado</surname><given-names>J.</given-names></name><name><surname>Covas</surname><given-names>M. I.</given-names></name><name><surname>Corella</surname><given-names>D.</given-names></name><name><surname>Aros</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Primary prevention of cardiovascular disease with a Mediterranean diet</article-title>. <source/>N. Eng. J. Med.
<volume>368</volume> (<issue>14</issue>), <fpage>1279</fpage>–<lpage>1290</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1200303</pub-id>
</mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fanelli</surname><given-names>C.</given-names></name><name><surname>Arias</surname><given-names>S. C. A.</given-names></name><name><surname>Machado</surname><given-names>F. G.</given-names></name><name><surname>Okuma</surname><given-names>J. K.</given-names></name><name><surname>Malheiros</surname><given-names>D.</given-names></name><name><surname>Azevedo</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Innate and adaptive immunity are progressively activated in parallel with renal injury in the 5/6 renal ablation model</article-title>. <source/>Sci. Rep.
<volume>7</volume> (<issue>1</issue>), <fpage>3192</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-02915-6</pub-id>
<pub-id pub-id-type="pmid">28600543</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Faustino</surname><given-names>V. D.</given-names></name><name><surname>Arias</surname><given-names>S. C. A.</given-names></name><name><surname>Ferreira Avila</surname><given-names>V.</given-names></name><name><surname>Foresto-Neto</surname><given-names>O.</given-names></name><name><surname>Zambom</surname><given-names>F. F. F.</given-names></name><name><surname>Machado</surname><given-names>F. G.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Simultaneous activation of innate and adaptive immunity participates in the development of renal injury in a model of heavy proteinuria</article-title>. <source/>Bioscie Rep.
<volume>38</volume> (<issue>4</issue>), <fpage>1</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1042/BSR20180762</pub-id>
</mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Floege</surname><given-names>J.</given-names></name><name><surname>Burns</surname><given-names>M. W.</given-names></name><name><surname>Alpers</surname><given-names>C. E.</given-names></name><name><surname>Yoshimura</surname><given-names>A.</given-names></name><name><surname>Pritzl</surname><given-names>P.</given-names></name><name><surname>Gordon</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>1992</year>). <article-title>Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model</article-title>. <source/>Kidney Int.
<volume>41</volume> (<issue>2</issue>), <fpage>297</fpage>–<lpage>309</lpage>. <pub-id pub-id-type="doi">10.1038/ki.1992.42</pub-id>
<pub-id pub-id-type="pmid">1313122</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Foresto-Neto</surname><given-names>O.</given-names></name><name><surname>Ávila</surname><given-names>V. F.</given-names></name><name><surname>Arias</surname><given-names>S. C. A.</given-names></name><name><surname>Zambom</surname><given-names>F. F. F.</given-names></name><name><surname>Rempel</surname><given-names>L. C. T.</given-names></name><name><surname>Faustino</surname><given-names>V. D.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>NLRP3 inflammasome inhibition ameliorates tubulointerstitial injury in the remnant kidney model</article-title>. <source/>Lab. Invest.
<volume>98</volume> (<issue>6</issue>), <fpage>773</fpage>–<lpage>782</lpage>. <pub-id pub-id-type="doi">10.1038/s41374-018-0029-4</pub-id>
<pub-id pub-id-type="pmid">29511302</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Francescato</surname><given-names>H. D.</given-names></name><name><surname>Costa</surname><given-names>R. S.</given-names></name><name><surname>Scavone</surname><given-names>C.</given-names></name><name><surname>Coimbra</surname><given-names>T. M.</given-names></name></person-group> (<year>2007</year>). <article-title>Parthenolide reduces cisplatin-induced renal damage</article-title>. <source/>Toxicology
<volume>230</volume> (<issue>1</issue>), <fpage>64</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/j.tox.2006.10.025</pub-id>
<pub-id pub-id-type="pmid">17156909</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frost</surname><given-names>G.</given-names></name><name><surname>Sleeth</surname><given-names>M. L.</given-names></name><name><surname>Sahuri-Arisoylu</surname><given-names>M.</given-names></name><name><surname>Lizarbe</surname><given-names>B.</given-names></name><name><surname>Cerdan</surname><given-names>S.</given-names></name><name><surname>Brody</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>The short-chain fatty acid acetate reduces appetite <italic>via a</italic> central homeostatic mechanism</article-title>. <source/>Nat. Commun.
<volume>5</volume>, <fpage>3611</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms4611</pub-id>
<pub-id pub-id-type="pmid">24781306</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fujihara</surname><given-names>C. K.</given-names></name><name><surname>Velho</surname><given-names>M.</given-names></name><name><surname>Malheiros</surname><given-names>D. M.</given-names></name><name><surname>Zatz</surname><given-names>R.</given-names></name></person-group> (<year>2005</year>). <article-title>An extremely high dose of losartan affords superior renoprotection in the remnant model</article-title>. <source/>Kidney Int.
<volume>67</volume> (<issue>5</issue>), <fpage>1913</fpage>–<lpage>1924</lpage>. <pub-id pub-id-type="doi">10.1111/j.1523-1755.2005.00290.x</pub-id>
<pub-id pub-id-type="pmid">15840039</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fujihara</surname><given-names>C. K.</given-names></name><name><surname>Antunes</surname><given-names>G. R.</given-names></name><name><surname>Mattar</surname><given-names>A. L.</given-names></name><name><surname>Malheiros</surname><given-names>D. M.</given-names></name><name><surname>Vieira</surname><given-names>J. M.</given-names></name><name><surname>Zatz</surname><given-names>R.</given-names></name></person-group> (<year>2007</year>b). <article-title>Chronic inhibition of nuclear factor-kappaB attenuates renal injury in the 5/6 renal ablation model</article-title>. <source/>Am. J. Physiol. Renal Physiol.
<volume>292</volume> (<issue>1</issue>), <fpage>F92</fpage>–<lpage>F99</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.00184.2006</pub-id>
<pub-id pub-id-type="pmid">16896182</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fujihara</surname><given-names>C. K.</given-names></name><name><surname>Malheiros</surname><given-names>D. M.</given-names></name><name><surname>Zatz</surname><given-names>R.</given-names></name></person-group> (<year>2007</year>a). <article-title>Losartan–hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model</article-title>. <source/>Am. J. Physiol. Renal Physiol.
<volume>292</volume> (<issue>6</issue>), <fpage>F1810</fpage>–<lpage>F1818</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.00521.2006</pub-id>
<pub-id pub-id-type="pmid">17344184</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gamboa</surname><given-names>J. L.</given-names></name><name><surname>Pretorius</surname><given-names>M.</given-names></name><name><surname>Todd-Tzanetos</surname><given-names>D. R.</given-names></name><name><surname>Luther</surname><given-names>J. M.</given-names></name><name><surname>Yu</surname><given-names>C.</given-names></name><name><surname>Ikizler</surname><given-names>T. A.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>23</volume> (<issue>2</issue>), <fpage>334</fpage>–<lpage>342</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2011030287</pub-id>
<pub-id pub-id-type="pmid">22158433</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>B.</given-names></name><name><surname>Tu</surname><given-names>P.</given-names></name><name><surname>Bian</surname><given-names>X.</given-names></name><name><surname>Chi</surname><given-names>L.</given-names></name><name><surname>Ru</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>K.</given-names></name></person-group> (<year>2017</year>). <article-title>Profound perturbation induced by triclosan exposure in mouse gut microbiome: a less resilient microbial community with elevated antibiotic and metal resistomes</article-title>. <source/>BMC Pharmacol. Toxicol.
<volume>18</volume> (<issue>1</issue>), <fpage>46</fpage>. <pub-id pub-id-type="doi">10.1186/s40360-017-0150-9</pub-id>
<pub-id pub-id-type="pmid">28606169</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ge</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Weiszmann</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Baribault</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>J. L.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids</article-title>. <source/>Endocrinology
<volume>149</volume> (<issue>9</issue>), <fpage>4519</fpage>–<lpage>4526</lpage>. <pub-id pub-id-type="doi">10.1210/en.2008-0059</pub-id>
<pub-id pub-id-type="pmid">18499755</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Geissmann</surname><given-names>F.</given-names></name><name><surname>Jung</surname><given-names>S.</given-names></name><name><surname>Littman</surname><given-names>D. R.</given-names></name></person-group> (<year>2003</year>). <article-title>Blood monocytes consist of two principal subsets with distinct migratory properties</article-title>. <source/>Immunity
<volume>19</volume> (<issue>1</issue>), <fpage>71</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/S1074-7613(03)00174-2</pub-id>
<pub-id pub-id-type="pmid">12871640</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>R. E.</given-names></name><name><surname>Wu</surname><given-names>L. L.</given-names></name><name><surname>Kelly</surname><given-names>D. J.</given-names></name><name><surname>Cox</surname><given-names>A.</given-names></name><name><surname>Wilkinson-Berka</surname><given-names>J. L.</given-names></name><name><surname>Johnston</surname><given-names>C. I.</given-names></name><etal></etal></person-group> (<year>1999</year>). <article-title>Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis</article-title>. <source/>Am. J. Pathol.
<volume>155</volume> (<issue>2</issue>), <fpage>429</fpage>–<lpage>440</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9440(10)65139-5</pub-id>
<pub-id pub-id-type="pmid">10433936</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goicoechea</surname><given-names>M.</given-names></name><name><surname>de Vinuesa</surname><given-names>S. G.</given-names></name><name><surname>Verdalles</surname><given-names>U.</given-names></name><name><surname>Ruiz-Caro</surname><given-names>C.</given-names></name><name><surname>Ampuero</surname><given-names>J.</given-names></name><name><surname>Rincón</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Effect of allopurinol in chronic kidney disease progression and cardiovascular risk</article-title>. <source/>Clin. J. Am. Soc. Nephrol.
<volume>5</volume> (<issue>8</issue>), <fpage>1388</fpage>–<lpage>1393</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.01580210</pub-id>
<pub-id pub-id-type="pmid">20538833</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goicoechea</surname><given-names>M.</given-names></name></person-group>, Garcia <person-group person-group-type="author"><name><surname>de Vinuesa</surname><given-names>S.</given-names></name><name><surname>Verdalles</surname><given-names>U.</given-names></name><name><surname>Verde</surname><given-names>E.</given-names></name><name><surname>Macias</surname><given-names>N.</given-names></name><name><surname>Santos</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial</article-title>. <source/>Am. J. Kidney Dis.
<volume>65</volume> (<issue>4</issue>), <fpage>543</fpage>–<lpage>549</lpage>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2014.11.016</pub-id>
<pub-id pub-id-type="pmid">25595565</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gonçalves</surname><given-names>A. R.</given-names></name><name><surname>Fujihara</surname><given-names>C. K.</given-names></name><name><surname>Mattar</surname><given-names>A. L.</given-names></name><name><surname>Malheiros</surname><given-names>D. M.</given-names></name></person-group>, IeL, Noronha, <person-group person-group-type="author"><name><surname>de Nucci</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory</article-title>. <source/>Am. J. Physiol. Renal Physiol.
<volume>286</volume> (<issue>5</issue>), <fpage>F945</fpage>–<lpage>F954</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.00238.2003</pub-id>
<pub-id pub-id-type="pmid">15075190</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gräfe</surname><given-names>M.</given-names></name><name><surname>Auch-Schwelk</surname><given-names>W.</given-names></name><name><surname>Zakrzewicz</surname><given-names>A.</given-names></name><name><surname>Regitz-Zagrosek</surname><given-names>V.</given-names></name><name><surname>Bartsch</surname><given-names>P.</given-names></name><name><surname>Graf</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>1997</year>). <article-title>Angiotensin II–induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin</article-title>. <source/>Circ Res.
<volume>81</volume> (<issue>5</issue>), <fpage>804</fpage>–<lpage>811</lpage>. <pub-id pub-id-type="doi">10.1161/01.RES.81.5.804</pub-id>
<pub-id pub-id-type="pmid">9351454</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Griffin</surname><given-names>K. A.</given-names></name><name><surname>Bidani</surname><given-names>A. K.</given-names></name></person-group> (<year>2006</year>). <article-title>Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade</article-title>. <source/>Clin. J. Am. Soc. Nephrol.
<volume>1</volume> (<issue>5</issue>), <fpage>1054</fpage>–<lpage>1065</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.02231205</pub-id>
<pub-id pub-id-type="pmid">17699327</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guida</surname><given-names>B.</given-names></name><name><surname>Germano</surname><given-names>R.</given-names></name><name><surname>Trio</surname><given-names>R.</given-names></name><name><surname>Russo</surname><given-names>D.</given-names></name><name><surname>Memoli</surname><given-names>B.</given-names></name><name><surname>Grumetto</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: a randomized clinical trial</article-title>. <source/>Nutr. Metab. Cardiovasc. Dis.
<volume>24</volume> (<issue>9</issue>), <fpage>1043</fpage>–<lpage>1049</lpage>. <pub-id pub-id-type="doi">10.1016/j.numecd.2014.04.007</pub-id>
<pub-id pub-id-type="pmid">24929795</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Halkjaer</surname><given-names>S. I.</given-names></name><name><surname>Christensen</surname><given-names>A. H.</given-names></name><name><surname>Lo</surname><given-names>B. Z. S.</given-names></name><name><surname>Browne</surname><given-names>P. D.</given-names></name><name><surname>Gunther</surname><given-names>S.</given-names></name><name><surname>Hansen</surname><given-names>L. H.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study</article-title>. <source/>Gut
<volume>67</volume> (<issue>12</issue>), <fpage>2107</fpage>–<lpage>2115</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2018-316434</pub-id>
<pub-id pub-id-type="pmid">29980607</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hara</surname><given-names>T.</given-names></name><name><surname>Kimura</surname><given-names>I.</given-names></name><name><surname>Inoue</surname><given-names>D.</given-names></name><name><surname>Ichimura</surname><given-names>A.</given-names></name><name><surname>Hirasawa</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Free fatty acid receptors and their role in regulation of energy metabolism</article-title>. <source/>Rev. Physiol. Biochem. Pharmacol.
<volume>164</volume>, <fpage>77</fpage>–<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1007/112_2013_13</pub-id>
<pub-id pub-id-type="pmid">23625068</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hempel</surname><given-names>S.</given-names></name><name><surname>Newberry</surname><given-names>S. J.</given-names></name><name><surname>Maher</surname><given-names>A. R.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Miles</surname><given-names>J. N.</given-names></name><name><surname>Shanman</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis</article-title>. <source/>Jama.
<volume>307</volume> (<issue>18</issue>), <fpage>1959</fpage>–<lpage>1969</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2012.3507</pub-id>
<pub-id pub-id-type="pmid">22570464</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Henkel</surname><given-names>T.</given-names></name><name><surname>Machleidt</surname><given-names>T.</given-names></name><name><surname>Alkalay</surname><given-names>I.</given-names></name><name><surname>Krönke</surname><given-names>M.</given-names></name><name><surname>Ben-Neriah</surname><given-names>Y.</given-names></name><name><surname>Baeuerle</surname><given-names>P. A.</given-names></name></person-group> (<year>1993</year>). <article-title>Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B</article-title>. <source/>Nature
<volume>6442</volume> (<issue>365</issue>), <fpage>182</fpage>–<lpage>185</lpage>. <pub-id pub-id-type="doi">10.1038/365182a0</pub-id>
</mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Herbert</surname><given-names>D. R.</given-names></name><name><surname>Holscher</surname><given-names>C.</given-names></name><name><surname>Mohrs</surname><given-names>M.</given-names></name><name><surname>Arendse</surname><given-names>B.</given-names></name><name><surname>Schwegmann</surname><given-names>A.</given-names></name><name><surname>Radwanska</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology</article-title>. <source/>Immunity
<volume>20</volume> (<issue>5</issue>), <fpage>623</fpage>–<lpage>635</lpage>. <pub-id pub-id-type="doi">10.1016/S1074-7613(04)00107-4</pub-id>
<pub-id pub-id-type="pmid">15142530</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heymann</surname><given-names>F.</given-names></name><name><surname>Meyer-Schwesinger</surname><given-names>C.</given-names></name><name><surname>Hamilton-Williams</surname><given-names>E. E.</given-names></name><name><surname>Hammerich</surname><given-names>L.</given-names></name><name><surname>Panzer</surname><given-names>U.</given-names></name><name><surname>Kaden</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury</article-title>. <source/>J. Clin. Investig.
<volume>119</volume> (<issue>5</issue>), <fpage>1286</fpage>–<lpage>1297</lpage>. <pub-id pub-id-type="doi">10.1172/JCI38399</pub-id>
<pub-id pub-id-type="pmid">19381017</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hida</surname><given-names>M.</given-names></name><name><surname>Aiba</surname><given-names>Y.</given-names></name><name><surname>Sawamura</surname><given-names>S.</given-names></name><name><surname>Suzuki</surname><given-names>N.</given-names></name><name><surname>Satoh</surname><given-names>T.</given-names></name><name><surname>Koga</surname><given-names>Y.</given-names></name></person-group> (<year>1996</year>). <article-title>Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis</article-title>. <source/>Nephron.
<volume>74</volume> (<issue>2</issue>), <fpage>349</fpage>–<lpage>355</lpage>. <pub-id pub-id-type="doi">10.1159/000189334</pub-id>
<pub-id pub-id-type="pmid">8893154</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hill</surname><given-names>C.</given-names></name><name><surname>Guarner</surname><given-names>F.</given-names></name><name><surname>Reid</surname><given-names>G.</given-names></name><name><surname>Gibson</surname><given-names>G. R.</given-names></name><name><surname>Merenstein</surname><given-names>D. J.</given-names></name><name><surname>Pot</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic</article-title>. <source/>Nat. Rev. Gastroenterol. Hepatol.
<volume>11</volume> (<issue>8</issue>), <fpage>506</fpage>–<lpage>514</lpage>. <pub-id pub-id-type="doi">10.1038/nrgastro.2014.66</pub-id>
<pub-id pub-id-type="pmid">24912386</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hisada</surname><given-names>Y.</given-names></name><name><surname>Sugaya</surname><given-names>T.</given-names></name><name><surname>Yamanouchi</surname><given-names>M.</given-names></name><name><surname>Uchida</surname><given-names>H.</given-names></name><name><surname>Fujimura</surname><given-names>H.</given-names></name><name><surname>Sakurai</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>1999</year>). <article-title>Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice</article-title>. <source/>J. Clin. Invest.
<volume>103</volume> (<issue>5</issue>), <fpage>627</fpage>–<lpage>635</lpage>. <pub-id pub-id-type="doi">10.1172/JCI2454</pub-id>
<pub-id pub-id-type="pmid">10074479</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoesel</surname><given-names>L. M.</given-names></name><name><surname>Neff</surname><given-names>T. A.</given-names></name><name><surname>Neff</surname><given-names>S. B.</given-names></name><name><surname>Younger</surname><given-names>J. G.</given-names></name><name><surname>Olle</surname><given-names>E. W.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>Harmful and protective roles of neutrophils in sepsis</article-title>. <source/>Shock
<volume>24</volume> (<issue>1</issue>), <fpage>40</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1097/01.shk.0000170353.80318.d5</pub-id>
</mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoste</surname><given-names>E. A.</given-names></name><name><surname>Bagshaw</surname><given-names>S. M.</given-names></name><name><surname>Bellomo</surname><given-names>R.</given-names></name><name><surname>Cely</surname><given-names>C. M.</given-names></name><name><surname>Colman</surname><given-names>R.</given-names></name><name><surname>Cruz</surname><given-names>D. N.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study</article-title>. <source/>Intensive Care Med.
<volume>41</volume> (<issue>8</issue>), <fpage>1411</fpage>–<lpage>1423</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-015-3934-7</pub-id>
<pub-id pub-id-type="pmid">26162677</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hughes-Large</surname><given-names>J. M.</given-names></name><name><surname>Pang</surname><given-names>D. K.</given-names></name><name><surname>Robson</surname><given-names>D. L.</given-names></name><name><surname>Chan</surname><given-names>P.</given-names></name><name><surname>Toma</surname><given-names>J.</given-names></name><name><surname>Borradaile</surname><given-names>N. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Niacin receptor activation improves human microvascular endothelial cell angiogenic function during lipotoxicity</article-title>. <source/>Atherosclerosis.
<volume>237</volume> (<issue>2</issue>), <fpage>696</fpage>–<lpage>704</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2014.10.090</pub-id>
<pub-id pub-id-type="pmid">25463108</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal">Human <person-group person-group-type="author"><name><surname>Microbiome Project</surname><given-names>C.</given-names></name></person-group> (<year>2012</year>). <article-title>Structure, function and diversity of the healthy human microbiome</article-title>. <source/>Nature
<volume>486</volume> (<issue>7402</issue>), <fpage>207</fpage>–<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1038/nature11234</pub-id>
<pub-id pub-id-type="pmid">22699609</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iyer</surname><given-names>S. S.</given-names></name><name><surname>Pulskens</surname><given-names>W. P.</given-names></name><name><surname>Sadler</surname><given-names>J. J.</given-names></name><name><surname>Butter</surname><given-names>L. M.</given-names></name><name><surname>Teske</surname><given-names>G. J.</given-names></name><name><surname>Ulland</surname><given-names>T. K.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>106</volume> (<issue>48</issue>), <fpage>20388</fpage>–<lpage>20393</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0908698106</pub-id>
<pub-id pub-id-type="pmid">19918053</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jang</surname><given-names>H. R.</given-names></name><name><surname>Gandolfo</surname><given-names>M. T.</given-names></name><name><surname>Ko</surname><given-names>G. J.</given-names></name><name><surname>Satpute</surname><given-names>S.</given-names></name><name><surname>Racusen</surname><given-names>L.</given-names></name><name><surname>Rabb</surname><given-names>H.</given-names></name></person-group> (<year>2009</year>). <article-title>Early exposure to germs modifies kidney damage and inflammation after experimental ischemia–reperfusion injury</article-title>. <source/>Am. J. Physiol. Renal Physiol.
<volume>297</volume> (<issue>5</issue>), <fpage>F1457</fpage>–<lpage>F1465</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.90769.2008</pub-id>
<pub-id pub-id-type="pmid">19675178</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jerke</surname><given-names>U.</given-names></name><name><surname>Hernandez</surname><given-names>D. P.</given-names></name><name><surname>Beaudette</surname><given-names>P.</given-names></name><name><surname>Korkmaz</surname><given-names>B.</given-names></name><name><surname>Dittmar</surname><given-names>G.</given-names></name><name><surname>Kettritz</surname><given-names>R.</given-names></name></person-group> (<year>2015</year>). <article-title>Neutrophil serine proteases exert proteolytic activity on endothelial cells</article-title>. <source/>Kidney Int.
<volume>88</volume> (<issue>4</issue>), <fpage>764</fpage>–<lpage>775</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2015.159</pub-id>
<pub-id pub-id-type="pmid">26061547</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jimenez</surname><given-names>E.</given-names></name><name><surname>Fernandez</surname><given-names>L.</given-names></name><name><surname>Marin</surname><given-names>M. L.</given-names></name><name><surname>Martin</surname><given-names>R.</given-names></name><name><surname>Odriozola</surname><given-names>J. M.</given-names></name><name><surname>Nueno-Palop</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>Isolation of commensal bacteria from umbilical cord blood of healthy neonates born by cesarean section</article-title>. <source/>Curr. Microbiol.
<volume>51</volume> (<issue>4</issue>), <fpage>270</fpage>–<lpage>274</lpage>. <pub-id pub-id-type="doi">10.1007/s00284-005-0020-3</pub-id>
<pub-id pub-id-type="pmid">16187156</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jimenez</surname><given-names>E.</given-names></name><name><surname>Marin</surname><given-names>M. L.</given-names></name><name><surname>Martin</surname><given-names>R.</given-names></name><name><surname>Odriozola</surname><given-names>J. M.</given-names></name><name><surname>Olivares</surname><given-names>M.</given-names></name><name><surname>Xaus</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Is meconium from healthy newborns actually sterile</article-title>? <source/>Res. Microbiol.
<volume>159</volume> (<issue>3</issue>), <fpage>187</fpage>–<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1016/j.resmic.2007.12.007</pub-id>
<pub-id pub-id-type="pmid">18281199</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jo</surname><given-names>S. K.</given-names></name><name><surname>Sung</surname><given-names>S. A.</given-names></name><name><surname>Cho</surname><given-names>W. Y.</given-names></name><name><surname>Go</surname><given-names>K. J.</given-names></name><name><surname>Kim</surname><given-names>H. K.</given-names></name></person-group> (<year>2006</year>). <article-title>Macrophages contribute to the initiation of ischaemic acute renal failure in rats</article-title>. <source/>Nephrol. Dialysis Transplant.
<volume>21</volume> (<issue>5</issue>), <fpage>1231</fpage>–<lpage>1239</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfk047</pub-id>
</mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johnson</surname><given-names>R. J.</given-names></name><name><surname>Alpers</surname><given-names>C. E.</given-names></name><name><surname>Yoshimura</surname><given-names>A.</given-names></name><name><surname>Lombardi</surname><given-names>D.</given-names></name><name><surname>Pritzl</surname><given-names>P.</given-names></name><name><surname>Floege</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>1992</year>). <article-title>Renal injury from angiotensin II–mediated hypertension</article-title>. <source/>Hypertension
<volume>19</volume> (<issue>5</issue>), <fpage>464</fpage>–<lpage>474</lpage>. <pub-id pub-id-type="doi">10.1161/01.HYP.19.5.464</pub-id>
<pub-id pub-id-type="pmid">1568765</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>J. M.</given-names></name></person-group> (<year>2014</year>). <article-title>CODEX-aligned dietary fiber definitions help to bridge the ‘fiber gap’</article-title>. <source/>Nutr. J.
<volume>13</volume>, <fpage>34</fpage>. <pub-id pub-id-type="doi">10.1186/1475-2891-13-34</pub-id>
<pub-id pub-id-type="pmid">24725724</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kagami</surname><given-names>S.</given-names></name><name><surname>Border</surname><given-names>W. A.</given-names></name><name><surname>Miller</surname><given-names>D. E.</given-names></name><name><surname>Noble</surname><given-names>N. A.</given-names></name></person-group> (<year>1994</year>). <article-title>Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells</article-title>. <source/>J. Clin. Invest.
<volume>93</volume> (<issue>6</issue>), <fpage>2431</fpage>–<lpage>2437</lpage>. <pub-id pub-id-type="doi">10.1172/JCI117251</pub-id>
<pub-id pub-id-type="pmid">8200978</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalantar-Zadeh</surname><given-names>K.</given-names></name><name><surname>Kopple</surname><given-names>J. D.</given-names></name><name><surname>Deepak</surname><given-names>S.</given-names></name><name><surname>Block</surname><given-names>D.</given-names></name><name><surname>Block</surname><given-names>G.</given-names></name></person-group> (<year>2002</year>). <article-title>Food intake characteristics of hemodialysis patients as obtained by Food Frequency Questionnaire</article-title>. <source/>J. Renal Nutr.
<volume>12</volume> (<issue>1</issue>), <fpage>17</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1053/jren.2002.29598</pub-id>
</mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kang</surname><given-names>D. W.</given-names></name><name><surname>Adams</surname><given-names>J. B.</given-names></name><name><surname>Gregory</surname><given-names>A. C.</given-names></name><name><surname>Borody</surname><given-names>T.</given-names></name><name><surname>Chittick</surname><given-names>L.</given-names></name><name><surname>Fasano</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Microbiota Transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study</article-title>. <source/>Microbiome.
<volume>5</volume> (<issue>1</issue>), <fpage>10</fpage>. <pub-id pub-id-type="doi">10.1186/s40168-016-0225-7</pub-id>
<pub-id pub-id-type="pmid">28122648</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karasawa</surname><given-names>K.</given-names></name><name><surname>Asano</surname><given-names>K.</given-names></name><name><surname>Moriyama</surname><given-names>S.</given-names></name><name><surname>Ushiki</surname><given-names>M.</given-names></name><name><surname>Monya</surname><given-names>M.</given-names></name><name><surname>Iida</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Vascular-resident CD169-positive monocytes and macrophages control neutrophil accumulation in the kidney with ischemia–reperfusion injury</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>26</volume> (<issue>4</issue>), <fpage>896</fpage>–<lpage>906</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2014020195</pub-id>
<pub-id pub-id-type="pmid">25266072</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kawakami</surname><given-names>T.</given-names></name><name><surname>Lichtnekert</surname><given-names>J.</given-names></name><name><surname>Thompson</surname><given-names>L. J.</given-names></name><name><surname>Karna</surname><given-names>P.</given-names></name><name><surname>Bouabe</surname><given-names>H.</given-names></name><name><surname>Hohl</surname><given-names>T. M.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Resident renal mononuclear phagocytes comprise five discrete populations with distinct phenotypes and functions</article-title>. <source/>J. Immunol.
<volume>191</volume> (<issue>6</issue>), <fpage>3358</fpage>–<lpage>3372</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1300342</pub-id>
<pub-id pub-id-type="pmid">23956422</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kayabasi</surname><given-names>H.</given-names></name><name><surname>Yilmaz</surname><given-names>Z.</given-names></name><name><surname>Sit</surname><given-names>D.</given-names></name><name><surname>Kadiroglu</surname><given-names>A. K.</given-names></name><name><surname>Yilmaz</surname><given-names>E.</given-names></name></person-group> (<year>2013</year>). <article-title>The effects of losartan on oxidative stress and inflammation in non-diabetic patients undergoing chronic hemodialysis</article-title>. <source/>Eur. Rev. Med. Pharmacol. Sci.
<volume>17</volume> (<issue>2</issue>), <fpage>235</fpage>–<lpage>242</lpage>. <pub-id pub-id-type="pmid">23377814</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>H. J.</given-names></name><name><surname>Lee</surname><given-names>D. W.</given-names></name><name><surname>Ravichandran</surname><given-names>K.</given-names></name></person-group>, OK, D., <person-group person-group-type="author"><name><surname>Akcay</surname><given-names>A.</given-names></name><name><surname>Nguyen</surname><given-names>Q.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>NLRP3 inflammasome knockout mice are protected against ischemic but not cisplatin-induced acute kidney injury</article-title>. <source/>J. Pharmacol .Exp. Ther.
<volume>346</volume> (<issue>3</issue>), <fpage>465</fpage>–<lpage>472</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.113.205732</pub-id>
<pub-id pub-id-type="pmid">23833276</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>S. M.</given-names></name><name><surname>Lee</surname><given-names>S. H.</given-names></name><name><surname>Kim</surname><given-names>Y. G.</given-names></name><name><surname>Kim</surname><given-names>S. Y.</given-names></name><name><surname>Seo</surname><given-names>J. W.</given-names></name><name><surname>Choi</surname><given-names>Y. W.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy</article-title>. <source/>Am. J. Physiol. Renal Physiol.
<volume>308</volume> (<issue>9</issue>), <fpage>F993</fpage>–<lpage>F1003</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.00637.2014</pub-id>
<pub-id pub-id-type="pmid">25651569</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kimura</surname><given-names>I.</given-names></name><name><surname>Inoue</surname><given-names>D.</given-names></name><name><surname>Maeda</surname><given-names>T.</given-names></name><name><surname>Hara</surname><given-names>T.</given-names></name><name><surname>Ichimura</surname><given-names>A.</given-names></name><name><surname>Miyauchi</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Short-chain fatty acids and ketones directly regulate sympathetic nervous system <italic>via</italic> G protein–coupled receptor 41 (GPR41)</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>108</volume> (<issue>19</issue>), <fpage>8030</fpage>–<lpage>8035</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1016088108</pub-id>
<pub-id pub-id-type="pmid">21518883</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kinsey</surname><given-names>G. R.</given-names></name><name><surname>Sharma</surname><given-names>R.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Vergis</surname><given-names>A. L.</given-names></name><name><surname>Ye</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Regulatory T cells suppress innate immunity in kidney ischemia–reperfusion injury</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>20</volume> (<issue>8</issue>), <fpage>1744</fpage>–<lpage>1753</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2008111160</pub-id>
<pub-id pub-id-type="pmid">19497969</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Konstantinov</surname><given-names>S. R.</given-names></name><name><surname>Smidt</surname><given-names>H.</given-names></name><name><surname>de Vos</surname><given-names>W. M.</given-names></name><name><surname>Bruijns</surname><given-names>S. C.</given-names></name><name><surname>Singh</surname><given-names>S. K.</given-names></name><name><surname>Valence</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>S layer protein A of <italic>Lactobacillus acidophilus</italic> NCFM regulates immature dendritic cell and T cell functions</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>105</volume> (<issue>49</issue>), <fpage>19474</fpage>–<lpage>19479</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0810305105</pub-id>
<pub-id pub-id-type="pmid">19047644</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koropatkin</surname><given-names>N. M.</given-names></name><name><surname>Cameron</surname><given-names>E. A.</given-names></name><name><surname>Martens</surname><given-names>E. C.</given-names></name></person-group> (<year>2012</year>). <article-title>How glycan metabolism shapes the human gut microbiota</article-title>. <source/>Nat. Rev. Microbiol.
<volume>10</volume> (<issue>5</issue>), <fpage>323</fpage>–<lpage>335</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro2746</pub-id>
<pub-id pub-id-type="pmid">22491358</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kostylina</surname><given-names>G.</given-names></name><name><surname>Simon</surname><given-names>D.</given-names></name><name><surname>Fey</surname><given-names>M. F.</given-names></name><name><surname>Yousefi</surname><given-names>S.</given-names></name><name><surname>Simon</surname><given-names>H. U.</given-names></name></person-group> (<year>2008</year>). <article-title>Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A)</article-title>. <source/>Cell Death Differ.
<volume>15</volume> (<issue>1</issue>), <fpage>134</fpage>–<lpage>142</lpage>. <pub-id pub-id-type="doi">10.1038/sj.cdd.4402238</pub-id>
<pub-id pub-id-type="pmid">17932499</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kramer</surname><given-names>A. A.</given-names></name><name><surname>Postler</surname><given-names>G.</given-names></name><name><surname>Salhab</surname><given-names>K. F.</given-names></name><name><surname>Mendez</surname><given-names>C.</given-names></name><name><surname>Carey</surname><given-names>L. C.</given-names></name><name><surname>Rabb</surname><given-names>H.</given-names></name></person-group> (<year>1999</year>). <article-title>Renal ischemia/reperfusion leads to macrophage-mediated increase in pulmonary vascular permeability</article-title>. <source/>Kidney Int.
<volume>55</volume> (<issue>6</issue>), <fpage>2362</fpage>–<lpage>2367</lpage>. <pub-id pub-id-type="doi">10.1046/j.1523-1755.1999.00460.x</pub-id>
<pub-id pub-id-type="pmid">10354283</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krishnamurthy</surname><given-names>V. M.</given-names></name><name><surname>Wei</surname><given-names>G.</given-names></name><name><surname>Baird</surname><given-names>B. C.</given-names></name><name><surname>Murtaugh</surname><given-names>M.</given-names></name><name><surname>Chonchol</surname><given-names>M. B.</given-names></name><name><surname>Raphael</surname><given-names>K. L.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease</article-title>. <source/>Kidney Int.
<volume>81</volume> (<issue>3</issue>), <fpage>300</fpage>–<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2011.355</pub-id>
<pub-id pub-id-type="pmid">22012132</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kristensen</surname><given-names>N. B.</given-names></name><name><surname>Bryrup</surname><given-names>T.</given-names></name><name><surname>Allin</surname><given-names>K. H.</given-names></name><name><surname>Nielsen</surname><given-names>T.</given-names></name><name><surname>Hansen</surname><given-names>T. H.</given-names></name><name><surname>Pedersen</surname><given-names>O.</given-names></name></person-group> (<year>2016</year>). <article-title>Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials</article-title>. <source/>Genome Med.
<volume>8</volume> (<issue>1</issue>), <fpage>52</fpage>. <pub-id pub-id-type="doi">10.1186/s13073-016-0300-5</pub-id>
<pub-id pub-id-type="pmid">27159972</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kruger</surname><given-names>B.</given-names></name><name><surname>Krick</surname><given-names>S.</given-names></name><name><surname>Dhillon</surname><given-names>N.</given-names></name><name><surname>Lerner</surname><given-names>S. M.</given-names></name><name><surname>Ames</surname><given-names>S.</given-names></name><name><surname>Bromberg</surname><given-names>J. S.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>106</volume> (<issue>9</issue>), <fpage>3390</fpage>–<lpage>3395</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0810169106</pub-id>
<pub-id pub-id-type="pmid">19218437</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kurts</surname><given-names>C.</given-names></name><name><surname>Panzer</surname><given-names>U.</given-names></name><name><surname>Anders</surname><given-names>H. J.</given-names></name><name><surname>Rees</surname><given-names>A. J.</given-names></name></person-group> (<year>2013</year>). <article-title>The immune system and kidney disease: basic concepts and clinical implications</article-title>. <source/>Nat. Rev. Immunol.
<volume>13</volume> (<issue>10</issue>), <fpage>738</fpage>–<lpage>753</lpage>. <pub-id pub-id-type="doi">10.1038/nri3523</pub-id>
<pub-id pub-id-type="pmid">24037418</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Latz</surname><given-names>E.</given-names></name><name><surname>Xiao</surname><given-names>T. S.</given-names></name><name><surname>Stutz</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Activation and regulation of the inflammasomes</article-title>. <source/>Nat. Rev. Immunol.
<volume>13</volume> (<issue>6</issue>), <fpage>397</fpage>–<lpage>411</lpage>. <pub-id pub-id-type="doi">10.1038/nri3452</pub-id>
<pub-id pub-id-type="pmid">23702978</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Le Poul</surname><given-names>E.</given-names></name><name><surname>Loison</surname><given-names>C.</given-names></name><name><surname>Struyf</surname><given-names>S.</given-names></name><name><surname>Springael</surname><given-names>J. Y.</given-names></name><name><surname>Lannoy</surname><given-names>V.</given-names></name><name><surname>Decobecq</surname><given-names>M. E.</given-names></name><etal></etal></person-group> (<year>2003</year>). <article-title>Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation</article-title>. <source/>J. Biol. Chem.
<volume>278</volume> (<issue>28</issue>), <fpage>25481</fpage>–<lpage>25489</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M301403200</pub-id>
<pub-id pub-id-type="pmid">12711604</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>F. T.</given-names></name><name><surname>Cao</surname><given-names>Z.</given-names></name><name><surname>Long</surname><given-names>D. M.</given-names></name><name><surname>Panagiotopoulos</surname><given-names>S.</given-names></name><name><surname>Jerums</surname><given-names>G.</given-names></name><name><surname>Cooper</surname><given-names>M. E.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Interactions between angiotensin II and NF-kappaB–dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>15</volume> (<issue>8</issue>), <fpage>2139</fpage>–<lpage>2151</lpage>. <pub-id pub-id-type="doi">10.1097/01.ASN.0000135055.61833.A8</pub-id>
<pub-id pub-id-type="pmid">15284299</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Nho</surname><given-names>D.</given-names></name><name><surname>Chung</surname><given-names>H. S.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Shin</surname><given-names>M. K.</given-names></name><name><surname>Kim</surname><given-names>S. H.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells attenuate cisplatin-induced nephrotoxicity in mice</article-title>. <source/>Kidney Int.
<volume>78</volume> (<issue>11</issue>), <fpage>1100</fpage>–<lpage>1109</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2010.139</pub-id>
<pub-id pub-id-type="pmid">20463654</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Huen</surname><given-names>S.</given-names></name><name><surname>Nishio</surname><given-names>H.</given-names></name><name><surname>Nishio</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>H. K.</given-names></name><name><surname>Choi</surname><given-names>B. S.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Distinct macrophage phenotypes contribute to kidney injury and repair</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>22</volume> (<issue>2</issue>), <fpage>317</fpage>–<lpage>326</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2009060615</pub-id>
<pub-id pub-id-type="pmid">21289217</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>J. W.</given-names></name><name><surname>Bae</surname><given-names>E.</given-names></name><name><surname>Kwon</surname><given-names>S. H.</given-names></name><name><surname>Yu</surname><given-names>M. Y.</given-names></name><name><surname>Cha</surname><given-names>R. H.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Transcriptional modulation of the T helper 17/interleukin 17 axis ameliorates renal ischemia–reperfusion injury</article-title>. <source/>Nephrol. Dialysis Transplant.
<volume>34</volume>, <fpage>1481</fpage>–<lpage>1498</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfy370</pub-id>
</mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leemans</surname><given-names>J. C.</given-names></name><name><surname>Stokman</surname><given-names>G.</given-names></name><name><surname>Claessen</surname><given-names>N.</given-names></name><name><surname>Rouschop</surname><given-names>K. M.</given-names></name><name><surname>Teske</surname><given-names>G. J.</given-names></name><name><surname>Kirschning</surname><given-names>C. J.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney</article-title>. <source/>J. Clin. Investig.
<volume>115</volume> (<issue>10</issue>), <fpage>2894</fpage>–<lpage>2903</lpage>. <pub-id pub-id-type="doi">10.1172/JCI22832</pub-id>
<pub-id pub-id-type="pmid">16167081</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leemans</surname><given-names>J. C.</given-names></name><name><surname>Butter</surname><given-names>L. M.</given-names></name><name><surname>Pulskens</surname><given-names>W. P.</given-names></name><name><surname>Teske</surname><given-names>G. J.</given-names></name><name><surname>Claessen</surname><given-names>N.</given-names></name><name><surname>van der Poll</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>The role of Toll-like receptor 2 in inflammation and fibrosis during progressive renal injury</article-title>. <source/>PloS one
<month>5</month>
<volume>274</volume> (<issue>5</issue>), <elocation-id>e5704</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0005704</pub-id>
</mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leliefeld</surname><given-names>P. H.</given-names></name><name><surname>Wessels</surname><given-names>C. M.</given-names></name><name><surname>Leenen</surname><given-names>L. P.</given-names></name><name><surname>Koenderman</surname><given-names>L.</given-names></name><name><surname>Pillay</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>The role of neutrophils in immune dysfunction during severe inflammation</article-title>. <source/>Crit. Care.
<volume>20</volume>, <fpage>73</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-016-1250-4</pub-id>
<pub-id pub-id-type="pmid">27005275</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lemley</surname><given-names>K. V.</given-names></name><name><surname>Kriz</surname><given-names>W.</given-names></name></person-group> (<year>1991</year>). <article-title>Anatomy of the renal interstitium</article-title>. <source/>Kidney Int.
<volume>39</volume> (<issue>3</issue>), <fpage>370</fpage>–<lpage>381</lpage>. <pub-id pub-id-type="doi">10.1038/ki.1991.49</pub-id>
<pub-id pub-id-type="pmid">2062030</pub-id></mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewis</surname><given-names>E. J.</given-names></name><name><surname>Hunsicker</surname><given-names>L. G.</given-names></name><name><surname>Bain</surname><given-names>R. P.</given-names></name><name><surname>Rohde</surname><given-names>R. D.</given-names></name></person-group> (<year>1993</year>). <article-title>The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group</article-title>. <source/>N. Engl. J. Med.
<volume>329</volume> (<issue>20</issue>), <fpage>1456</fpage>–<lpage>1462</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM199311113292004</pub-id>
<pub-id pub-id-type="pmid">8413456</pub-id></mixed-citation>
</ref>
<ref id="B128">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewis</surname><given-names>E. J.</given-names></name><name><surname>Hunsicker</surname><given-names>L. G.</given-names></name><name><surname>Clarke</surname><given-names>W. R.</given-names></name><name><surname>Berl</surname><given-names>T.</given-names></name><name><surname>Pohl</surname><given-names>M. A.</given-names></name><name><surname>Lewis</surname><given-names>J. B.</given-names></name><etal></etal></person-group> (<year>2001</year>). <article-title>Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes</article-title>. <source/>N. Engl. J. Med.
<volume>345</volume> (<issue>12</issue>), <fpage>851</fpage>–<lpage>860</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa011303</pub-id>
<pub-id pub-id-type="pmid">11565517</pub-id></mixed-citation>
</ref>
<ref id="B129">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Tang</surname><given-names>P. M. K.</given-names></name><name><surname>Lv</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>X. R.</given-names></name><name><surname>Carlsson-Skwirut</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Blocking macrophage migration inhibitory factor protects against cisplatin-induced acute kidney injury in mice</article-title>. <source/>Mol Ther.
<volume>26</volume> (<issue>10</issue>), <fpage>2523</fpage>–<lpage>2532</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2018.07.014</pub-id>
<pub-id pub-id-type="pmid">30077612</pub-id></mixed-citation>
</ref>
<ref id="B130">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liano</surname><given-names>F.</given-names></name><name><surname>Felipe</surname><given-names>C.</given-names></name><name><surname>Tenorio</surname><given-names>M. T.</given-names></name><name><surname>Rivera</surname><given-names>M.</given-names></name><name><surname>Abraira</surname><given-names>V.</given-names></name></person-group>, Saez-de-<person-group person-group-type="author"><name><surname>Urturi</surname><given-names>J. M.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Long-term outcome of acute tubular necrosis: a contribution to its natural history</article-title>. <source/>Kidney Int.
<volume>71</volume> (<issue>7</issue>), <fpage>679</fpage>–<lpage>686</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ki.5002086</pub-id>
<pub-id pub-id-type="pmid">17264879</pub-id></mixed-citation>
</ref>
<ref id="B131">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>C. S.</given-names></name><name><surname>Lee</surname><given-names>W. L.</given-names></name><name><surname>Hung</surname><given-names>Y. J.</given-names></name><name><surname>Lee</surname><given-names>D. Y.</given-names></name><name><surname>Chen</surname><given-names>K. F.</given-names></name><name><surname>Chi</surname><given-names>W. C.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Prevalence of hyperuricemia and its association with antihypertensive treatment in hypertensive patients in Taiwan</article-title>. <source/>Int. J. Cardiol.
<volume>156</volume> (<issue>1</issue>), <fpage>41</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2010.10.033</pub-id>
<pub-id pub-id-type="pmid">21095025</pub-id></mixed-citation>
</ref>
<ref id="B132">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Kou</surname><given-names>P.</given-names></name><name><surname>Zeng</surname><given-names>Q.</given-names></name><name><surname>Pei</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>CD4<sup>+</sup> T Lymphocytes, especially T<sub>H</sub>2 cells, contribute to the progress of renal fibrosis</article-title>. <source/>Am. J. Nephrol.
<volume>36</volume> (<issue>4</issue>), <fpage>386</fpage>–<lpage>396</lpage>. <pub-id pub-id-type="doi">10.1159/000343283</pub-id>
<pub-id pub-id-type="pmid">23052013</pub-id></mixed-citation>
</ref>
<ref id="B133">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Krautzberger</surname><given-names>A. M.</given-names></name><name><surname>Sui</surname><given-names>S. H.</given-names></name><name><surname>Hofmann</surname><given-names>O. M.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Baetscher</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Cell-specific translational profiling in acute kidney injury</article-title>. <source/>J. Clin. Investig.
<volume>124</volume> (<issue>3</issue>), <fpage>1242</fpage>–<lpage>1254</lpage>. <pub-id pub-id-type="doi">10.1172/JCI72126</pub-id>
<pub-id pub-id-type="pmid">24569379</pub-id></mixed-citation>
</ref>
<ref id="B134">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study</article-title>. <source/>Clin Endocrinol (Oxf).
<volume>83</volume> (<issue>4</issue>), <fpage>475</fpage>–<lpage>482</lpage>. <pub-id pub-id-type="doi">10.1111/cen.12673</pub-id>
<pub-id pub-id-type="pmid">25400252</pub-id></mixed-citation>
</ref>
<ref id="B135">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lloyd-Price</surname><given-names>J.</given-names></name><name><surname>Abu-Ali</surname><given-names>G.</given-names></name><name><surname>Huttenhower</surname><given-names>C.</given-names></name></person-group> (<year>2016</year>). <article-title>The healthy human microbiome</article-title>. <source/>Genome Med.
<volume>8</volume> (<issue>1</issue>), <fpage>51</fpage>. <pub-id pub-id-type="doi">10.1186/s13073-016-0307-y</pub-id>
<pub-id pub-id-type="pmid">27122046</pub-id></mixed-citation>
</ref>
<ref id="B136">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>López-Franco</surname><given-names>O.</given-names></name><name><surname>Hernández-Vargas</surname><given-names>P.</given-names></name><name><surname>Ortiz-Muñoz</surname><given-names>G.</given-names></name><name><surname>Sanjuán</surname><given-names>G.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name><name><surname>Ortega</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>Parthenolide modulates the NF-kappaB–mediated inflammatory responses in experimental atherosclerosis</article-title>. <source/>Arterioscler. Thromb. Vasc. Biol.
<volume>26</volume> (<issue>8</issue>), <fpage>1864</fpage>–<lpage>1870</lpage>. <pub-id pub-id-type="doi">10.1161/01.ATV.0000229659.94020.53</pub-id>
<pub-id pub-id-type="pmid">16741149</pub-id></mixed-citation>
</ref>
<ref id="B137">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>L. H.</given-names></name><name><surname>Oh</surname><given-names>D. J.</given-names></name><name><surname>Dursun</surname><given-names>B.</given-names></name><name><surname>He</surname><given-names>Z.</given-names></name><name><surname>Hoke</surname><given-names>T. S.</given-names></name><name><surname>Faubel</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Increased macrophage infiltration and fractalkine expression in cisplatin-induced acute renal failure in mice</article-title>. <source/>J. Pharmacol .Exp. Ther.
<volume>324</volume> (<issue>1</issue>), <fpage>111</fpage>–<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.107.130161</pub-id>
<pub-id pub-id-type="pmid">17932247</pub-id></mixed-citation>
</ref>
<ref id="B138">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Machado</surname><given-names>F. G.</given-names></name><name><surname>Poppi</surname><given-names>E. P.</given-names></name><name><surname>Fanelli</surname><given-names>C.</given-names></name><name><surname>Malheiros</surname><given-names>D. M.</given-names></name><name><surname>Zatz</surname><given-names>R.</given-names></name><name><surname>Fujihara</surname><given-names>C. K.</given-names></name></person-group> (<year>2008</year>). <article-title>AT1 blockade during lactation as a model of chronic nephropathy: mechanisms of renal injury</article-title>. <source/>Am. J. Physiol. Renal Physiol.
<volume>294</volume> (<issue>6</issue>), <fpage>F1345</fpage>–<lpage>F1353</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.00020.2008</pub-id>
<pub-id pub-id-type="pmid">18400868</pub-id></mixed-citation>
</ref>
<ref id="B139">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>MacIver</surname><given-names>N. J.</given-names></name><name><surname>Michalek</surname><given-names>R. D.</given-names></name><name><surname>Rathmell</surname><given-names>J. C.</given-names></name></person-group> (<year>2013</year>). <article-title>Metabolic regulation of T lymphocytes</article-title>. <source/>Annu. Rev. Immunol.
<volume>31</volume>, <fpage>259</fpage>–<lpage>283</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-095956</pub-id>
<pub-id pub-id-type="pmid">23298210</pub-id></mixed-citation>
</ref>
<ref id="B140">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Makkawi</surname><given-names>S.</given-names></name><name><surname>Camara-Lemarroy</surname><given-names>C.</given-names></name><name><surname>Metz</surname><given-names>L.</given-names></name></person-group> (<year>2018</year>). <article-title>Fecal microbiota transplantation associated with 10 years of stability in a patient with SPMS</article-title>. <source/>Neurol. Neuroimmunol. Neuroinflammation
<volume>5</volume> (<issue>4</issue>), <elocation-id>e459</elocation-id>. <pub-id pub-id-type="doi">10.1212/NXI.0000000000000459</pub-id>
</mixed-citation>
</ref>
<ref id="B141">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maravitsa</surname><given-names>P.</given-names></name><name><surname>Adamopoulou</surname><given-names>M.</given-names></name><name><surname>Pistiki</surname><given-names>A.</given-names></name><name><surname>Netea</surname><given-names>M. G.</given-names></name><name><surname>Louis</surname><given-names>K.</given-names></name><name><surname>Giamarellos-Bourboulis</surname><given-names>E. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Systemic over-release of interleukin-17 in acute kidney injury after septic shock: clinical and experimental evidence</article-title>. <source/>Immunol. Lett.
<volume>178</volume>, <fpage>68</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/j.imlet.2016.08.002</pub-id>
<pub-id pub-id-type="pmid">27515003</pub-id></mixed-citation>
</ref>
<ref id="B142">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marques</surname><given-names>V. P.</given-names></name><name><surname>Goncalves</surname><given-names>G. M.</given-names></name><name><surname>Feitoza</surname><given-names>C. Q.</given-names></name><name><surname>Cenedeze</surname><given-names>M. A.</given-names></name><name><surname>Fernandes Bertocchi</surname><given-names>A. P.</given-names></name><name><surname>Damiao</surname><given-names>M. J.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>Influence of T<sub>H</sub>1/T<sub>H</sub>2 switched immune response on renal ischemia–reperfusion injury</article-title>. <source/>Nephron Exp. Nephrol.
<volume>104</volume> (<issue>1</issue>), <fpage>e48</fpage>–<lpage>e56</lpage>. <pub-id pub-id-type="doi">10.1159/000093676</pub-id>
<pub-id pub-id-type="pmid">16741373</pub-id></mixed-citation>
</ref>
<ref id="B143">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martin</surname><given-names>V.</given-names></name><name><surname>Maldonado-Barragan</surname><given-names>A.</given-names></name><name><surname>Moles</surname><given-names>L.</given-names></name><name><surname>Rodriguez-Banos</surname><given-names>M.</given-names></name><name><surname>Campo</surname><given-names>R. D.</given-names></name><name><surname>Fernandez</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Sharing of bacterial strains between breast milk and infant feces</article-title>. <source/>J. Hum. Lactation
<volume>28</volume> (<issue>1</issue>), <fpage>36</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1177/0890334411424729</pub-id>
</mixed-citation>
</ref>
<ref id="B144">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martina</surname><given-names>M. N.</given-names></name><name><surname>Noel</surname><given-names>S.</given-names></name><name><surname>Saxena</surname><given-names>A.</given-names></name><name><surname>Bandapalle</surname><given-names>S.</given-names></name><name><surname>Majithia</surname><given-names>R.</given-names></name><name><surname>Jie</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Double-negative alphabeta T cells are early responders to aki and are found in human kidney</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>27</volume> (<issue>4</issue>), <fpage>1113</fpage>–<lpage>1123</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2014121214</pub-id>
<pub-id pub-id-type="pmid">26315532</pub-id></mixed-citation>
</ref>
<ref id="B145">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martinez</surname><given-names>I.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Duffy</surname><given-names>P. R.</given-names></name><name><surname>Schlegel</surname><given-names>V. L.</given-names></name><name><surname>Walter</surname><given-names>J.</given-names></name></person-group> (<year>2010</year>). <article-title>Resistant starches types 2 and 4 have differential effects on the composition of the fecal microbiota in human subjects</article-title>. <source/>PloS one
<volume>5</volume> (<issue>11</issue>), <elocation-id>e15046</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0015046</pub-id>
<pub-id pub-id-type="pmid">21151493</pub-id></mixed-citation>
</ref>
<ref id="B146">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McIntyre</surname><given-names>C. W.</given-names></name><name><surname>Harrison</surname><given-names>L. E.</given-names></name><name><surname>Eldehni</surname><given-names>M. T.</given-names></name><name><surname>Jefferies</surname><given-names>H. J.</given-names></name><name><surname>Szeto</surname><given-names>C. C.</given-names></name><name><surname>John</surname><given-names>S. G.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease</article-title>. <source/>Clin J. Am. Soc. Nephrol.
<volume>6</volume> (<issue>1</issue>), <fpage>133</fpage>–<lpage>141</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.04610510</pub-id>
<pub-id pub-id-type="pmid">20876680</pub-id></mixed-citation>
</ref>
<ref id="B147">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meijers</surname><given-names>B. K.</given-names></name><name><surname>Claes</surname><given-names>K.</given-names></name><name><surname>Bammens</surname><given-names>B.</given-names></name><name><surname>de Loor</surname><given-names>H.</given-names></name><name><surname>Viaene</surname><given-names>L.</given-names></name><name><surname>Verbeke</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2010</year>a). <article-title>p-Cresol and cardiovascular risk in mild-to-moderate kidney disease</article-title>. <source/>Clin J. Am. Soc. Nephrol.
<volume>5</volume> (<issue>7</issue>), <fpage>1182</fpage>–<lpage>1189</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.07971109</pub-id>
<pub-id pub-id-type="pmid">20430946</pub-id></mixed-citation>
</ref>
<ref id="B148">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meijers</surname><given-names>B. K.</given-names></name><name><surname>De Preter</surname><given-names>V.</given-names></name><name><surname>Verbeke</surname><given-names>K.</given-names></name><name><surname>Vanrenterghem</surname><given-names>Y.</given-names></name><name><surname>Evenepoel</surname><given-names>P.</given-names></name></person-group> (<year>2010</year>b). <article-title>p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin</article-title>. <source/>Nephrol. Dialysis Transplant.
<volume>25</volume> (<issue>1</issue>), <fpage>219</fpage>–<lpage>224</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfp414</pub-id>
</mixed-citation>
</ref>
<ref id="B149">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Merino</surname><given-names>A.</given-names></name><name><surname>Alvarez-Lara</surname><given-names>M. A.</given-names></name><name><surname>Ramirez</surname><given-names>R.</given-names></name><name><surname>Carracedo</surname><given-names>J.</given-names></name><name><surname>Martin-Malo</surname><given-names>A.</given-names></name><name><surname>Aljama</surname><given-names>P.</given-names></name></person-group> (<year>2012</year>). <article-title>Losartan prevents the development of the pro-inflammatory monocytes CD14<sup>+</sup>CD16<sup>+</sup> in haemodialysis patients</article-title>. <source/>Nephrol. Dial. Transplant.
<volume>27</volume> (<issue>7</issue>), <fpage>2907</fpage>–<lpage>2912</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfr767</pub-id>
<pub-id pub-id-type="pmid">22247233</pub-id></mixed-citation>
</ref>
<ref id="B150">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Monteiro</surname><given-names>R. M.</given-names></name><name><surname>Camara</surname><given-names>N. O.</given-names></name><name><surname>Rodrigues</surname><given-names>M. M.</given-names></name><name><surname>Tzelepis</surname><given-names>F.</given-names></name><name><surname>Damiao</surname><given-names>M. J.</given-names></name><name><surname>Cenedeze</surname><given-names>M. A.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>A role for regulatory T cells in renal acute kidney injury</article-title>. <source/>Transpl. Immunol.
<volume>21</volume> (<issue>1</issue>), <fpage>50</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.trim.2009.02.003</pub-id>
<pub-id pub-id-type="pmid">19233269</pub-id></mixed-citation>
</ref>
<ref id="B151">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Motojima</surname><given-names>M.</given-names></name><name><surname>Hosokawa</surname><given-names>A.</given-names></name><name><surname>Yamato</surname><given-names>H.</given-names></name><name><surname>Muraki</surname><given-names>T.</given-names></name><name><surname>Yoshioka</surname><given-names>T.</given-names></name></person-group> (<year>2003</year>). <article-title>Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells</article-title>. <source/>Kidney Int.
<volume>63</volume> (<issue>5</issue>), <fpage>1671</fpage>–<lpage>1680</lpage>. <pub-id pub-id-type="doi">10.1046/j.1523-1755.2003.00906.x</pub-id>
<pub-id pub-id-type="pmid">12675842</pub-id></mixed-citation>
</ref>
<ref id="B152">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mulay</surname><given-names>S. R.</given-names></name><name><surname>Anders</surname><given-names>H. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Crystal nephropathies: mechanisms of crystal-induced kidney injury</article-title>. <source/>Nat. Rev. Nephrol.
<volume>13</volume> (<issue>4</issue>), <fpage>226</fpage>–<lpage>240</lpage>. <pub-id pub-id-type="doi">10.1038/nrneph.2017.10</pub-id>
<pub-id pub-id-type="pmid">28218266</pub-id></mixed-citation>
</ref>
<ref id="B153">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakabayashi</surname><given-names>I.</given-names></name><name><surname>Nakamura</surname><given-names>M.</given-names></name><name><surname>Kawakami</surname><given-names>K.</given-names></name><name><surname>Ohta</surname><given-names>T.</given-names></name><name><surname>Kato</surname><given-names>I.</given-names></name><name><surname>Uchida</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study</article-title>. <source/>Nephrol. Dialysis Transplant.
<volume>26</volume> (<issue>3</issue>), <fpage>1094</fpage>–<lpage>1098</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfq624</pub-id>
</mixed-citation>
</ref>
<ref id="B154">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nataraj</surname><given-names>C.</given-names></name><name><surname>Oliverio</surname><given-names>M. I.</given-names></name><name><surname>Mannon</surname><given-names>R. B.</given-names></name><name><surname>Mannon</surname><given-names>P. J.</given-names></name><name><surname>Audoly</surname><given-names>L. P.</given-names></name><name><surname>Amuchastegui</surname><given-names>C. S.</given-names></name><etal></etal></person-group> (<year>1999</year>). <article-title>Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway</article-title>. <source/>J. Clin. Invest.
<volume>104</volume> (<issue>12</issue>), <fpage>1693</fpage>–<lpage>1701</lpage>. <pub-id pub-id-type="doi">10.1172/JCI7451</pub-id>
<pub-id pub-id-type="pmid">10606623</pub-id></mixed-citation>
</ref>
<ref id="B155">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nelson</surname><given-names>P. J.</given-names></name><name><surname>Rees</surname><given-names>A. J.</given-names></name><name><surname>Griffin</surname><given-names>M. D.</given-names></name><name><surname>Hughes</surname><given-names>J.</given-names></name><name><surname>Kurts</surname><given-names>C.</given-names></name><name><surname>Duffield</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>The renal mononuclear phagocytic system</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>23</volume> (<issue>2</issue>), <fpage>194</fpage>–<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2011070680</pub-id>
<pub-id pub-id-type="pmid">22135312</pub-id></mixed-citation>
</ref>
<ref id="B156">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>J. K.</given-names></name><name><surname>Holmes</surname><given-names>E.</given-names></name><name><surname>Kinross</surname><given-names>J.</given-names></name><name><surname>Burcelin</surname><given-names>R.</given-names></name><name><surname>Gibson</surname><given-names>G.</given-names></name><name><surname>Jia</surname><given-names>W.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Host-gut microbiota metabolic interactions</article-title>. <source/>Science
<volume>336</volume> (<issue>6086</issue>), <fpage>1262</fpage>–<lpage>1267</lpage>. <pub-id pub-id-type="doi">10.1126/science.1223813</pub-id>
<pub-id pub-id-type="pmid">22674330</pub-id></mixed-citation>
</ref>
<ref id="B157">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nogueira</surname><given-names>E.</given-names></name><name><surname>Salomao</surname><given-names>R.</given-names></name><name><surname>Brunialti</surname><given-names>M. K.</given-names></name><name><surname>Ozaki</surname><given-names>K. S.</given-names></name><name><surname>Marques</surname><given-names>G. D.</given-names></name><name><surname>Cenedeze</surname><given-names>M. A.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Expression of TLR-4 and -2 in peripheral mononuclear cells in renal transplant patients with TLR-4 gene polymorphism</article-title>. <source/>Int. Immunopharmacol.
<volume>10</volume> (<issue>12</issue>), <fpage>1481</fpage>–<lpage>1485</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2010.09.005</pub-id>
<pub-id pub-id-type="pmid">20951669</pub-id></mixed-citation>
</ref>
<ref id="B158">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ogryzlo</surname><given-names>M. A.</given-names></name><name><surname>Urowitz</surname><given-names>M. B.</given-names></name><name><surname>Weber</surname><given-names>H. M.</given-names></name><name><surname>Houpt</surname><given-names>J. B.</given-names></name></person-group> (<year>1966</year>). <article-title>The treatment of gout and disorders of uric acid metabolism with allopurinol</article-title>. <source/>Can Med Assoc J.
<volume>95</volume> (<issue>22</issue>), <fpage>1120</fpage>–<lpage>1127</lpage>. <pub-id pub-id-type="pmid">5923471</pub-id></mixed-citation>
</ref>
<ref id="B159">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Okabe</surname><given-names>C.</given-names></name><name><surname>Borges</surname><given-names>R. L.</given-names></name><name><surname>de Almeida</surname><given-names>D. C.</given-names></name><name><surname>Fanelli</surname><given-names>C.</given-names></name><name><surname>Barlette</surname><given-names>G. P.</given-names></name><name><surname>Machado</surname><given-names>F. G.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>NF-kappaB activation mediates crystal translocation and interstitial inflammation in adenine overload nephropathy</article-title>. <source/>Am. J. Physiol. Renal Physiol.
<volume>305</volume> (<issue>2</issue>), <fpage>F155</fpage>–<lpage>F163</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.00491.2012</pub-id>
<pub-id pub-id-type="pmid">23657853</pub-id></mixed-citation>
</ref>
<ref id="B160">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Okabe</surname><given-names>C.</given-names></name><name><surname>Borges</surname><given-names>R. L.</given-names></name><name><surname>de Almeida</surname><given-names>D. C.</given-names></name><name><surname>Fanelli</surname><given-names>C.</given-names></name><name><surname>Barlette</surname><given-names>G. P.</given-names></name><name><surname>Machado</surname><given-names>F. G.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>NF-κB activation mediates crystal translocation and interstitial inflammation in adenine overload nephropathy</article-title>. <source/>Am. J. Physiol. Renal Physiol.
<volume>305</volume> (<issue>2</issue>), <fpage>F155</fpage>–<lpage>F163</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.00491.2012</pub-id>
<pub-id pub-id-type="pmid">23657853</pub-id></mixed-citation>
</ref>
<ref id="B161">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ordaz-Medina</surname><given-names>S. M.</given-names></name><name><surname>González-Plascencia</surname><given-names>J.</given-names></name></person-group>, Martín <person-group person-group-type="author"><name><surname>del Campo</surname><given-names>F.</given-names></name><name><surname>Rojas-Campos</surname><given-names>E.</given-names></name><name><surname>Montañez-Fernández</surname><given-names>J. L.</given-names></name><name><surname>Espinoza-Gómez</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Is systemic inflammation of hemodialysis patients improved with the use of enalapril? Results of a randomized, double-blinded, placebo-controlled clinical trial</article-title>. <source/>ASAIO J. 2010
<volume>56</volume> (<issue>1</issue>), <fpage>37</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1097/MAT.0b013e3181c1d830</pub-id>
</mixed-citation>
</ref>
<ref id="B162">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parikh</surname><given-names>C. R.</given-names></name><name><surname>Jani</surname><given-names>A.</given-names></name><name><surname>Mishra</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>Q.</given-names></name><name><surname>Kelly</surname><given-names>C.</given-names></name><name><surname>Barasch</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation</article-title>. <source/>Am. J. Transplant.
<volume>6</volume> (<issue>7</issue>), <fpage>1639</fpage>–<lpage>1645</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-6143.2006.01352.x</pub-id>
<pub-id pub-id-type="pmid">16827865</pub-id></mixed-citation>
</ref>
<ref id="B163">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parish</surname><given-names>I. A.</given-names></name><name><surname>Kaech</surname><given-names>S. M.</given-names></name></person-group> (<year>2009</year>). <article-title>Diversity in CD8(+) T cell differentiation</article-title>. <source/>Curr. Opin. Immunol.
<volume>21</volume> (<issue>3</issue>), <fpage>291</fpage>–<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2009.05.008</pub-id>
<pub-id pub-id-type="pmid">19497720</pub-id></mixed-citation>
</ref>
<ref id="B164">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patel</surname><given-names>R. M.</given-names></name><name><surname>Denning</surname><given-names>P. W.</given-names></name></person-group> (<year>2013</year>). <article-title>Therapeutic use of prebiotics, probiotics, and postbiotics to prevent necrotizing enterocolitis: what is the current evidence</article-title>? <source/>Clin. Perinatol.
<volume>40</volume> (<issue>1</issue>), <fpage>11</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.clp.2012.12.002</pub-id>
<pub-id pub-id-type="pmid">23415261</pub-id></mixed-citation>
</ref>
<ref id="B165">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pavan</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Influence of prebiotic and probiotic supplementation on the progression of chronic kidney disease</article-title>. <source/>Minerva Urol Nefrol = Ital. J. Urol. Nephrol.
<volume>68</volume> (<issue>2</issue>), <fpage>222</fpage>–<lpage>226</lpage>. </mixed-citation>
</ref>
<ref id="B166">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perez-Cobas</surname><given-names>A. E.</given-names></name><name><surname>Gosalbes</surname><given-names>M. J.</given-names></name><name><surname>Friedrichs</surname><given-names>A.</given-names></name><name><surname>Knecht</surname><given-names>H.</given-names></name><name><surname>Artacho</surname><given-names>A.</given-names></name><name><surname>Eismann</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Gut microbiota disturbance during antibiotic therapy: a multi-omic approach</article-title>. <source/>Gut
<volume>62</volume> (<issue>11</issue>), <fpage>1591</fpage>–<lpage>1601</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2012-303184</pub-id>
<pub-id pub-id-type="pmid">23236009</pub-id></mixed-citation>
</ref>
<ref id="B167">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peters</surname><given-names>C. D.</given-names></name><name><surname>Kjaergaard</surname><given-names>K. D.</given-names></name><name><surname>Nielsen</surname><given-names>C. H.</given-names></name><name><surname>Christensen</surname><given-names>K. L.</given-names></name><name><surname>Bibby</surname><given-names>B. M.</given-names></name><name><surname>Jensen</surname><given-names>J. D.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Long-term effects of angiotensin II blockade with irbesartan on inflammatory markers in hemodialysis patients: a randomized double blind placebo controlled trial (SAFIR study)</article-title>. <source/>Hemodial. Int.
<volume>21</volume> (<issue>1</issue>), <fpage>47</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1111/hdi.12436</pub-id>
<pub-id pub-id-type="pmid">27346437</pub-id></mixed-citation>
</ref>
<ref id="B168">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pinero-Lambea</surname><given-names>C.</given-names></name><name><surname>Ruano-Gallego</surname><given-names>D.</given-names></name><name><surname>Fernandez</surname><given-names>L. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Engineered bacteria as therapeutic agents</article-title>. <source/>Curr. Opin. Biotechnol.
<volume>35</volume>, <fpage>94</fpage>–<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1016/j.copbio.2015.05.004</pub-id>
<pub-id pub-id-type="pmid">26070111</pub-id></mixed-citation>
</ref>
<ref id="B169">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Poesen</surname><given-names>R.</given-names></name><name><surname>Windey</surname><given-names>K.</given-names></name><name><surname>Neven</surname><given-names>E.</given-names></name><name><surname>Kuypers</surname><given-names>D.</given-names></name><name><surname>De Preter</surname><given-names>V.</given-names></name><name><surname>Augustijns</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>The influence of CKD on colonic microbial metabolism</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>27</volume> (<issue>5</issue>), <fpage>1389</fpage>–<lpage>1399</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2015030279</pub-id>
<pub-id pub-id-type="pmid">26400570</pub-id></mixed-citation>
</ref>
<ref id="B170">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prakash</surname><given-names>S.</given-names></name><name><surname>Chang</surname><given-names>T. M.</given-names></name></person-group> (<year>1996</year>). <article-title>Microencapsulated genetically engineered live <italic>E. coli</italic> DH5 cells administered orally to maintain normal plasma urea level in uremic rats</article-title>. <source/>Nat. Med.
<volume>2</volume> (<issue>8</issue>), <fpage>883</fpage>–<lpage>887</lpage>. <pub-id pub-id-type="doi">10.1038/nm0896-883</pub-id>
<pub-id pub-id-type="pmid">8705857</pub-id></mixed-citation>
</ref>
<ref id="B171">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pulskens</surname><given-names>W. P.</given-names></name><name><surname>Rampanelli</surname><given-names>E.</given-names></name><name><surname>Teske</surname><given-names>G. J.</given-names></name><name><surname>Butter</surname><given-names>L. M.</given-names></name><name><surname>Claessen</surname><given-names>N.</given-names></name><name><surname>Luirink</surname><given-names>I. K.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>TLR4 promotes fibrosis but attenuates tubular damage in progressive renal injury</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>21</volume> (<issue>8</issue>), <fpage>1299</fpage>–<lpage>1308</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2009070722</pub-id>
<pub-id pub-id-type="pmid">20595685</pub-id></mixed-citation>
</ref>
<ref id="B172">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pulskens</surname><given-names>W. P.</given-names></name><name><surname>Butter</surname><given-names>L. M.</given-names></name><name><surname>Teske</surname><given-names>G. J.</given-names></name><name><surname>Claessen</surname><given-names>N.</given-names></name><name><surname>Dessing</surname><given-names>M. C.</given-names></name><name><surname>Flavell</surname><given-names>R. A.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Nlrp3 prevents early renal interstitial edema and vascular permeability in unilateral ureteral obstruction</article-title>. <source/>PloS one
<volume>9</volume> (<issue>1</issue>), <elocation-id>e85775</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0085775</pub-id>
<pub-id pub-id-type="pmid">24454932</pub-id></mixed-citation>
</ref>
<ref id="B173">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rabb</surname><given-names>H.</given-names></name><name><surname>Daniels</surname><given-names>F.</given-names></name><name><surname>O’Donnell</surname><given-names>M.</given-names></name><name><surname>Haq</surname><given-names>M.</given-names></name><name><surname>Saba</surname><given-names>S. R.</given-names></name><name><surname>Keane</surname><given-names>W.</given-names></name><etal></etal></person-group> (<year>2000</year>). <article-title>Pathophysiological role of T lymphocytes in renal ischemia–reperfusion injury in mice</article-title>. <source/>Am. J. Physiol. Renal Physiol.
<volume>279</volume> (<issue>3</issue>), <fpage>F525</fpage>–<lpage>F531</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.2000.279.3.F525</pub-id>
<pub-id pub-id-type="pmid">10966932</pub-id></mixed-citation>
</ref>
<ref id="B174">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ranganathan</surname><given-names>N.</given-names></name><name><surname>Patel</surname><given-names>B.</given-names></name><name><surname>Ranganathan</surname><given-names>P.</given-names></name><name><surname>Marczely</surname><given-names>J.</given-names></name><name><surname>Dheer</surname><given-names>R.</given-names></name><name><surname>Chordia</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>Probiotic amelioration of azotemia in 5/6th nephrectomized Sprague-Dawley rats</article-title>. <source/>Sci. World J.
<volume>5</volume>, <fpage>652</fpage>–<lpage>660</lpage>. <pub-id pub-id-type="doi">10.1100/tsw.2005.86</pub-id>
</mixed-citation>
</ref>
<ref id="B175">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ranganathan</surname><given-names>N.</given-names></name><name><surname>Patel</surname><given-names>B. G.</given-names></name><name><surname>Ranganathan</surname><given-names>P.</given-names></name><name><surname>Marczely</surname><given-names>J.</given-names></name><name><surname>Dheer</surname><given-names>R.</given-names></name><name><surname>Pechenyak</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>In vitro and <italic>in vivo</italic> assessment of intraintestinal bacteriotherapy in chronic kidney disease</article-title>. <source/>ASAIO J.
<volume>52</volume> (<issue>1</issue>), <fpage>70</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1097/01.mat.0000191345.45735.00</pub-id>
<pub-id pub-id-type="pmid">16436893</pub-id></mixed-citation>
</ref>
<ref id="B176">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ranganathan</surname><given-names>N.</given-names></name><name><surname>Ranganathan</surname><given-names>P.</given-names></name><name><surname>Friedman</surname><given-names>E. A.</given-names></name><name><surname>Joseph</surname><given-names>A.</given-names></name><name><surname>Delano</surname><given-names>B.</given-names></name><name><surname>Goldfarb</surname><given-names>D. S.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease</article-title>. <source/>Adv. Ther.
<volume>27</volume> (<issue>9</issue>), <fpage>634</fpage>–<lpage>647</lpage>. <pub-id pub-id-type="doi">10.1007/s12325-010-0059-9</pub-id>
<pub-id pub-id-type="pmid">20721651</pub-id></mixed-citation>
</ref>
<ref id="B177">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raup-Konsavage</surname><given-names>W. M.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>W. W.</given-names></name><name><surname>Feliers</surname><given-names>D.</given-names></name><name><surname>Ruan</surname><given-names>H.</given-names></name><name><surname>Reeves</surname><given-names>W. B.</given-names></name></person-group> (<year>2018</year>). <article-title>Neutrophil peptidyl arginine deiminase-4 has a pivotal role in ischemia/reperfusion-induced acute kidney injury</article-title>. <source/>Kidney Int.
<volume>93</volume> (<issue>2</issue>), <fpage>365</fpage>–<lpage>374</lpage>. <pub-id pub-id-type="doi">10.1016/j.kint.2017.08.014</pub-id>
<pub-id pub-id-type="pmid">29061334</pub-id></mixed-citation>
</ref>
<ref id="B178">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rice</surname><given-names>J. L.</given-names></name><name><surname>Romero</surname><given-names>K. M.</given-names></name><name><surname>Galvez Davila</surname><given-names>R. M.</given-names></name><name><surname>Meza</surname><given-names>C. T.</given-names></name><name><surname>Bilderback</surname><given-names>A.</given-names></name><name><surname>Williams</surname><given-names>D. L.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Association between adherence to the mediterranean diet and asthma in Peruvian children</article-title>. <source/>Lung
<volume>193</volume> (<issue>6</issue>), <fpage>893</fpage>–<lpage>899</lpage>. <pub-id pub-id-type="doi">10.1007/s00408-015-9792-9</pub-id>
<pub-id pub-id-type="pmid">26335393</pub-id></mixed-citation>
</ref>
<ref id="B179">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Richter</surname><given-names>C. K.</given-names></name><name><surname>Skulas-Ray</surname><given-names>A. C.</given-names></name><name><surname>Champagne</surname><given-names>C. M.</given-names></name><name><surname>Kris-Etherton</surname><given-names>P. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Plant protein and animal proteins: do they differentially affect cardiovascular disease risk</article-title>? <source/>Adv. Nutr.
<volume>6</volume> (<issue>6</issue>), <fpage>712</fpage>–<lpage>728</lpage>. <pub-id pub-id-type="doi">10.3945/an.115.009654</pub-id>
<pub-id pub-id-type="pmid">26567196</pub-id></mixed-citation>
</ref>
<ref id="B180">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rook</surname><given-names>G. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Regulation of the immune system by biodiversity from the natural environment: an ecosystem service essential to health</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>110</volume> (<issue>46</issue>), <fpage>18360</fpage>–<lpage>18367</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1313731110</pub-id>
<pub-id pub-id-type="pmid">24154724</pub-id></mixed-citation>
</ref>
<ref id="B181">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rooks</surname><given-names>M. G.</given-names></name><name><surname>Garrett</surname><given-names>W. S.</given-names></name></person-group> (<year>2016</year>). <article-title>Gut microbiota, metabolites and host immunity</article-title>. <source/>Nat. Rev. Immunol.
<volume>16</volume> (<issue>6</issue>), <fpage>341</fpage>–<lpage>352</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2016.42</pub-id>
<pub-id pub-id-type="pmid">27231050</pub-id></mixed-citation>
</ref>
<ref id="B182">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosin</surname><given-names>D. L.</given-names></name><name><surname>Okusa</surname><given-names>M. D.</given-names></name></person-group> (<year>2011</year>). <article-title>Dangers within: DAMP responses to damage and cell death in kidney disease</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>22</volume> (<issue>3</issue>), <fpage>416</fpage>–<lpage>425</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2010040430</pub-id>
<pub-id pub-id-type="pmid">21335516</pub-id></mixed-citation>
</ref>
<ref id="B183">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rossi</surname><given-names>M.</given-names></name><name><surname>Johnson</surname><given-names>D. W.</given-names></name><name><surname>Morrison</surname><given-names>M.</given-names></name><name><surname>Pascoe</surname><given-names>E. M.</given-names></name><name><surname>Coombes</surname><given-names>J. S.</given-names></name><name><surname>Forbes</surname><given-names>J. M.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): a randomized trial</article-title>. <source/>Clin. J. Am. Soc. Nephrol.
<volume>11</volume> (<issue>2</issue>), <fpage>223</fpage>–<lpage>231</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.05240515</pub-id>
<pub-id pub-id-type="pmid">26772193</pub-id></mixed-citation>
</ref>
<ref id="B184">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rostron</surname><given-names>A. J.</given-names></name><name><surname>Cork</surname><given-names>D. M.</given-names></name><name><surname>Avlonitis</surname><given-names>V. S.</given-names></name><name><surname>Fisher</surname><given-names>A. J.</given-names></name><name><surname>Dark</surname><given-names>J. H.</given-names></name><name><surname>Kirby</surname><given-names>J. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Contribution of Toll-like receptor activation to lung damage after donor brain death</article-title>. <source/>Transplantation
<volume>90</volume> (<issue>7</issue>), <fpage>732</fpage>–<lpage>739</lpage>. <pub-id pub-id-type="doi">10.1097/TP.0b013e3181eefe02</pub-id>
<pub-id pub-id-type="pmid">20671596</pub-id></mixed-citation>
</ref>
<ref id="B185">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rowland</surname><given-names>I.</given-names></name><name><surname>Gibson</surname><given-names>G.</given-names></name><name><surname>Heinken</surname><given-names>A.</given-names></name><name><surname>Scott</surname><given-names>K.</given-names></name><name><surname>Swann</surname><given-names>J.</given-names></name><name><surname>Thiele</surname><given-names>I.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Gut microbiota functions: metabolism of nutrients and other food components</article-title>. <source/>Eur. J. Nutr.
<volume>57</volume> (<issue>1</issue>), <fpage>1</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1007/s00394-017-1445-8</pub-id>
</mixed-citation>
</ref>
<ref id="B186">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ruiz-Ortega</surname><given-names>M.</given-names></name><name><surname>Bustos</surname><given-names>C.</given-names></name><name><surname>Hernández-Presa</surname><given-names>M. A.</given-names></name><name><surname>Lorenzo</surname><given-names>O.</given-names></name><name><surname>Plaza</surname><given-names>J. J.</given-names></name><name><surname>Egido</surname><given-names>J.</given-names></name></person-group> (<year>1998</year>). <article-title>Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis</article-title>. <source/>J. Immunol.
<volume>161</volume> (<issue>1</issue>), <fpage>430</fpage>–<lpage>439</lpage>. <pub-id pub-id-type="pmid">9647253</pub-id></mixed-citation>
</ref>
<ref id="B187">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ruiz-Ortega</surname><given-names>M.</given-names></name><name><surname>Rupérez</surname><given-names>M.</given-names></name><name><surname>Esteban</surname><given-names>V.</given-names></name><name><surname>Rodríguez-Vita</surname><given-names>J.</given-names></name><name><surname>Sánchez-López</surname><given-names>E.</given-names></name><name><surname>Carvajal</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases</article-title>. <source/>Nephrol. Dial. Transplant.
<volume>21</volume> (<issue>1</issue>), <fpage>16</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfi265</pub-id>
<pub-id pub-id-type="pmid">16280370</pub-id></mixed-citation>
</ref>
<ref id="B188">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Russell</surname><given-names>W. R.</given-names></name><name><surname>Gratz</surname><given-names>S. W.</given-names></name><name><surname>Duncan</surname><given-names>S. H.</given-names></name><name><surname>Holtrop</surname><given-names>G.</given-names></name><name><surname>Ince</surname><given-names>J.</given-names></name><name><surname>Scobbie</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>High-protein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health</article-title>. <source/>Am. J. Clin. Nutr.
<volume>93</volume> (<issue>5</issue>), <fpage>1062</fpage>–<lpage>1072</lpage>. <pub-id pub-id-type="doi">10.3945/ajcn.110.002188</pub-id>
<pub-id pub-id-type="pmid">21389180</pub-id></mixed-citation>
</ref>
<ref id="B189">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sanchez-Villegas</surname><given-names>A.</given-names></name><name><surname>Henriquez-Sanchez</surname><given-names>P.</given-names></name><name><surname>Ruiz-Canela</surname><given-names>M.</given-names></name><name><surname>Lahortiga</surname><given-names>F.</given-names></name><name><surname>Molero</surname><given-names>P.</given-names></name><name><surname>Toledo</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>A longitudinal analysis of diet quality scores and the risk of incident depression in the SUN Project</article-title>. <source/>BMC Med.
<volume>13</volume>, <fpage>197</fpage>. <pub-id pub-id-type="doi">10.1186/s12916-015-0428-y</pub-id>
<pub-id pub-id-type="pmid">26377327</pub-id></mixed-citation>
</ref>
<ref id="B190">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sanders</surname><given-names>S. A.</given-names></name><name><surname>Eisenthal</surname><given-names>R.</given-names></name><name><surname>Harrison</surname><given-names>R.</given-names></name></person-group> (<year>1997</year>). <article-title>NADH oxidase activity of human xanthine oxidoreductase—generation of superoxide anion</article-title>. <source/>Eur. J. Biochem.
<volume>245</volume> (<issue>3</issue>), <fpage>541</fpage>–<lpage>548</lpage>. <pub-id pub-id-type="doi">10.1111/j.1432-1033.1997.00541.x</pub-id>
<pub-id pub-id-type="pmid">9182988</pub-id></mixed-citation>
</ref>
<ref id="B191">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sanz</surname><given-names>A. B.</given-names></name><name><surname>Sanchez-Niño</surname><given-names>M. D.</given-names></name><name><surname>Ramos</surname><given-names>A. M.</given-names></name><name><surname>Moreno</surname><given-names>J. A.</given-names></name><name><surname>Santamaria</surname><given-names>B.</given-names></name><name><surname>Ruiz-Ortega</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>NF-kappaB in renal inflammation</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>21</volume> (<issue>8</issue>), <fpage>1254</fpage>–<lpage>1262</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2010020218</pub-id>
<pub-id pub-id-type="pmid">20651166</pub-id></mixed-citation>
</ref>
<ref id="B192">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saran</surname><given-names>R.</given-names></name><name><surname>Robinson</surname><given-names>B.</given-names></name><name><surname>Abbott</surname><given-names>K. C.</given-names></name><name><surname>Agodoa</surname><given-names>L. Y.</given-names></name><name><surname>Albertus</surname><given-names>P.</given-names></name><name><surname>Ayanian</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>US Renal Data System 2016 annual data report: epidemiology of kidney disease in the United States</article-title>. <source/>Am. J. Kidney Dis.
<volume>69</volume> (<issue> Suppl 1</issue>), <fpage>A7</fpage>–<lpage>A8</lpage>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2016.12.004</pub-id>
<pub-id pub-id-type="pmid">28236831</pub-id></mixed-citation>
</ref>
<ref id="B193">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saran</surname><given-names>R.</given-names></name><name><surname>Robinson</surname><given-names>B.</given-names></name><name><surname>Abbott</surname><given-names>K. C.</given-names></name><name><surname>Agodoa</surname><given-names>L. Y. C.</given-names></name><name><surname>Bhave</surname><given-names>N.</given-names></name><name><surname>Bragg-Gresham</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>US Renal Data System 2017 annual data report: epidemiology of kidney disease in the United States</article-title>. <source/>Am. J. Kidney Dis.
<volume>71</volume> (<issue>3S1</issue>), <fpage>A7</fpage>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2018.01.002</pub-id>
<pub-id pub-id-type="pmid">29477157</pub-id></mixed-citation>
</ref>
<ref id="B194">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schreck</surname><given-names>R.</given-names></name><name><surname>Meier</surname><given-names>B.</given-names></name><name><surname>Männel</surname><given-names>D. N.</given-names></name><name><surname>Dröge</surname><given-names>W.</given-names></name><name><surname>Baeuerle</surname><given-names>P. A.</given-names></name></person-group> (<year>1992</year>). <article-title>Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells</article-title>. <source/>J. Exp. Med.
<volume>175</volume> (<issue>5</issue>), <fpage>1181</fpage>–<lpage>1194</lpage>. <pub-id pub-id-type="doi">10.1084/jem.175.5.1181</pub-id>
<pub-id pub-id-type="pmid">1314883</pub-id></mixed-citation>
</ref>
<ref id="B195">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shan</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name></person-group> (<year>2010</year>). <article-title>Prevalence and risk factors associated with chronic kidney disease in adults over 40 years: a population study from Central China</article-title>. <source/>Nephrology (Carlton).
<volume>15</volume> (<issue>3</issue>), <fpage>354</fpage>–<lpage>361</lpage>. <pub-id pub-id-type="doi">10.1111/j.1440-1797.2009.01249.x</pub-id>
<pub-id pub-id-type="pmid">20470307</pub-id></mixed-citation>
</ref>
<ref id="B196">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shenderov</surname><given-names>B. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Metabiotics: novel idea or natural development of probiotic conception</article-title>. <source/>Microbial Ecol. Health Dis.
<volume>24</volume>, <fpage>1</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.3402/mehd.v24i0.20399</pub-id>
</mixed-citation>
</ref>
<ref id="B197">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shigeoka</surname><given-names>A. A.</given-names></name><name><surname>Holscher</surname><given-names>T. D.</given-names></name><name><surname>King</surname><given-names>A. J.</given-names></name><name><surname>Hall</surname><given-names>F. W.</given-names></name><name><surname>Kiosses</surname><given-names>W. B.</given-names></name><name><surname>Tobias</surname><given-names>P. S.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and -independent pathways</article-title>. <source/>J. Immunol.
<volume>178</volume> (<issue>10</issue>), <fpage>6252</fpage>–<lpage>6258</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.178.10.6252</pub-id>
<pub-id pub-id-type="pmid">17475853</pub-id></mixed-citation>
</ref>
<ref id="B198">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shigeoka</surname><given-names>A. A.</given-names></name><name><surname>Kambo</surname><given-names>A.</given-names></name><name><surname>Mathison</surname><given-names>J. C.</given-names></name><name><surname>King</surname><given-names>A. J.</given-names></name><name><surname>Hall</surname><given-names>W. F.</given-names></name><name><surname>da Silva Correia</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2010</year>a). <article-title>Nod1 and nod2 are expressed in human and murine renal tubular epithelial cells and participate in renal ischemia reperfusion injury</article-title>. <source/>J. Immunol.
<volume>184</volume> (<issue>5</issue>), <fpage>2297</fpage>–<lpage>2304</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0903065</pub-id>
<pub-id pub-id-type="pmid">20124104</pub-id></mixed-citation>
</ref>
<ref id="B199">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shigeoka</surname><given-names>A. A.</given-names></name><name><surname>Mueller</surname><given-names>J. L.</given-names></name><name><surname>Kambo</surname><given-names>A.</given-names></name><name><surname>Mathison</surname><given-names>J. C.</given-names></name><name><surname>King</surname><given-names>A. J.</given-names></name><name><surname>Hall</surname><given-names>W. F.</given-names></name><etal></etal></person-group> (<year>2010</year>b). <article-title>An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemia–reperfusion injury</article-title>. <source/>J. Immunol.
<volume>185</volume> (<issue>10</issue>), <fpage>6277</fpage>–<lpage>6285</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1002330</pub-id>
<pub-id pub-id-type="pmid">20962258</pub-id></mixed-citation>
</ref>
<ref id="B200">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shimada</surname><given-names>K.</given-names></name><name><surname>Yazaki</surname><given-names>Y.</given-names></name></person-group> (<year>1978</year>). <article-title>Binding sites for angiotensin II in human mononuclear leucocytes</article-title>. <source/>J. Biochem.
<volume>84</volume> (<issue>4</issue>), <fpage>1013</fpage>–<lpage>1015</lpage>. <pub-id pub-id-type="doi">10.1093/oxfordjournals.jbchem.a132183</pub-id>
<pub-id pub-id-type="pmid">213422</pub-id></mixed-citation>
</ref>
<ref id="B201">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Silk</surname><given-names>D. B.</given-names></name><name><surname>Davis</surname><given-names>A.</given-names></name><name><surname>Vulevic</surname><given-names>J.</given-names></name><name><surname>Tzortzis</surname><given-names>G.</given-names></name><name><surname>Gibson</surname><given-names>G. R.</given-names></name></person-group> (<year>2009</year>). <article-title>Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome</article-title>. <source/>Alimentary Pharmacol. Ther.
<volume>29</volume> (<issue>5</issue>), <fpage>508</fpage>–<lpage>518</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2036.2008.03911.x</pub-id>
</mixed-citation>
</ref>
<ref id="B202">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Simenhoff</surname><given-names>M. L.</given-names></name><name><surname>Dunn</surname><given-names>S. R.</given-names></name><name><surname>Zollner</surname><given-names>G. P.</given-names></name><name><surname>Fitzpatrick</surname><given-names>M. E.</given-names></name><name><surname>Emery</surname><given-names>S. M.</given-names></name><name><surname>Sandine</surname><given-names>W. E.</given-names></name><etal></etal></person-group> (<year>1996</year>). <article-title>Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried <italic>Lactobacillus acidophilus</italic>
</article-title>. <source/>Mineral Electrolyte Metab.
<volume>22</volume> (<issue>1-3</issue>), <fpage>92</fpage>–<lpage>96</lpage>. </mixed-citation>
</ref>
<ref id="B203">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singbartl</surname><given-names>K.</given-names></name><name><surname>Formeck</surname><given-names>C. L.</given-names></name><name><surname>Kellum</surname><given-names>J. A.</given-names></name></person-group> (<year>2019</year>). <article-title>Kidney–immune system crosstalk in AKI</article-title>. <source/>Semin Nephrol.
<volume>39</volume> (<issue>1</issue>), <fpage>96</fpage>–<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1016/j.semnephrol.2018.10.007</pub-id>
<pub-id pub-id-type="pmid">30606411</pub-id></mixed-citation>
</ref>
<ref id="B204">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>R.</given-names></name><name><surname>van Nood</surname><given-names>E.</given-names></name><name><surname>Nieuwdorp</surname><given-names>M.</given-names></name><name><surname>van Dam</surname><given-names>B.</given-names></name><name><surname>Berge</surname><given-names>I. J.</given-names></name><name><surname>Geerlings</surname><given-names>S. E.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Donor feces infusion for eradication of extended spectrum beta-lactamase producing <italic>Escherichia coli</italic> in a patient with end stage renal disease</article-title>. <source/>Clin. Microbiol. Infect.
<volume>20</volume> (<issue>11</issue>), <fpage>O977</fpage>–<lpage>O978</lpage>. <pub-id pub-id-type="doi">10.1111/1469-0691.12683</pub-id>
<pub-id pub-id-type="pmid">24845223</pub-id></mixed-citation>
</ref>
<ref id="B205">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sirich</surname><given-names>T. L.</given-names></name><name><surname>Plummer</surname><given-names>N. S.</given-names></name><name><surname>Gardner</surname><given-names>C. D.</given-names></name><name><surname>Hostetter</surname><given-names>T. H.</given-names></name><name><surname>Meyer</surname><given-names>T. W.</given-names></name></person-group> (<year>2014</year>). <article-title>Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients</article-title>. <source/>Clin. J. Am. Soc. Nephrol.
<volume>9</volume> (<issue>9</issue>), <fpage>1603</fpage>–<lpage>1610</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.00490114</pub-id>
<pub-id pub-id-type="pmid">25147155</pub-id></mixed-citation>
</ref>
<ref id="B206">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Siu</surname><given-names>Y. P.</given-names></name><name><surname>Leung</surname><given-names>K. T.</given-names></name><name><surname>Tong</surname><given-names>M. K.</given-names></name><name><surname>Kwan</surname><given-names>T. H.</given-names></name></person-group> (<year>2006</year>). <article-title>Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level</article-title>. <source/>Am. J. Kidney Dis.
<volume>47</volume> (<issue>1</issue>), <fpage>51</fpage>–<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2005.10.006</pub-id>
<pub-id pub-id-type="pmid">16377385</pub-id></mixed-citation>
</ref>
<ref id="B207">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>P. M.</given-names></name><name><surname>Howitt</surname><given-names>M. R.</given-names></name><name><surname>Panikov</surname><given-names>N.</given-names></name><name><surname>Michaud</surname><given-names>M.</given-names></name><name><surname>Gallini</surname><given-names>C. A.</given-names></name><name><surname>Bohlooly</surname><given-names>Y. M.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis</article-title>. <source/>Science
<volume>341</volume> (<issue>6145</issue>), <fpage>569</fpage>–<lpage>573</lpage>. <pub-id pub-id-type="doi">10.1126/science.1241165</pub-id>
<pub-id pub-id-type="pmid">23828891</pub-id></mixed-citation>
</ref>
<ref id="B208">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Snelgrove</surname><given-names>S. L.</given-names></name><name><surname>Lo</surname><given-names>C.</given-names></name><name><surname>Hall</surname><given-names>P.</given-names></name><name><surname>Lo</surname><given-names>C. Y.</given-names></name><name><surname>Alikhan</surname><given-names>M. A.</given-names></name><name><surname>Coates</surname><given-names>P. T.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Activated renal dendritic cells cross present intrarenal antigens after ischemia–reperfusion injury</article-title>. <source/>Transplantation
<volume>101</volume> (<issue>5</issue>), <fpage>1013</fpage>–<lpage>1024</lpage>. <pub-id pub-id-type="doi">10.1097/TP.0000000000001427</pub-id>
<pub-id pub-id-type="pmid">27495751</pub-id></mixed-citation>
</ref>
<ref id="B209">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>So</surname><given-names>A.</given-names></name><name><surname>Thorens</surname><given-names>B.</given-names></name></person-group> (<year>2010</year>). <article-title>Uric acid transport and disease</article-title>. <source/>J. Clin. Invest.
<volume>120</volume> (<issue>6</issue>), <fpage>1791</fpage>–<lpage>1799</lpage>. <pub-id pub-id-type="doi">10.1172/JCI42344</pub-id>
<pub-id pub-id-type="pmid">20516647</pub-id></mixed-citation>
</ref>
<ref id="B210">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sola</surname><given-names>R.</given-names></name><name><surname>Godas</surname><given-names>G.</given-names></name><name><surname>Ribalta</surname><given-names>J.</given-names></name><name><surname>Vallve</surname><given-names>J. C.</given-names></name><name><surname>Girona</surname><given-names>J.</given-names></name><name><surname>Anguera</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Effects of soluble fiber (Plantago ovata husk) on plasma lipids, lipoproteins, and apolipoproteins in men with ischemic heart disease</article-title>. <source/>Am. J. Clin. Nutr.
<volume>85</volume> (<issue>4</issue>), <fpage>1157</fpage>–<lpage>1163</lpage>. <pub-id pub-id-type="doi">10.1093/ajcn/85.4.1157</pub-id>
<pub-id pub-id-type="pmid">17413119</pub-id></mixed-citation>
</ref>
<ref id="B211">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soty</surname><given-names>M.</given-names></name><name><surname>Penhoat</surname><given-names>A.</given-names></name><name><surname>Amigo-Correig</surname><given-names>M.</given-names></name><name><surname>Vinera</surname><given-names>J.</given-names></name><name><surname>Sardella</surname><given-names>A.</given-names></name><name><surname>Vullin-Bouilloux</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>A gut–brain neural circuit controlled by intestinal gluconeogenesis is crucial in metabolic health</article-title>. <source/>Mol Med.
<volume>4</volume> (<issue>2</issue>), <fpage>106</fpage>–<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmet.2014.12.009</pub-id>
</mixed-citation>
</ref>
<ref id="B212">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stamatiades</surname><given-names>E. G.</given-names></name><name><surname>Tremblay</surname><given-names>M. E.</given-names></name><name><surname>Bohm</surname><given-names>M.</given-names></name><name><surname>Crozet</surname><given-names>L.</given-names></name><name><surname>Bisht</surname><given-names>K.</given-names></name><name><surname>Kao</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Immune monitoring of trans-endothelial transport by kidney-resident macrophages</article-title>. <source/>Cell.
<volume>166</volume> (<issue>4</issue>), <fpage>991</fpage>–<lpage>1003</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.06.058</pub-id>
<pub-id pub-id-type="pmid">27477514</pub-id></mixed-citation>
</ref>
<ref id="B213">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stenvinkel</surname><given-names>P.</given-names></name><name><surname>Andersson</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Lindholm</surname><given-names>B.</given-names></name><name><surname>Bergström</surname><given-names>J.</given-names></name><name><surname>Palmblad</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>1999</year>). <article-title>Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure</article-title>? <source/>J. Intern. Med.
<volume>246</volume> (<issue>5</issue>), <fpage>503</fpage>–<lpage>507</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2796.1999.00560.x</pub-id>
<pub-id pub-id-type="pmid">10583720</pub-id></mixed-citation>
</ref>
<ref id="B214">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stubbs</surname><given-names>J. R.</given-names></name><name><surname>House</surname><given-names>J. A.</given-names></name><name><surname>Ocque</surname><given-names>A. J.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Johnson</surname><given-names>C.</given-names></name><name><surname>Kimber</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>27</volume> (<issue>1</issue>), <fpage>305</fpage>–<lpage>313</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2014111063</pub-id>
<pub-id pub-id-type="pmid">26229137</pub-id></mixed-citation>
</ref>
<ref id="B215">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Surawicz</surname><given-names>C. M.</given-names></name><name><surname>Brandt</surname><given-names>L. J.</given-names></name><name><surname>Binion</surname><given-names>D. G.</given-names></name><name><surname>Ananthakrishnan</surname><given-names>A. N.</given-names></name><name><surname>Curry</surname><given-names>S. R.</given-names></name><name><surname>Gilligan</surname><given-names>P. H.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Guidelines for diagnosis, treatment, and prevention of <italic>Clostridium difficile</italic> infections</article-title>. <source/>Am. J. Gastroenterol.
<volume>108</volume> (<issue>4</issue>), 478–98; quiz <fpage>99</fpage>. <pub-id pub-id-type="doi">10.1038/ajg.2013.4</pub-id>
<pub-id pub-id-type="pmid">23032984</pub-id></mixed-citation>
</ref>
<ref id="B216">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tadagavadi</surname><given-names>R. K.</given-names></name><name><surname>Reeves</surname><given-names>W. B.</given-names></name></person-group> (<year>2010</year>). <article-title>Renal dendritic cells ameliorate nephrotoxic acute kidney injury</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>21</volume> (<issue>1</issue>), <fpage>53</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2009040407</pub-id>
<pub-id pub-id-type="pmid">19875815</pub-id></mixed-citation>
</ref>
<ref id="B217">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takayama</surname><given-names>F.</given-names></name><name><surname>Taki</surname><given-names>K.</given-names></name><name><surname>Niwa</surname><given-names>T.</given-names></name></person-group> (<year>2003</year>). <article-title>Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis</article-title>. <source/>Am. J. Kidney Dis.
<volume>41</volume> (<issue> Suppl 1</issue>), <fpage>S142</fpage>–<lpage>S145</lpage>. <pub-id pub-id-type="doi">10.1053/ajkd.2003.50104</pub-id>
<pub-id pub-id-type="pmid">12612972</pub-id></mixed-citation>
</ref>
<ref id="B218">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taki</surname><given-names>K.</given-names></name><name><surname>Takayama</surname><given-names>F.</given-names></name><name><surname>Niwa</surname><given-names>T.</given-names></name></person-group> (<year>2005</year>). <article-title>Beneficial effects of bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients</article-title>. <source/>J. Renal Nutr.
<volume>15</volume> (<issue>1</issue>), <fpage>77</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1053/j.jrn.2004.09.028</pub-id>
</mixed-citation>
</ref>
<ref id="B219">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takiishi</surname><given-names>T.</given-names></name><name><surname>Korf</surname><given-names>H.</given-names></name><name><surname>Van Belle</surname><given-names>T. L.</given-names></name><name><surname>Robert</surname><given-names>S.</given-names></name><name><surname>Grieco</surname><given-names>F. A.</given-names></name><name><surname>Caluwaerts</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified <italic>Lactococcus lactis</italic> in mice</article-title>. <source/>J. Clin. Investig.
<volume>122</volume> (<issue>5</issue>), <fpage>1717</fpage>–<lpage>1725</lpage>. <pub-id pub-id-type="doi">10.1172/JCI60530</pub-id>
<pub-id pub-id-type="pmid">22484814</pub-id></mixed-citation>
</ref>
<ref id="B220">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>W. H.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Kennedy</surname><given-names>D. J.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Buffa</surname><given-names>J. A.</given-names></name><name><surname>Agatisa-Boyle</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Gut microbiota–dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease</article-title>. <source/>Circ Res.
<volume>116</volume> (<issue>3</issue>), <fpage>448</fpage>–<lpage>455</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.305360</pub-id>
<pub-id pub-id-type="pmid">25599331</pub-id></mixed-citation>
</ref>
<ref id="B221">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Teles</surname><given-names>F.</given-names></name><name><surname>Machado</surname><given-names>F. G.</given-names></name><name><surname>Ventura</surname><given-names>B. H.</given-names></name><name><surname>Malheiros</surname><given-names>D. M.</given-names></name><name><surname>Fujihara</surname><given-names>C. K.</given-names></name><name><surname>Silva</surname><given-names>L. F.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Regression of glomerular injury by losartan in experimental diabetic nephropathy</article-title>. <source/>Kidney Int.
<volume>75</volume> (<issue>1</issue>), <fpage>72</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2008.528</pub-id>
<pub-id pub-id-type="pmid">18946500</pub-id></mixed-citation>
</ref>
<ref id="B222">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thorburn</surname><given-names>A. N.</given-names></name><name><surname>McKenzie</surname><given-names>C. I.</given-names></name><name><surname>Shen</surname><given-names>S.</given-names></name><name><surname>Stanley</surname><given-names>D.</given-names></name><name><surname>Macia</surname><given-names>L.</given-names></name><name><surname>Mason</surname><given-names>L. J.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Evidence that asthma is a developmental origin disease influenced by maternal diet and bacterial metabolites</article-title>. <source/>Nat. Commun.
<month>6</month>
<volume>236</volume>, <fpage>7320</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms8320</pub-id>
</mixed-citation>
</ref>
<ref id="B223">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thornton</surname><given-names>M. A.</given-names></name><name><surname>Winn</surname><given-names>R.</given-names></name><name><surname>Alpers</surname><given-names>C. E.</given-names></name><name><surname>Zager</surname><given-names>R. A.</given-names></name></person-group> (<year>1989</year>). <article-title>An evaluation of the neutrophil as a mediator of <italic>in vivo</italic> renal ischemic–reperfusion injury</article-title>. <source/>Am. J. Pathol.
<volume>135</volume> (<issue>3</issue>), <fpage>509</fpage>–<lpage>515</lpage>. <pub-id pub-id-type="pmid">2782382</pub-id></mixed-citation>
</ref>
<ref id="B224">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tittel</surname><given-names>A. P.</given-names></name><name><surname>Heuser</surname><given-names>C.</given-names></name><name><surname>Ohliger</surname><given-names>C.</given-names></name><name><surname>Knolle</surname><given-names>P. A.</given-names></name><name><surname>Engel</surname><given-names>D. R.</given-names></name><name><surname>Kurts</surname><given-names>C.</given-names></name></person-group> (<year>2011</year>). <article-title>Kidney dendritic cells induce innate immunity against bacterial pyelonephritis</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>22</volume> (<issue>8</issue>), <fpage>1435</fpage>–<lpage>1441</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2010101072</pub-id>
<pub-id pub-id-type="pmid">21757770</pub-id></mixed-citation>
</ref>
<ref id="B225">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Trentin-Sonoda</surname><given-names>M.</given-names></name><name><surname>da Silva</surname><given-names>R. C.</given-names></name><name><surname>Kmit</surname><given-names>F. V.</given-names></name><name><surname>Abrahao</surname><given-names>M. V.</given-names></name><name><surname>Monnerat Cahli</surname><given-names>G.</given-names></name><name><surname>Brasil</surname><given-names>G. V.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Knockout of Toll-like receptors 2 and 4 prevents renal ischemia–reperfusion–induced cardiac hypertrophy in mice</article-title>. <source/>PloS one
<volume>10</volume> (<issue>10</issue>), <elocation-id>e0139350</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0139350</pub-id>
<pub-id pub-id-type="pmid">26448184</pub-id></mixed-citation>
</ref>
<ref id="B226">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Usami</surname><given-names>M.</given-names></name><name><surname>Kishimoto</surname><given-names>K.</given-names></name><name><surname>Ohata</surname><given-names>A.</given-names></name><name><surname>Miyoshi</surname><given-names>M.</given-names></name><name><surname>Aoyama</surname><given-names>M.</given-names></name><name><surname>Fueda</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells</article-title>. <source/>Nutr. Res.
<volume>28</volume> (<issue>5</issue>), <fpage>321</fpage>–<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1016/j.nutres.2008.02.012</pub-id>
<pub-id pub-id-type="pmid">19083427</pub-id></mixed-citation>
</ref>
<ref id="B227">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Valette</surname><given-names>X.</given-names></name><name><surname>Savary</surname><given-names>B.</given-names></name><name><surname>Nowoczyn</surname><given-names>M.</given-names></name><name><surname>Daubin</surname><given-names>C.</given-names></name><name><surname>Pottier</surname><given-names>V.</given-names></name><name><surname>Terzi</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Accuracy of plasma neutrophil gelatinase-associated lipocalin in the early diagnosis of contrast-induced acute kidney injury in critical illness</article-title>. <source/>Intensive Care Med.
<volume>39</volume> (<issue>5</issue>), <fpage>857</fpage>–<lpage>865</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-013-2826-y</pub-id>
<pub-id pub-id-type="pmid">23361630</pub-id></mixed-citation>
</ref>
<ref id="B228">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vandenbroucke</surname><given-names>K.</given-names></name><name><surname>de Haard</surname><given-names>H.</given-names></name><name><surname>Beirnaert</surname><given-names>E.</given-names></name><name><surname>Dreier</surname><given-names>T.</given-names></name><name><surname>Lauwereys</surname><given-names>M.</given-names></name><name><surname>Huyck</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Orally administered <italic>L. lactis</italic> secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis</article-title>. <source/>Mucosal Immunol.
<volume>3</volume> (<issue>1</issue>), <fpage>49</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1038/mi.2009.116</pub-id>
<pub-id pub-id-type="pmid">19794409</pub-id></mixed-citation>
</ref>
<ref id="B229">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vandeputte</surname><given-names>D.</given-names></name><name><surname>Falony</surname><given-names>G.</given-names></name><name><surname>Vieira-Silva</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Sailer</surname><given-names>M.</given-names></name><name><surname>Theis</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Prebiotic inulin-type fructans induce specific changes in the human gut microbiota</article-title>. <source/>Gut
<volume>66</volume> (<issue>11</issue>), <fpage>1968</fpage>–<lpage>1974</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2016-313271</pub-id>
<pub-id pub-id-type="pmid">28213610</pub-id></mixed-citation>
</ref>
<ref id="B230">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vaziri</surname><given-names>N. D.</given-names></name><name><surname>Wong</surname><given-names>J.</given-names></name><name><surname>Pahl</surname><given-names>M.</given-names></name><name><surname>Piceno</surname><given-names>Y. M.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>DeSantis</surname><given-names>T. Z.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Chronic kidney disease alters intestinal microbial flora</article-title>. <source/>Kidney Int.
<volume>83</volume> (<issue>2</issue>), <fpage>308</fpage>–<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2012.345</pub-id>
<pub-id pub-id-type="pmid">22992469</pub-id></mixed-citation>
</ref>
<ref id="B231">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vaziri</surname><given-names>N. D.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Nazertehrani</surname><given-names>S.</given-names></name><name><surname>Ni</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name></person-group> (<year>2013</year>). <article-title>Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction</article-title>. <source/>Am. J. Nephrol.
<volume>38</volume> (<issue>2</issue>), <fpage>99</fpage>–<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1159/000353764</pub-id>
<pub-id pub-id-type="pmid">23887095</pub-id></mixed-citation>
</ref>
<ref id="B232">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vaziri</surname><given-names>N. D.</given-names></name><name><surname>Liu</surname><given-names>S. M.</given-names></name><name><surname>Lau</surname><given-names>W. L.</given-names></name><name><surname>Khazaeli</surname><given-names>M.</given-names></name><name><surname>Nazertehrani</surname><given-names>S.</given-names></name><name><surname>Farzaneh</surname><given-names>S. H.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease</article-title>. <source/>PloS one
<volume>9</volume> (<issue>12</issue>), <elocation-id>e114881</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0114881</pub-id>
<pub-id pub-id-type="pmid">25490712</pub-id></mixed-citation>
</ref>
<ref id="B233">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Venkatachalam</surname><given-names>M. A.</given-names></name><name><surname>Griffin</surname><given-names>K. A.</given-names></name><name><surname>Lan</surname><given-names>R.</given-names></name><name><surname>Geng</surname><given-names>H.</given-names></name><name><surname>Saikumar</surname><given-names>P.</given-names></name><name><surname>Bidani</surname><given-names>A. K.</given-names></name></person-group> (<year>2010</year>). <article-title>Acute kidney injury: a springboard for progression in chronic kidney disease</article-title>. <source/>Am. J. Physiol. Renal Physiol.
<volume>298</volume> (<issue>5</issue>), <fpage>F1078</fpage>–<lpage>F1094</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.00017.2010</pub-id>
<pub-id pub-id-type="pmid">20200097</pub-id></mixed-citation>
</ref>
<ref id="B234">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Verzola</surname><given-names>D.</given-names></name><name><surname>Cappuccino</surname><given-names>L.</given-names></name><name><surname>D’Amato</surname><given-names>E.</given-names></name><name><surname>Villaggio</surname><given-names>B.</given-names></name><name><surname>Gianiorio</surname><given-names>F.</given-names></name><name><surname>Mij</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria</article-title>. <source/>Kidney Int.
<volume>86</volume> (<issue>6</issue>), <fpage>1229</fpage>–<lpage>1243</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2014.116</pub-id>
<pub-id pub-id-type="pmid">24786705</pub-id></mixed-citation>
</ref>
<ref id="B235">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vinolo</surname><given-names>M. A.</given-names></name><name><surname>Rodrigues</surname><given-names>H. G.</given-names></name><name><surname>Hatanaka</surname><given-names>E.</given-names></name><name><surname>Sato</surname><given-names>F. T.</given-names></name><name><surname>Sampaio</surname><given-names>S. C.</given-names></name><name><surname>Curi</surname><given-names>R.</given-names></name></person-group> (<year>2011</year>). <article-title>Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils</article-title>. <source/>J. Nutr. Biochem.
<volume>22</volume> (<issue>9</issue>), <fpage>849</fpage>–<lpage>855</lpage>. <pub-id pub-id-type="doi">10.1016/j.jnutbio.2010.07.009</pub-id>
<pub-id pub-id-type="pmid">21167700</pub-id></mixed-citation>
</ref>
<ref id="B236">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vrieze</surname><given-names>A.</given-names></name><name><surname>Van Nood</surname><given-names>E.</given-names></name><name><surname>Holleman</surname><given-names>F.</given-names></name><name><surname>Salojarvi</surname><given-names>J.</given-names></name><name><surname>Kootte</surname><given-names>R. S.</given-names></name><name><surname>Bartelsman</surname><given-names>J. F.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome</article-title>. <source/>Gastroenterology
<volume>143</volume> (<issue>4</issue>), <page-range>913–6</page-range>
<elocation-id>e7</elocation-id>. <pub-id pub-id-type="doi">10.1053/j.gastro.2012.06.031</pub-id>
</mixed-citation>
</ref>
<ref id="B237">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wanders</surname><given-names>D.</given-names></name><name><surname>Graff</surname><given-names>E. C.</given-names></name><name><surname>Judd</surname><given-names>R. L.</given-names></name></person-group> (<year>2012</year>). <article-title>Effects of high fat diet on GPR109A and GPR81 gene expression</article-title>. <source/>Biochemi. Biophysi. Res. Commun.
<volume>425</volume> (<issue>2</issue>), <fpage>278</fpage>–<lpage>283</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2012.07.082</pub-id>
</mixed-citation>
</ref>
<ref id="B238">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y. H.</given-names></name><name><surname>Zhang</surname><given-names>Y. G.</given-names></name></person-group> (<year>2017</year>). <article-title>Kidney and innate immunity</article-title>. <source/>Immunol. Lett.
<volume>183</volume>, <fpage>73</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.imlet.2017.01.011</pub-id>
<pub-id pub-id-type="pmid">28143791</pub-id></mixed-citation>
</ref>
<ref id="B239">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>H. B.</given-names></name><name><surname>Wang</surname><given-names>P. Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Wan</surname><given-names>Y. L.</given-names></name><name><surname>Liu</surname><given-names>Y. C.</given-names></name></person-group> (<year>2012</year>). <article-title>Butyrate enhances intestinal epithelial barrier function <italic>via</italic> up-regulation of tight junction protein claudin-1 transcription</article-title>. <source/>Digest. Dis. Scie.
<volume>57</volume> (<issue>12</issue>), <fpage>3126</fpage>–<lpage>3135</lpage>. <pub-id pub-id-type="doi">10.1007/s10620-012-2259-4</pub-id>
</mixed-citation>
</ref>
<ref id="B240">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>I. K.</given-names></name><name><surname>Lai</surname><given-names>H. C.</given-names></name><name><surname>Yu</surname><given-names>C. J.</given-names></name><name><surname>Liang</surname><given-names>C. C.</given-names></name><name><surname>Chang</surname><given-names>C. T.</given-names></name><name><surname>Kuo</surname><given-names>H. L.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Real-time PCR analysis of the intestinal microbiotas in peritoneal dialysis patients</article-title>. <source/>Appl. Environ. Microbiol.
<volume>78</volume> (<issue>4</issue>), <fpage>1107</fpage>–<lpage>1112</lpage>. <pub-id pub-id-type="doi">10.1128/AEM.05605-11</pub-id>
<pub-id pub-id-type="pmid">22179250</pub-id></mixed-citation>
</ref>
<ref id="B241">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Liang</surname><given-names>H.</given-names></name><name><surname>Zen</surname><given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>Molecular mechanisms that influence the macrophage m1-m2 polarization balance</article-title>. <source/>Front. Immunol.
<volume>5</volume>, <fpage>614</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2014.00614</pub-id>
<pub-id pub-id-type="pmid">25506346</pub-id></mixed-citation>
</ref>
<ref id="B242">
<mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>X. M.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Flt3 inhibition alleviates chronic kidney disease by suppressing CD103<sup>+</sup> dendritic cell–mediated T cell activation</article-title>. <source/>Nephrol. Dialysis Transplant.
<pub-id pub-id-type="doi">10.1093/ndt/gfy385</pub-id>
</mixed-citation>
</ref>
<ref id="B243">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>H.</given-names></name><name><surname>Miyamoto</surname><given-names>Y.</given-names></name><name><surname>Honda</surname><given-names>D.</given-names></name><name><surname>Tanaka</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Endo</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase</article-title>. <source/>Kidney Int.
<volume>83</volume> (<issue>4</issue>), <fpage>582</fpage>–<lpage>592</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2012.448</pub-id>
<pub-id pub-id-type="pmid">23325087</pub-id></mixed-citation>
</ref>
<ref id="B244">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Watson</surname><given-names>C.</given-names></name></person-group> (<year>1899</year>). <article-title>Uric acid and gout: some points in the physiology of uric acid</article-title>. <source/>Br Med J.
<volume>1</volume> (<issue>1987</issue>), <fpage>205</fpage>–<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.1.1987.205</pub-id>
</mixed-citation>
</ref>
<ref id="B245">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wen</surname><given-names>H.</given-names></name><name><surname>Miao</surname><given-names>E. A.</given-names></name><name><surname>Ting</surname><given-names>J. P.</given-names></name></person-group> (<year>2013</year>). <article-title>Mechanisms of NOD-like receptor-associated inflammasome activation</article-title>. <source/>Immunity
<volume>39</volume> (<issue>3</issue>), <fpage>432</fpage>–<lpage>441</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2013.08.037</pub-id>
<pub-id pub-id-type="pmid">24054327</pub-id></mixed-citation>
</ref>
<ref id="B246">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wikoff</surname><given-names>W. R.</given-names></name><name><surname>Anfora</surname><given-names>A. T.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Schultz</surname><given-names>P. G.</given-names></name><name><surname>Lesley</surname><given-names>S. A.</given-names></name><name><surname>Peters</surname><given-names>E. C.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>106</volume> (<issue>10</issue>), <fpage>3698</fpage>–<lpage>3703</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0812874106</pub-id>
<pub-id pub-id-type="pmid">19234110</pub-id></mixed-citation>
</ref>
<ref id="B247">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>J.</given-names></name><name><surname>Piceno</surname><given-names>Y. M.</given-names></name><name><surname>DeSantis</surname><given-names>T. Z.</given-names></name><name><surname>Pahl</surname><given-names>M.</given-names></name><name><surname>Andersen</surname><given-names>G. L.</given-names></name><name><surname>Vaziri</surname><given-names>N. D.</given-names></name></person-group> (<year>2014</year>). <article-title>Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD</article-title>. <source/>Am. J. Nephrol.
<volume>39</volume> (<issue>3</issue>), <fpage>230</fpage>–<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1159/000360010</pub-id>
<pub-id pub-id-type="pmid">24643131</pub-id></mixed-citation>
</ref>
<ref id="B248">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Wyburn</surname><given-names>K. R.</given-names></name><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Bertolino</surname><given-names>P.</given-names></name><name><surname>Eris</surname><given-names>J. M.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>TLR4 activation mediates kidney ischemia/reperfusion injury</article-title>. <source/>J. Clin. Investig.
<volume>117</volume> (<issue>10</issue>), <fpage>2847</fpage>–<lpage>2859</lpage>. <pub-id pub-id-type="doi">10.1172/JCI31008</pub-id>
<pub-id pub-id-type="pmid">17853945</pub-id></mixed-citation>
</ref>
<ref id="B249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Corpuz</surname><given-names>T. M.</given-names></name><name><surname>Panchapakesan</surname><given-names>U.</given-names></name><name><surname>Wyburn</surname><given-names>K. R.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>HMGB1 contributes to kidney ischemia reperfusion injury</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>21</volume> (<issue>11</issue>), <fpage>1878</fpage>–<lpage>1890</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2009101048</pub-id>
<pub-id pub-id-type="pmid">20847143</pub-id></mixed-citation>
</ref>
<ref id="B250">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wynn</surname><given-names>T. A.</given-names></name><name><surname>Barron</surname><given-names>L.</given-names></name></person-group> (<year>2010</year>). <article-title>Macrophages: master regulators of inflammation and fibrosis</article-title>. <source/>Semi. Liver Dis.
<volume>30</volume> (<issue>3</issue>), <fpage>245</fpage>–<lpage>257</lpage>. <pub-id pub-id-type="doi">10.1055/s-0030-1255354</pub-id>
</mixed-citation>
</ref>
<ref id="B251">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiao</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>X. L.</given-names></name><name><surname>Fu</surname><given-names>C.</given-names></name><name><surname>Han</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Soluble uric acid increases NALP3 inflammasome and interleukin-1β expression in human primary renal proximal tubule epithelial cells through the Toll-like receptor 4–mediated pathway</article-title>. <source/>Int. J. Mol. Med.
<volume>35</volume> (<issue>5</issue>), <fpage>1347</fpage>–<lpage>1354</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2015.2148</pub-id>
<pub-id pub-id-type="pmid">25813103</pub-id></mixed-citation>
</ref>
<ref id="B252">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yatsunenko</surname><given-names>T.</given-names></name><name><surname>Rey</surname><given-names>F. E.</given-names></name><name><surname>Manary</surname><given-names>M. J.</given-names></name><name><surname>Trehan</surname><given-names>I.</given-names></name><name><surname>Dominguez-Bello</surname><given-names>M. G.</given-names></name><name><surname>Contreras</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Human gut microbiome viewed across age and geography</article-title>. <source/>Nature
<volume>486</volume> (<issue>7402</issue>), <fpage>222</fpage>–<lpage>227</lpage>. <pub-id pub-id-type="doi">10.1038/nature11053</pub-id>
<pub-id pub-id-type="pmid">22699611</pub-id></mixed-citation>
</ref>
<ref id="B253">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoshifuji</surname><given-names>A.</given-names></name><name><surname>Wakino</surname><given-names>S.</given-names></name><name><surname>Irie</surname><given-names>J.</given-names></name><name><surname>Tajima</surname><given-names>T.</given-names></name><name><surname>Hasegawa</surname><given-names>K.</given-names></name><name><surname>Kanda</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Gut Lactobacillus protects against the progression of renal damage by modulating the gut environment in rats</article-title>. <source/>Nephrol. Dialysis Transplant.
<volume>31</volume> (<issue>3</issue>), <fpage>401</fpage>–<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfv353</pub-id>
</mixed-citation>
</ref>
<ref id="B254">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Ramesh</surname><given-names>G.</given-names></name><name><surname>Uematsu</surname><given-names>S.</given-names></name><name><surname>Akira</surname><given-names>S.</given-names></name><name><surname>Reeves</surname><given-names>W. B.</given-names></name></person-group> (<year>2008</year>). <article-title>TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>19</volume> (<issue>5</issue>), <fpage>923</fpage>–<lpage>932</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2007090982</pub-id>
<pub-id pub-id-type="pmid">18256356</pub-id></mixed-citation>
</ref>
<ref id="B255">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Luo</surname><given-names>W.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Fan</surname><given-names>Z.</given-names></name><name><surname>Ji</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>Should we standardize the 1,700-year-old fecal microbiota transplantation</article-title>? <source/>Am. J. Gastroenterol.
<volume>107</volume> (<issue>11</issue>), <fpage>1755</fpage>. <pub-id pub-id-type="doi">10.1038/ajg.2012.251</pub-id>
<pub-id pub-id-type="pmid">23160295</pub-id></mixed-citation>
</ref>
<ref id="B256">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Ding</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>G.</given-names></name><name><surname>Lam</surname><given-names>Y. Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes</article-title>. <source/>Science
<volume>359</volume> (<issue>6380</issue>), <fpage>1151</fpage>–<lpage>1156</lpage>. <pub-id pub-id-type="doi">10.1126/science.aao5774</pub-id>
<pub-id pub-id-type="pmid">29590046</pub-id></mixed-citation>
</ref>
<ref id="B257">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Yamane</surname><given-names>H.</given-names></name><name><surname>Paul</surname><given-names>W. E.</given-names></name></person-group> (<year>2010</year>). <article-title>Differentiation of effector CD4 T cell populations (*)</article-title>. <source/>Annu. Rev. Immunol.
<volume>28</volume>, <fpage>445</fpage>–<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-immunol-030409-101212</pub-id>
<pub-id pub-id-type="pmid">20192806</pub-id></mixed-citation>
</ref>
<ref id="B258">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zoccali</surname><given-names>C.</given-names></name><name><surname>Vanholder</surname><given-names>R.</given-names></name><name><surname>Massy</surname><given-names>Z. A.</given-names></name><name><surname>Ortiz</surname><given-names>A.</given-names></name><name><surname>Sarafidis</surname><given-names>P.</given-names></name><name><surname>Dekker</surname><given-names>F. W.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>The systemic nature of CKD</article-title>. <source/>Nat. Rev. Nephrol.
<volume>13</volume> (<issue>6</issue>), <fpage>344</fpage>–<lpage>358</lpage>. <pub-id pub-id-type="doi">10.1038/nrneph.2017.52</pub-id>
<pub-id pub-id-type="pmid">28435157</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>